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Abstract 
 
Tuberculosis (TB) is a chronic disease, with one third of the worlds’ population infected. Multi drug 
resistant Mycobacterium tuberculosis strains have evolved, which are unaffected by the commonly 
used antibiotics. If the disease is not treated it could spread uncontrollably and become a pandemy. It 
is therefore imperative to identify novel drug targets. There is a great interest in adenylyl cyclases 
(ACs) from M. tuberculosis, which generate the universal second messenger cAMP, mostly since 
regulatory processes involving cAMP are vital for the pathogen. Elevated levels of cAMP are 
observed in phagosomes during infection, which protects the bacteria from elimination. The high 
number of ACs in M. tuberculosis suggests that the pathogen has the ability to sense and respond to a 
number of extracellular and intracellular signals through cAMP signalling. These processes are of 
fundamental interest, but investigation of the involved enzymes may also directly lead into the drug 
discovery process and result in new strategies for treatment. 
 
This study deals with the X-ray crystallographic structure determination of the catalytic core of 
cyclase homology domain (CHD) of the class III adenylyl cyclase Rv0386 from Mycobacterium 
tuberculosis. This CHD is exceptional as it can use both, ATP and GTP, as substrates. Class III CHDs 
have been shown to exist as dimers in a head-to-tail arrangement. In contrast, the structure presented 
here identifies a novel dimeric contact, which we define as head-to-head. In this state, the CHD can 
not form proper active sites and thus is inhibited. This is in line with the low catalytic activity 
observed in vitro. The interface contact of the Rv0386 CHD dimer is substantial and buries 1497 Å2. 
To test whether the contact was generated during crystallisation, the in-solution properties of Rv0386 
CHD were examined by small angle X-ray scattering, which confirmed the head-to-head interface.  
 
To learn about the substrate recognition of the Rv0386 CHD, a model of the active state was created. 
It shows GTP/ATP binding by the non-canonical purine binding residues Asn106 and Gln57 made 
possible with 180° rotation of both amide side chains. A discussion of homologous AC structures 
reveals that in the commonly observed eight-stranded β-sheet Rv0386 lacks the conserved β-strand 
β5. In the head-to-tail arrangement of a catalytically active dimer, β5 contributes to the interface 
which suggests that β5 forms in Rv0386 when in the active conformation. Since β5 also carries 
catalytic residue Asn106, this region might be an activity switch operated on homo-dimerisation of the 
enzyme. To obtain the active conformation, one of the two CHDs of Rv0386 as observed in the crystal 
structure would have to rotate around 48.2° and translated by 16.8 Å.  
 
Crystallisation trials to obtain the active state were carried out in the presence of substrates or 
inhibitors. However, the dimer contact of Rv0386 CHD to form the head-to-head dimer is clearly 
more stable than the head-to-tail dimer in the active state, even when attempting to occupy the 
substrate binding pockets. The cofactor manganese is required for Rv0386 CHD catalytic activity in 
vitro. In this work manganese additionally was identified to interfere with dimerisation of Rv0386 
CHD, which was unexpected. In the presence of Mn2+, Rv0386 CHD is monomeric as characterised by 
size exclusion chromatography, analytical ultracentrifugation and small angle X-ray scattering. 
Attempts were made to convert the monomeric species to a catalytic dimer by addition of substrate 
analogs. Initial crystals obtained would require further improvement. 
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Zusammenfassung 
 
Tuberkulose (TB) ist eine chronische Krankheit, an der ein Drittel der Weltbevölkerung infiziert ist. 
Mehrfachresistente Mycobacterium tuberculosis-Stämme sind entstanden, die durch bisher 
existierende Antibiotika nicht bekämpft werden können. Wird die Krankheit nicht behandelt, könnte 
sie sich unkontrolliert ausbreiten und zur Pandemie anwachsen. Es ist daher dringend geboten, neue 
Methoden zur Bekämpfung von Tuberkulose zu finden. Das Interesse an mycobakteriellen Adenylat-
Zyklasen (Adenylyl Cyclases, ACs), die den universellen second messenger cAMP herstellen, ist groß, 
insbesondere weil regulatorische Prozesse, an denen cAMP beteiligt ist, lebenswichtig für dieses 
Pathogen zu sein scheinen. Man findet erhöhte cAMP Konzentrationen während der Infektion in den 
Phagosomen, und dies scheint die Bakterien vor ihrer Vernichtung zu bewahren. Die große Zahl von 
ACn bei M. tuberculosis legt nahe, daß das Pathogen die Fähigkeit hat, extra- und intrazelluläre 
Signale wahrzunehmen und mittels cAMP darauf zu reagieren. Diese Vorgänge sind von 
fundamentalem Interesse, Studie der involvierten Enzyme könnte aber direkt zur Entwicklung von 
Medikamenten und damit zu neuen Behandlungsmethoden führen. 
 
In dieser Studie wird die kristallographische Röntgenstruktur der katalytischen Domäne (cyclase 
homology domain, CHD) der Klasse III-Adenylatzyklase Rv0386 aus Mycobacterium tuberculosis  
untersucht. Rv0386 ist eine außergewöhnliche Adenylatzyklase, da sie sowohl ATP als auch GTP als 
Substrat verwenden kann. Bisher wurden Klasse III-ACs als gegenläufige Dimere (head-to-tail) 
gefunden. Im Gegensatz dazu zeigt die Struktur von Rv0386 CHD einem neuen, Kopf-Kopf 
homodimeren Zustand, in dem sich keine aktiven Zentren ausbilden. Dies erklärt auch die geringe 
Aktivität des Proteins in vitro. Die Kontaktfläche des Dimers ist mit 1497 Å2 recht groß. Um diesen 
neuen Dimer hinsichtlich der Kristallisation abzuklären, wurden die Eigenschaften in Lösung mittels 
Kleinwinkelröntgenstreuung untersucht. Dabei konnte der Kopf-Kopf Dimer verfiziert werden. 
 
Um die Substraterkennung zu studieren, wurde hier ein Modell des aktiven Zustands erstellt. Gezeigt 
werden die ATP- und GTP bindenden Aminosäuren Asn106 und Gln57, die beide Substrate erkennen 
können, wenn die Seitenketten jeweils um 180° gedreht werden. Eine Diskussion der homologen AC-
Strukturen zeigt, dass im Gegensatz zum üblicherweise identifizierten achtsträngigen β-Faltblatt der 
Klasse III-ACs bei Rv0386 CHD β-Strang β5 fehlt. Bei den gegenläufigen Dimeren trägt β5 zum 
Interface bei, was vermuten läßt, daß β5 in Rv0386 beim Übergang vom inhibierten zum aktiven 
Zustand gebildet wird. Da β5 zusätzlich das katalytische Asn106 trägt, kann diese Region als 
Aktivitätsschalter während der Interaktion der Monomere im katalytischen Dimer angesehen werden. 
Um vom inaktiven Dimer zum katalytisch aktiven Dimer zu gelangen, müsste man eines der 
Monomeren um 48,2° drehen und 16,8 Å entlang der Rotationsachse verschieben. 
 
Kristallisation wurde mit zusätzliche Substraten oder Inhibitoren versucht. Allerdings scheint der 
Kopf-Kopf Dimer von Rv0386 CHD so stabil zu sein, dass der gegenläufige Dimer des aktiven 
Zustands nicht gebildet wird, sogar nach dem Versuch, die Substrat-Bindungsstellen zu besetzen. Co-
Faktor Mangan ist notwendig für die Katalyse von Rv0386 CHD in vitro. Unerwarteterweise wird in 
dieser Arbeit gezeigt, dass Mangan zusätzlich das Oligomerisierungsverhalten beeinflusst. In 
Gegenwart von Mn2+ ist Rv0386 CHD ein Monomer, wie über Gel-Chromatographie, analytische 
Ultrazentrifugation und Kleinwinkelstreuung nachgewiesen. Versuche, den Monomer über Zugabe 
von Substrat-Analoga in den Dimer zu überführen, führte zu Kristallen, die jedoch für die Analyse 
noch weiter verbessert werden müssten. 
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5´GMP  guanosine 5’monophosphate 
GPCR  G-protein coupled receptor 
Gs  stimulatory heterotrimeric G protein  
GTP guanosine triphosphate  
 ix
HAMP histidine kinases, adenylyl cyclases, methyl-accepting 
chemotaxis proteins and phosphatases 
HCO3- bicarbonate 
Hepes 4-(2-hydroxyethyl)piperazine-1-ethanesulphonic acid  
HisK  histidine kinase domains 
HIV human immunodeficiency virus 
HR highest resolution bin 
H.sapiens Homo sapiens 
HTH helix-turn-helix DNA binding domain  
IPTG isopropyl-thio-β-D-galactopyranoside  
I(q) scattering intensity 
KanR kanamycin resistant 
kD kilodalton 
Kd dissociation constant 
λ wavelength 
mAC mammalian adenylyl cyclase 
MAD multiple anomalous dispersion 
MDR multidrug-resistant 
Me metal binding 
MtAC AC from M.tuberculosis  
M. tuberculosis Mycobacterium tuberculosis 
Mw molecular weight 
N-His N-terminal histag 
NMR nuclear magnetic resonance 
OD600 optical density at λ = 600 nm 
ON over night 
Pα α-phosphate 
Pβ β-phosphate  
PAM protein associated with Myc 
PBS phosphor-buffered saline 
PCR polymerase chain reaction  
PDB protein database  
PDE  phosphodiesterase 
PEG polyethylene glycol  
Pγ γ-phosphate   
PKA protein kinase A 
PKC protein kinase C  
PP2B protein phosphatase 2B 
PPi pyrophosphate 
PPIase protein cis-trans peptidylprolyl isomerase 
P(q) form factor 
PVDF polyvinylidene difluoride  
rAC receptor-type membrane bound adenylyl cyclases 
r.m.s.d root mean square deviation 
RGS regulator of G protein signaling 
Rv0386 AC of M. tuberculosis, open reading frame number 386 
Rv1264 AC of M. tuberculosis, open reading frame number 1264 
Rv1900c AC of M. tuberculosis, open reading frame number 1900 
sAC soluble adenylate cyclase 
SAD single anomalous dispesion 
 
 x
SAXS small angle X-ray scattering 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel 
electrophoresis  
SeMet L-selenomethionine 
S(q) structure factor 
TB tuberculosis 
T.brucei Trypanosoma brucei 
6TM domain with 6 transmembrane helices 
TPR tetratricopeptide repeat domain 
Tr transition state 
TRIS tris-(hydroxymethyl)-aminomethane  
VE retention volume 
Vmax maximum velocity at infinite substrate concentration  
 
 
 
Abbreviations for Residues 
 
1 letter code 3 letter code Full name 
 
A  Ala  Alanine  
C  Cys  Cysteine  
D Asp  Aspartic acid  
E  Glu  Glutamic acid  
F  Phe  Phenylalanine  
G  Gly  Glycine  
H  His  Histidine  
I  Ile  Isoleucine  
K  Lys  Lysine  
L  Leu  Leucine  
M  Met  Methionine  
N  Asn  Asparagines  
P  Pro  Proline  
Q  Gln  Glutamine  
R  Arg  Arginine  
S  Ser Serine  
T  Thr  Threonine  
V  Val  Valine  
W  Trp  Tryptophane  
Y  Tyr   Tyrosine  
X   any residue  
aa   amino acid   
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Chapter 1 
 
 
INTRODUCTION 
 
 
_________________________________________________________________________ 
 
 
1.1 Adenylyl Cyclases 
 
1.1.a Intracellular Signals  
In the late 1950’s Sutherland and coworkers discovered the ubiquitous second messenger 3´,5´-
cyclic adenosine monophosphate (cAMP), which lead to the essential milestone for the prototype 
of hormone signaling through second messengers (Rall and Sutherland, 1962). Sutherland’s 
finding gave him the Nobel prise in 1971. The discovery that 3’,5’-cyclic guanosine 
monophosphate (cGMP) is as well substantial in signal transduction came shortly after the cAMP 
finding. The enzymes adenylyl cyclase (AC, EC 4.6.1.1) catalyses the synthesis of cyclic AMP 
and pyrophosphate (PPi) from adenosine triphosphate (ATP) (Rall and Sutherland, 1962) and 
guanylyl cyclase (GC, EC 4.6.1.2) catalyses the synthesis of cyclic GMP and PPi from guanosine 
triphosphate (GTP). Both cAMP and cGMP are degraded by cyclic AMP/GMP 
phosphodiesterases (PDEs) to adenosine 5’monophosphate (5’AMP) and guanosine 
5’monophosphate (5’GMP) respectively (Conti and Jin, 1999). 
 
Intracellular receptors such as cyclic nucleotide-dependent protein kinases, PDEs, cyclic 
nucleotide-gated ion channels, Rap1 guanine nucleotide-exchange factor (EPACs), (de Rooij et 
al., 1998) cGMP phosphodiesterases adenylyl cyclases and formate-hydrolase transcription 
activator (GAF) domains, can be activated by eukaryotic cAMP and cGMP. The key regulators 
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of these signaling pathways are kinases and their activation by second messengers initiate a 
cascade of downstream events resulting in a cellular response. Protein kinase A (PKA) regulates, 
sugar, glycogen and lipid metabolism and protein kinase C (PKC) regulates cell division and 
proliferation. As the second messenger cAMP controls many important functions in the cell, the 
significance of ACs is highlighted.  
 
 
1.1.b Adenylyl Cyclase Signaling Pathway in Mammals 
Mammalian and bacterial adenylyl cyclases are regulated in different manners. So far, the 
regulation of prokaryotic ACs is not very well understood. In contrast, the regulation of 
mammalian adenylyl cyclases (mACs) is most studied and will be described in the following 
paragraphs. G-protein coupled receptors (GPCRs) are found in all eukaryotes and belong to the 
largest family of cell surface receptors. They are known to be integral membrane proteins that 
comprise seven transmembrane helices and can be activated by a range of ligands, such as light, 
calcium, amino acids, fatty acids, neurotransmitters (serotonin), hormones (dopamine, adrenalin), 
odorants, pheromones, small molecules and proteins. The same ligand can activate many 
different G-protein linked receptors.  
 
Upon binding of an extracellular ligand to a GPCR, the receptor alters its conformation and 
activates the stimulatory heterotrimeric G protein (Gs) comprising subunits α, β and γ (Figure 
1.1). In doing so, Gsα releases GDP replacing it with GTP. GTP binding causes the G protein to 
dissociate into two activated components, Gα and Gβγ. The concomitant conformational change 
of Gα allows the interaction with its target proteins. The Gβγ conformation is not altered, but the 
functional surface interacting with Gα is now accessible. Target proteins of the dissociated G 
proteins are enzymes or ion channels localised in the plasma membrane. The active Gα binds to 
and stimulates the enzyme adenylyl cyclase to convert ATP to the second messenger cAMP. The 
lifetime of the active Gα is short, its GTPase activity is stimulated when bound to adenylyl 
cyclase. GTP hydrolyses to GDP, inactivates Gα and AC, and Gα reassociates with Gβγ. In most 
cells cAMP is found at a concentration of approximately 10-7 M in the cytosol. Cyclic AMP 
activates mainly cyclic–AMP-dependent PKA. The binding of four cAMPs to the regulatory 
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subunits of PKA, leads to a conformational change dissociating the regulatory from the catalytic 
subunits in order to activate the catalytic subunits of the kinase (Alberts et al., 2002).  
 
In addition, to stimulatory G protein (Gs) there is an inhibitory G protein (Gi). There are GPCRs, 
such as α2-adrenergic receptors that are coupled to adenylyl cyclase by an inhibitory G protein 
inhibiting the activity of the adenylyl cyclase. The Gi protein comprises the subunits β and γ, just 
as Gs, but Gi has a different α (αi), which inhibits the adenylyl cyclase. The complex of βγ 
dissociated from Gi, acts inhibitory by binding to free αs (Gs) available in the proximity.  
 
 
 
Figure 1.1: Adenylyl cyclase signaling pathway. An extracellular ligand binds to a G-protein coupled receptor (GPCR) 
which changes the conformation of the receptor and alters the conformation of the heterotrimeric G protein bound to 
the receptor. The G protein releases its bound GDP and replaces it with GTP, resulting in an activation and dissociation 
of Gα from Gβγ. The active Gα activates adenylyl cyclases, which in turn converts ATP to cAMP. The second 
messenger cAMP activates downstream proteins, such as cyclic AMP dependent protein kinases, phosphodiesterases, 
ions channels, exchange proteins directly activated by cAMP (EPAC) and cGMP phosphodiesterases adenylyl cyclases 
and formate-hydrolase transcription activator (GAF) proteins. 
INTRODUCTION 
___________________________________________________________________________ 
4
1.2  Classification of Adenylyl Cyclases 
 
In eukaryotic and eubacterial organisms adenylyl cyclases play an important role in signal 
transduction (Barzu and Danchin, 1994; Sunahara et al., 1996). On the basis of the amino acid 
sequence adenylyl cyclases are classified into three groups (Danchin, 1993). Recently, these were 
expanded into six classes based on homology and structural organisation (Cotta et al., 1998; 
Sismeiro et al., 1998; Tellez-Sosa et al., 2002).  
 
Class I adenylyl cyclases, “the enterobacterial class”, is highly conserved in enterobacteria 
(Baker and Kelly, 2004) and in many gram-negative bacteria (Barzu and Danchin, 1994). Class II 
adenylyl cyclases, present in the pathogens Bacillus anthracis (Gram-positive bacterium causing 
anthrax) and Bordetella pertussis (Gram-negative bacterium causing whooping cough) is for its 
occurrence called “the toxic class”. Class III adenylyl cyclases, the “universal class” are found in 
prokaryotes and eukaryotes. Class III are closely related to guanylyl cyclases (Linder and 
Schultz, 2003; Schultz et al., 1992) which suggest that guanylyl cyclases and adenylyl cyclases 
share a common ancestor. Class IV to VI are all found in microbes, but have not been studied 
extensively and contain only a single species each. The class IV AC is present in Aeromonas 
hydrophila (Sismeiro et al., 1998), class V adenylyl cyclase is found in Prevotella ruminicola 
(Cotta et al., 1998) and class VI AC in Rhizobium etli (Tellez-Sosa et al., 2002). ACs class I-III 
are sufficiently characterised and introduced in the following sections. 
 
 
1.2.a AC Class I  
The class I adenylyl cyclases are highly conserved. They occur in the human pathogens 
Salmonella typhimurium, Yersinia pestis and Escherichia coli and the Gram-negative bacteria 
Aeromonas hydrophila and Vibrio cholerae (Danchin, 1993). 
 
Class I adenylyl cyclases are characteristically rich in cysteine and histidine residues and 
consisting of two domains (Roy et al., 1983). The catalytic domain is situated at the N-terminus 
and the glucose sensitive regulatory domain at the C-terminus. The enzyme is activated by 
phosphorylation by an important histidine, located in the regulatory domain (Danchin, 1993). 
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The adenylyl cyclase CyaA of E. coli is regulated by glucose. Low levels of glucose increases the 
synthesis of cAMP and high glucose levels inhibit the AC. High levels of cAMP contribute to 
transcriptional activation of the catabolite gene activator protein (CAP). CAP activates genes that 
enable Escherichia coli to use alternative carbon sources, when the favoured glucose is 
unavailable. The complex of cAMP and CAP binds to specific DNA sequences near target 
promotors and thereby initiates transcription of various genes, including the lac operon. In this 
way, the level of cAMP in the cell determines if the expression of the target gene is switched on 
or off (Alberts et al., 2002; Baker and Kelly, 2004). So far, structural information from class I 
adenylyl cyclases is lacking.   
 
 
1.2.b AC Class II  
Class II ACs are present in Gram-negative bacterium Bordetella pertussis, causing whooping 
cough and the Gram-positive bacterium Bacillus anthracis causing anthrax. The AC toxins share 
structural and functional characteristics and they are activated by the host protein Ca2+ binding 
calmodulin (CaM), which is not present in bacteria (Glaser et al., 1988; Kather and Aktories, 
1983; Mock et al., 1988).    
 
Class II adenylyl cyclases are extracellular toxins. The enzymes are secreted, penetrating 
mammalian cells, and subsequently use mammalian CaM for activation to synthesize high levels 
of cyclic AMP. The accumulation of cAMP in the host cells disrupts the normal regulation of the 
host’s AC/PDE and intracellular signaling pathways (Ahuja et al., 2004; Barzu and Danchin, 
1994). The primary target of the ACs is the immune effector cells; CD11b+ dendritic cells which 
are the most potent antigen presenting, as well as CD8+ CTL and CD4+ T helper cells (Simsova et 
al., 2004). The ultimate goal of adenylyl cyclase toxins is to accumulate cAMP in the immune 
effector cells, which poisons the immune system and enables survival in the host. It is unknown if 
class II ACs also have an intracellular role in the pathogens (Ahuja et al., 2004; Barzu and 
Danchin, 1994).  
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Bacillus anthracis ACs comprise two domains, where the domain situated at the N-terminus is 
important for interacting with another bacterial toxin and the located domain at the C-terminus 
binds calmodulin (Ahuja et al., 2004). The crystal structures of the Bacillus anthracis anthrax 
oedema factor, a calmodulin activated AC has been determined with and without bound 
calmodulin (Drum et al., 2002). Oedema factor and mammalian ACs do not share structural 
homology. Additionally, oedema factor functions as monomer and mammalian ACs as dimers. 
 
1.2.c AC Class III  
Class III adenylyl cyclases are present in eukaryotic and prokaryotic species. The catalytic 
domain of class III ACs, also designated as the cyclase homology domain (CHD), is greatly 
diverging in their primary sequences (Barzu and Danchin, 1994; Sunahara et al., 1996) but shared 
by all class III ACs. The classification of class III was made based on Bayesian algorithms for 
multiple sequence alignment and database searching (McCue et al., 2000), suggesting class III 
adenylyl cyclases to be classified as cytoplasmic, receptor-type membrane bound and integral 
membrane proteins (Figure 1.2), as described below. 
 
Domain Organisation of Class III AC  
Two cyclase homology domains form one adenylyl cyclase with one or two active centres in the 
interface of the dimer. The active centre comprises six canonical catalytic residues involved in 
catalysis (Sunahara et al., 1998; Tesmer et al., 1999; Yan et al., 1997b). Soluble adenylyl 
cyclases (sACs) are mainly present in prokaryotes and form homodimers, with two symmetric 
catalytic centres including additional regulatory domains (Figure 1.2A). Receptor-type membrane 
bound adenylyl cyclases (rACs) do as well form homodimers with two symmetric catalytic sites 
and usually contain an additional extracellular domain (Figure 1.2B). Adenylyl cyclases arranged 
as integral membrane proteins are present in mammals and in some prokaryotes (Figure 1.2C) 
comprising 6 predicted transmembrane regions (6TM) followed by a cytoplasmic catalytic 
domain (C1, C2) in a dimeric arrangement; 6TM-C1-6TM-C2. The catalytic domains C1 and C2 
are homologous, well conserved with the sequence identity of 25 %. Biochemical and X-ray 
structures revealed that mammalian catalytic domains function as heterodimers with one 
pseudosymmetric catalytic centre and catalysis takes place at the interface of the dimer (Tesmer 
et al., 1997; Tesmer et al., 1999; Whisnant et al., 1996; Zhang et al., 1997). The function of the 
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transmembrane regions is unknown. So far, the transmembrane regions are known to localise in 
the membrane and to coordinate the interaction of the catalytic domain. The catalytic core alone 
is capable of the catalysis and it is still unknown why the transmembrane region comprise 12 
transmembrane helices, instead of two (Hurley, 1999; Tang and Hurley, 1998). Topological 
analogy to transporters has suggested a role in transmembrane transport, which has not been 
confirmed (Krupinski et al., 1989). 
 
 
AC Class IIIa-d 
Recently, a classification of class III adenylyl cyclases into subgroups IIIa to IIId has been 
presented by (Linder and Schultz, 2003) based on primary sequence alignment of cyclase 
homology domains (Figure 1.3) (Barzu and Danchin, 1994; Linder and Schultz, 2003). Six 
canonical residues have been identified important for substrate binding (Sunahara et al., 1998; 
Tesmer et al., 1999; Yan et al., 1997b). The substrate-defining residues Lys and Asp are selecting 
ATP over GTP. Two conserved Asp coordinate two metal-cofactors (Mg2+ and Mn2+), and Asn 
and Arg are involved in transition-state stabilisation. Additionally, the conserved Arg is binding 
to the γ-phosphate of the substrate. Another characteristic of class III ACs is the arm region, also 
 
Figure 1.2: Classification of class III adenylyl cyclases. Cyclic homology domains (C, C1, C2) are visible in 
green, transmembrane regions in dark blue and in light blue the extracellular -and regulatory (R) domains are 
shown. A) Cytoplasmic homodimeric ACs with two catalytic centres and additional regulatory domains attached. 
This is the most occurring subclass in prokaryotic ACs. B) Receptor-type ACs are homodimers comprising two 
catalytic centres, an extracellular domain and a single transmembrane helix. C) Integral membrane proteins 
include 6TM-C1-6TM-C2. The catalytic core contains one pseudosymmetric catalytic centre.  
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called dimerisation arm, situated in the interface of two cyclase homology domains, believed to 
be important for dimerisation of the catalytic core. Detailed descriptions of the differences in 
class IIIa-d are described below and for alignment see (Figure 1.3). 
 
AC Class IIIa 
Class IIIa adenylyl cyclases are pseudoheterodimeric in metazoans (Krupinski et al., 1989) and 
homodimeric in Mycobacterium tuberculosis (Guo et al., 2001) and the cyanobacterium Spirulina 
platensis (Kasahara et al., 2001). Distinctive signature motifs are the predicted (F/Y)XX(F/Y)D 
motif which seems to be important for interface formation (Tang et al., 1995; Tesmer et al., 1997) 
and the EKIK motif comprising the substrate defining lysine (underlined). Furthermore, class IIIa 
catalytic homology domains contain the conserved arm region (Tesmer et al., 1997) which is 14 
residues in length.  
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Figure 1.3: Sequence alignment of class III AC cyclase homology domains, sub-categorised in class IIIa-d. Residues similar 
in all cyclase homology domains have black background and conserved residues specific for its class are depicted in green for 
class IIIa, cyan for class IIIb, yellow for class IIIc and in red for class IIId. The six canonical residues are marked with Me: 
metal binding, Ad: adenine/purine binding, Tr: transition-state stabilising. The conserved Arg involved in γ-phosphate (Pγ) 
binding in class IIIa, IIIc and IIId is as well defined. The arm region is shown as a top bar, between the conserved Gly and the 
downstream adenine binding region. Image taken from (Linder and Schultz, 2003). 
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AC Class IIIb 
Class IIIb ACs are present in Gram-negative bacteria, Gram-positive bacteria like M. 
tuberculosis, protozoa like Plasmodium and in mammals. The characteristics of class IIIb cyclase 
homology domain is a replacement of the substrate–defining aspartate with a threonine or serine 
(Kanacher et al., 2002). Additionally, a phosphate–binding arginine is frequently replaced by a 
serine or glycine and the arm region mentioned above comprises 15 residues (Linder and Schultz, 
2003).  
 
AC Class IIIc 
Class IIIc adenylyl cyclases have been detected in Gram-negative and Gram-positive bacteria. 
The arm region is completely absent or shortened to only 7-11 residues (Linder et al., 2002; 
Linder and Schultz, 2003). Furthermore, several cyclase homology domains contain substitutions 
in the six canonical catalytic residues, suggestive of a number of different catalytic mechanisms 
(Linder and Schultz, 2003). 
 
AC Class IIId  
Class IIId ACs are present in trypanosomatids, protozoan and fungi (Naula et al., 2001). This 
class comprises a YEVKT motif which is a prominent signature sequence, neighbouring the 
substrate-defining lysine. The arm region usually contains 14 residues (Linder and Schultz, 
2003). An additional feature of this class is the ∆-subdomain (Bieger and Essen, 2001), existing 
in the trypanosomal cyclase homology domain. Interestingly, fungal class IIId does not contain 
any ∆-subdomain. So far, the function of this subdomain is unknown. 
 
 
 
1.3 Regulation of Class III Adenylyl Cyclases 
 
1.3.a Adenylyl Cyclase Class III Enzyme Cycle  
Mammalian class III adenylyl cyclases have ten different isoforms (AC I-AC X) (Sunahara and 
Taussig, 2002) and they are until now the best biophysically and biochemically characterised 
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ACs (Hurley, 1998; Sunahara et al., 1996; Tang and Gilman, 1992). The cytoplasmic catalytic 
core has mainly been studied, resulting in a model of the enzyme cycle (Figure 1.4) (Tang and 
Hurley, 1998).  
 
 
 
Mammalian adenylyl cyclases are present in the ground state (E), substrate-free activated state 
(E*) and substrate/product bound state (E**) (Tesmer et al., 1997; Zhang et al., 1997). The 
conformational transition of the cyclic homology domain from E to E* arise by activators or is 
blocked by inhibitors. Mammalian cyclase homology domains are activated by Gsα, Gβγ 
(interacting with Gsα), forskolin, Ca2+ -calmodulin and inhibited by Giα, Gβγ (interacting with 
Giα) and free Ca2+. The E* to E** transition occurs on substrate binding, which induces a 
conformational change required for catalysis to proceed. In the E** state ATP is converted to 
cAMP. The E* state is reformed after the release of the products cAMP and PPi (Tang and 
Hurley, 1998).  
 
Mammalian cyclase homology domains bind to ATP with affinity in micromolar range. P-site 
inhibitors are known adenosine analogs, named according to the intact purine ring (Desaubry et 
 
Figure 1.4: Model of the adenylyl cyclase catalysis cycle.  The apo-form of the enzyme (E) converts 
to the semi-activated state (E*) by an activator like Gsα. E* changes to the fully activated state (E**) 
in the substrate (ATP) bound form. Subsequently catalysis takes place and forms the products cAMP 
and pyrophosphate (PPi).  Adenosine analogs (A) are known as P-site inhibitors. Figure taken from 
(Tang and Hurley, 1998). 
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al., 1996b; Johnson et al., 1979; Johnson et al., 1989; Londos and Wolff, 1977; Wolff et al., 
1981)and bound in their product release state (E**:PPi). P-site inhibitors and cAMP compete to 
bind to the P-site of adenylyl cyclases in the presence of PPi. Interestingly, the adenosine analogs 
are not competing for the substrate binding in the absence of PPi. The pyrophosphate enhances 
the binding of P-site inhibitors, which have nanomolar affinity to the adenylyl cyclase. In 
contrast, cAMP is binding with low affinity (usually about 20 mM) to the enzyme (Dessauer and 
Gilman, 1997). The enzyme cycle outlined is not applicable for prokaryotic adenylyl cyclases, 
hence the low affinity of P-site inhibitors for bacterial adenylyl cyclases (Kanacher et al., 2002; 
Sinha et al., 2005). This is suggestive of a different E** state or no E** state for the prokaryotic 
adenylyl cyclases.  
 
 
1.3.b Regulation of mammalian Adenylyl Cyclases 
The mACs are postulated to be important for learning, memory, olfaction, drug dependency, 
long-term potentiation, sperm capacitation and synaptic plasticity (Sunahara and Taussig, 2002). 
Some prokaryotic ACs are regulated by the same effectors as the mammalian ACs. For 
comparison, a detailed description of the mammalian adenylyl cyclase effectors follows. 
Mammalian adenylyl cyclases are regulated via modulators, such as the heterotrimeric G protein 
(Gαβγ), P-site inhibitors, forskolin, pyrophosphate, calcium, calcium-calmodulin, bicarbonate, 
other proteins and posttranslational modification (Table 1.1).  
 
Stimulation by Gsα 
The GTP-bound G-protein α-subunit Gsα is known to activate all mammalian adenylyl cyclases 
(E to E*), except the soluble AC type X (Sunahara and Taussig, 2002). The complex of Gsα-GTP 
binds into the groove of the catalytic domain C2 including α2, α3 and the N-terminal catalytic 
domain C1 (Figure 1.5). The Gsα binding site is about 30 Å away from the catalytic site (Tesmer 
et al., 1997; Yan et al., 1997a; Zimmermann et al., 1998). The Gsα regions contributing to the 
binding is switch II, including α2 and the loop regions of α4/β6 and α3/β5. Switch II is highly 
mobile and is one of the regions that changes conformation upon binding to GTP (Berlot and 
Bourne, 1992; Lambright et al., 1994). It has been demonstrated that Gsα in the GTP-bound form 
activates the AC 10-fold compared to the GDP-bound form (Sunahara et al., 1997a). After the 
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GTP hydrolysis the dissociation of the Gsα from the AC takes place and Gsα reassembles with 
Gβγ. Subsequently, the signalling of Gsα and Gβγ is abolished. A specific regulator of G protein 
signaling (RGS), PXI-RGS serves as GTPase-activating proteins (GAP) for Gsα (Zheng et al., 
2001), and increases the low intrinsic hydrolysis rate. As a consequence, Gsα is inactivated. The 
GTPase activity of Gsα can weakly be increased by the adenylyl cyclase itself (Scholich et al., 
1999). 
 
 
 
Inhibition by Giα 
The members of the inhibitory G protein family, Giα include Giα1, Giα2, Giα3, Goα, Gzα and inhibit 
adenylyl cyclases (E state) (Sunahara and Taussig, 2002). Giα does not compete with Gsα for the 
binding to the enzymes. Instead, structural modelling and mutagenesis experiments propose a 
binding site for Giα, located in the crevice formed by α2 and α3 of C1, symmetrically opposite of 
the AC compared to Gsα, (Dessauer et al., 1998; Tesmer et al., 1997; Yan et al., 1997a). The Giα 
binding site is close to the AC active site. A rotation of the C1 catalytic domain is proposed as the 
inhibitory mechanism (Hurley, 1999) resulting in a prevention of ATP binding.  
 
 
Class Regulator H. sapiens ACs Effects 
Gs
α
 All except X + 
I - Gβγ 
II, IV, VII + 
Gi
α
 I, V, VI - 
Go
α
 I - 
G proteins  
Gz
α
 I, V - 
Forskolin All except IX, X + Small chemicals  
Adenosine All - 
PKA, PKC II, V, VI, VII +/- 
Ca
2+
/CaM I, V, VI, VIII +/- 
Feedback inhibition  
PP2B IX - 
Table 1.1: Regulators of mammalian adenylyl cyclases. ACI-X are regulated by a number of effectors, 
either stimulating or inhibiting the activity. PKA = protein kinase A, PKC = protein kinase C, PP2B = 
protein phosphatase 2B.  Taken from (Findeisen, 2005).
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Figure 1.5: The catalytic core of mammalian AC (VC1 and IIC2) in complex with bound ATP analog, forskolin 
in the interface if the heterodimer and Gsα · GTP analog (PDB: 1CJK). C1, C2 and Gsα are rendered in blue, 
grey and green respectively. The ATP analog and the activator forskolin are colored in yellow and violet 
respectively. The α1-helix in C1moves upon substrate binding and is displayed in magenta.  The switch II region 
(in orange) of the Gsα-GTP complex binds into the cavity of the C2 domain including α2, α3 and the N-terminal 
catalytic domain C1. 
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Regulation by Gβγ 
The G protein Gβγ subunits are strong modulators of adenylyl cyclases. They can act stimulatory 
or inhibitory depending on the AC type (Gao and Gilman, 1991; Tang and Gilman, 1991). The 
Gβγ heterodimer has proven to be the most potent negative regulator of AC type I and AC type 
VIII (E state), thus overriding the effect of forskolin, Ca2+-calmodulin and Gsα (Sternweis and 
Robishaw, 1984; Sunahara and Taussig, 2002). Shortly after the disassociation from Giα, Gβγ 
activates AC II, AC IV and AC VII, but only in presence of Gsα (E to E*), suggesting Gβγ 
enhances the capacity of Gsα to activate AC (Sunahara and Taussig, 2002). The Gβγ binding site 
of AC type II has been located with peptide competition studies (Chen et al., 1995). This region 
flanks the β3-α3 loop and the first two-thirds of the α3-helix (Zhang et al., 1997)is the proposed 
binding site for Gβγ close to the Gsα site, but the binding sites do not overlap (Hurley, 1999). 
 
Regulation by Forskolin 
The dipterine forskolin from the Ayurvedic herb Coleus forskohlii is a powerful, hydrophobic, in 
vitro activator of all mACs, except AC IX and AC X. The forskolin binding site is located on one 
moiety and the substrate binding catalytic site is located on the other moiety of the enzyme 
(Figure 1.5) (Tesmer et al., 1997). Forskolin binds in a hydrophobic crevice located in the 
interface of the cyclase homology domain (Liu et al., 1997; Sunahara and Taussig, 2002; Tesmer 
et al., 1997). Forskolin activates adenylyl cyclases (E to E*) by gluing the two catalytic domains 
C1 and C2 together and making hydrophobic and hydrogen bonding interactions (Zhang et al., 
1997). The AC residues binding forskolin are conserved in all types, with minor differences in 
AC type IX (Hurley, 1999). Type IX is not activated by forskolin, since the forskolin binding 
residues Ser and Leu are altered. Site-directed mutagenesis of Ala to Ser and Tyr to Leu, results 
in an activation of AC type IX with forskolin (Yan et al., 1998). 
 
In contrast to mammalian ACs, biochemical assays in vitro have shown that adenylyl cyclases 
from M. tuberculosis are not activated by forskolin (Castro, 2004; Linder), probably due to the 
substitution of the forskolin binding residue Ser to Asp in mycobacterial ACs.  
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Regulation by P-site inhibitors 
A class of adenosine analogs, known as P-site inhibitors, inhibit the activity of adenylyl cyclases, 
without competing with ATP for binding (Dessauer and Gilman, 1997; Florio and Ross, 1983; 
Londos and Wolff, 1977). Most of the P-site inhibitors lack one or more hydroxyl groups with 
respect to the ribose. The most potent are polyphosphorylated at the 3’-position, lack a 2’-
hydroxyl group (Desaubry and Johnson, 1998; Desaubry et al., 1996a; Desaubry et al., 1996b), 
and are analogs of cAMP (Desaubry et al., 1996a). P-site inhibitors inhibit the enzymes by 
binding to the conformation of the adenylyl cyclases that strongly resembles the posttransition 
state or product bound state (E**:PPi). The inhibitor binding is enhanced by the presence of 
pyrophosphate (Dessauer et al., 1999). It has been found that all AC isoforms, except the soluble 
AC X are inhibited by P-site inhibitors (Sunahara and Taussig, 2002). The soluble ACs from M. 
tuberculosis are not inhibited by P-site inhibitors. Canonical substrate binding residues vary in 
mammalian and mycobacterial ACs, which might give differences in potency of P-site inhibitors 
and possibly different catalytic mechanisms (Linder and Schultz, 2003). This could be important 
for drug development of mycobacterial ACs.  
 
Regulation by Pyrophosphate 
Adenylyl cyclase converts ATP to pyrophosphate and cyclic AMP. It was revealed that the rate-
limiting step is the release of pyrophosphate (Dessauer and Gilman, 1997). Therefore, high 
concentrations of pyrophosphate have been used to force the enzyme into the product-bound 
conformation and hinder ATP binding. Additionally, compounds such as foscarnet or 
phosphonoformic acid mimic pyrophosphate and are as well inhibiting the activity of AC 
(Kudlacek et al., 2001).  
 
Regulation by Ca2+-calmodulin 
Ca2+-calmodulin stimulates activity of AC I, AC VIII and probably AC III (Cali et al., 1994; Choi 
et al., 1992; Krupinski et al., 1989). Some agents, elevating Ca2+ levels in the cells are not able to 
activate Ca2+ sensitive ACs. In contrast, voltage-gated Ca2+channels stimulated by the change in 
the voltage across the membranes are effective in activating these AC isoforms (Fagan et al., 
2000; Gu and Cooper, 2000). In conclusion, Ca2+-sensitive ACs detect and respond to 
capacitative cation entry rather than global cytosolic cation concentrations (Gu and Cooper, 
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2000). Non-physiological concentrations of Ca2+ (mM) inhibit all ACs, but AC V and AC VI are 
inhibited by micromolar Ca2+ concentrations (Cooper et al., 1998). 
 
Regulation by Posttranslational Modification 
Posttranslational modification such as glycosylation, phosphorylation and S-nitrosylation are 
regulating the activity of ACs. Protein kinases phosphorylate ACs, mainly resulting in an 
inhibitory effect. The cyclic–AMP-dependent protein kinase A (PKA) inhibits AC V and AC VI 
through a negative feedback mechanism (Chen et al., 1997; Iwami et al., 1995). 
 
Regulation by Bicarbonate and Ca2+ 
The soluble mammalian AC type X (Buck et al., 1999) is not regulated by G proteins, hormones, 
P-site inhibitors or forskolin, but strongly activated by bicarbonate and Ca2+. AC X comprises a 
catalytic domain at the N-terminus and a domain at the C-terminus with an unknown function 
(Sunahara and Taussig, 2002). Based on amino acid analysis, AC type X has the highest 
similarity to the ACs from cyanobacteria. Furthermore, the cyanobacterial ACs are regulated by 
bicarbonate (Chen et al., 2000) and it has been suggested that AC type X functions as a metabolic 
sensor, resembling cyanobacterial ACs (Zippin et al., 2001).  
 
Regulation by Other Proteins 
Recently, several proteins have been identified to interact directly with adenylyl cyclases. They 
were identified through yeast two-hybrid and copurification experiments using the catalytic core 
as baits. The biological significance of the adenylyl cyclase interaction partners has yet to be 
determined. The protein associated with Myc (PAM) is a very potent inhibitor of AC type I and 
V (Scholich et al., 2001) and the E. coli protein cis-trans peptidylprolyl isomerase (PPIase) SlyD 
is interacting and inhibiting AC type VII (Yan et al., 2001). The interaction of the RGS2 protein 
and AC III is of higher importance (Sinnarajah et al., 2001), since the RGS proteins are known to 
increase the GTPase activity of the heterotrimeric G proteins Gαi and Gαq (Ingi et al., 1998; Kehrl 
and Sinnarajah, 2002). 
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1.3.c Regulation of ACs from M. tuberculosis 
There is a great interest in adenylyl cyclases from Mycobacterium tuberculosis (MtACs), mostly 
since regulatory processes involving cAMP seem important in this human pathogen as derived 
from the high number of predicted ACs, compared to other organisms of similar genome size. 15 
putative ACs have been found in the M. tuberculosis genome of 4400 genes (Cole et al., 1998) 
compared to the E. coli genome of 4300 genes containing only one AC, and the more complex 
organism of Homo sapiens comprising only 10 ACs in a genome of 28 000 genes. All 15 putative 
ACs from M. tuberculosis belong to class III (Table 1.2), and one of the adenylyl cyclases is 
receptor-type membrane bound, five are integral membrane proteins and nine are cytoplasmic. So 
far, nine ACs from M. tuberculosis have shown to posses in vitro AC activity e.g Rv1318c, 
Rv1319c, Rv1320c, Rv3645, Rv2212, Rv1900c (Linder et al., 2004; Motaal, 2006; Sinha et al., 
2005)Rv1625c, Rv1264 (Guo et al., 2001; Linder et al., 2002; Reddy et al., 2001) and Rv0386 
presented in this thesis (Castro et al., 2005) (Table 1.2). The high number of ACs in M. 
tuberculosis suggests that the pathogen has the ability to sense and respond to extracellular and 
intracellular signals through cAMP and that cAMP signalling is of high importance in the 
pathogenic agent (McCue et al., 2000).  
 
 
Regulation of Integral Membrane, Receptor-Type and Soluble MtACs 
In contrast to eukaryotic ACs the prokaryotic ACs are not regulated via protein kinase C and G-
protein coupled receptor (GPCR)- G-protein signal transduction pathways, (Cooper, 2003) since 
the GPCR-G-protein pathway is not existing in prokaryotes. Interestingly, adenylyl cyclases 
Rv2435c and Rv1625c from M. tuberculosis are classified as integral membrane proteins, 
possibly responding to extracellular signals and regulated by GTPases (G proteins). Sequence 
alignment of Rv1625c illustrates a similarity to eukaryotic ACs and suggests a horizontal gene 
transfer from eukaryotes, as a survival advantage for the pathogen. Receptor-type membrane 
bound ACs resemble the eukaryotic receptor guanylyl cyclases and are supposed to sense 
extracellular signals (McCue et al., 2000). From the genome sequences of prokaryotic soluble 
ACs, several regulatory domains directly attached to the catalytic domains have been identified. 
These regulatory domains and intracellular signals seem to regulate the catalytic domains of 
prokaryotic soluble ACs (Linder and Schultz, 2003). Additionally, the genome sequence of M. 
INTRODUCTION 
___________________________________________________________________________ 
19
tuberculosis H37Rv revealed eukaryotic–like protein kinases (Cole et al., 1998) which could be 
involved in intracellular signalling pathways mediated by cAMP. 
 
 
 
All class III adenylyl cyclases from M. tuberculosis comprise a cyclase homology domain on 
either the C-terminus or N-terminus with additional one or more putative regulatory domains 
(Figure 1.6). These include a helix-turn-helix DNA binding domain (HTH), an α/β-hydrolase-
fold, transmembrane helices, histidine kinase domains (HisK), HAMP domain, GAF domain, 
PAS domain etc (Linder and Schultz, 2003). For class III AC domains, not all regulatory 
processes are understood in full detail.  
 
 
Catalytic centre 
In contrast to mammalian heterodimeric ACs comprising one catalytic centre and a forskolin 
binding site, class III adenylyl cyclases from bacteria and protozoa form homodimeric ACs with 
two catalytic centres. The catalytic residues from both cyclase homology domains form the 
catalytic centres, located in the interface of the dimer. Class III cyclase homology domains 
comprise six conserved substrate binding residues. These residues are non-conserved in a number 
of class III adenylyl cyclases from prokaryotic organisms such as M. tuberculosis (Table 1.3) 
(Linder and Schultz, 2003). Most of the noncanonical cyclase homology domains still need to be 
examined in detail (Castro, 2004). However, ACs Rv1264, Rv2212 and Rv1647 from M. 
tuberculosis comprise the same canonical residues as previously described for mammalian ACs.  
Class IIIa Class IIIb Class IIIc 
Rv1625c Rv1318c Rv0386 
Rv2435c Rv1319c  
Rv1320c  
Rv3645 
Rv891c  
Rv1358 
Rv1359 
Rv1647 
  Rv1264 
  Rv1900c 
  Rv2212 
  Rv2488c 
Table 1.2: Classification of predicted adenylyl cyclases from M. tuberculosis.  AC activity could be shown in 
vitro for ACs highlighted in grey. All 15 ACs are categorised into class IIIa-c according to (Linder and Schultz, 
2003) 
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Figure 1.6: Schematic overview of examples of class III AC domain organisation. Represented are catalytic 
domains and a variety of regulatory domains from M. tuberculosis. The cyclase homology domains (CHD) are 
indicated by subscripts according to the subclassification IIIa-d.  Dark blue bars correspond to predicted 
transmembrane helices, HAMP: tandemly arranged amphoteric α-helices present in histidine kinases, adenylyl 
cyclases, methyl-accepting chemotaxis proteins and phosphatases, hydrol: α/β-hydrolase-fold, inhib: 
autoinhibitory domain. Figure according to (Linder and Schultz, 2003). 
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Regulation by Additional Domains 
AC Rv3645 from M. tuberculosis comprises the cyclase homology domain at the C terminus in 
addition to two regulatory domains at the N terminus (Figure 1.6). Biochemical assays have 
shown that the HAMP domain fused to the cyclase homology domain increased the activity 21-
fold. The HAMP domain is a direct modulator of the AC activity. This suggests that HAMP 
domains on their own have regulatory functions and in addition function as signal transducers 
(Linder et al., 2004). The numerous additional regulatory domains could increase the activity of 
low activity ACs from M. tuberculosis in vitro. 
 
Regulation by Bicarbonate 
Recently, it was demonstrated that Rv1319c class III AC containing the purine binding residues 
Lys and Thr (Table 1.3), was responsive to bicarbonate (Cann et al., 2003). Lys is believed to 
coordinate the bicarbonate in the catalytic cleft. In contrast, mycobacterial ACs like Rv1264 and 
Rv1625c having an Asp instead of Thr did not show any activation by bicarbonate. To date, all 
ACs regulated by HCO3- contain a Thr residue (Cann et al., 2003; Chen et al., 2000) and the 
unresponsive ones instead have Asp (Chen et al., 2000). This suggests that a large number of 
prokaryotic class III ACs, namely the ones with Thr at this position could be activated by HCO3- 
Adenylyl 
Cyclases  
Metal binding Purine binding Transition-state 
stabilisation 
Rv1625c D     D K     D N     R 
Rv2435c D     N R     D  S      Q 
Rv1318c D     D K     T N     R 
Rv1319c D     D K     T N     R 
Rv1320c D     D K     T N     R 
Rv3645 D     D K     T N     R 
Rv1647 D     D K     D N     R 
Rv1264 
Rv2212 
D     D  
D     D 
K     D  
K     D 
N     R  
N     R 
Rv0386 D     D Q     N N     R 
Rv891c D     D R     L N     R 
Rv1900c D     D N     D H     R 
Rv2488c D     D Q     N D     R 
Rv1358 D     S Q     T N     C 
Rv1359 G     D Q      I N     E 
Table 1.3: Overview of the six amino acids that form the catalytic centre of class III 
adenylyl cyclases from M. tuberculosis. Deviations of the conserved catalytic residues are 
coloured in cyan. 
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(Table 1.3). Additionally, a novel mechanism is also strongly indicated. Bicarbonate is 
ubiquitous in the extracellular, intracellular milieu and is important in the prokaryotic and 
eukaryotic systems. However, it is unknown by which mechanism the organisms detect and 
respond to HCO3- (Cann et al., 2003).  
 
 
Regulation by Mn2+ 
The physiological ATP concentration in Mycobacterium tuberculosis is reported to be 1 mM 
(Reddy et al., 2001), but the intracellular concentrations of the cations Mn2+and Mg2+ are 
unknown. Biochemical assays in vitro show that many prokaryotic cyclase homology domains 
require the cofactor Mn2+ for activity (Coudart-Cavalli et al., 1997; Kasahara et al., 2001). 
However, a few bacterial and mammalian ACs use Mg2+ as a cofactor, which is most likely the 
physiologically more important cation (Dessauer et al., 1997). It has been reported that ACs from 
M. tuberculosis require millimolar concentrations of Mn2+ for activity in vitro (Guo et al., 2001; 
Linder et al., 2004; Linder and Schultz, 2003; Shenoy et al., 2004). Mn2+ is possibly 
physiologically relevant in M. tuberculosis as the genome comprises a Mn2+ transporter that may 
be responsible for Mn2+ intracellular concentrations (Cole et al., 1998; Linder et al., 2004; Reddy 
et al., 2001). It has been reported that macrophages can import Mn2+ and thus provide elevated 
levels of Mn2+ for activation of resident mycobacterial ACs. The increased concentration of 
cAMP is secreted into the macrophages, resulting in inhibition of several phagocyte-related 
processes including phagosomes-lysosome fusion (Lowrie et al., 1975) and propagation of M. 
tuberculosis in the host macrophages.  
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1.4 Structural Characterisation of Class III ACs 
 
 
1.4.a Structures of Mammalian ACs 
 
Crystal Structures 
The first X-ray structure of an adenylyl cyclase was published in 1997, containing the catalytic 
domain of rat type II AC C2 homodimer in complex with its potent activator forskolin (Zhang et 
al., 1997). Mammalian homodimers are only formed under in vitro conditions and are inactive, 
since the C1 domain is lacking and with it some of the catalytic residues essential for binding of 
ATP. The typical CHD is structurally described by a three-layer α/β sandwich: a central β-sheet 
with eight β-strands surrounded by five α-helices (Figure 1.7). Furthermore, the structure shows 
the two catalytic domains in a dimeric assembly, including forskolin in the interface of the dimer. 
The AC dimer is in a head-to-tail conformation, also called wreath-like.  
 
Subsequently, the crystal structure of the activated Gsα·GTPγS (Sunahara et al., 1997b) in 
complex with AC rat IIC2 · canine VC1 · forskolin was determined (Tesmer et al., 1997). 
Additionally, crystal structures were determined of the apo form as well as of complexes with a 
range of ATP analogs, divalent metal ions and P-site inhibitors (Tesmer et al., 2000; Tesmer et 
al., 1997; Tesmer et al., 1999).  
 
 
Active Site  
The C1 and C2 domains form the catalytic core of mammalian ACs. The active site is located in a 
deep cleft at the interface between the C1 and C2 domains, and its asymmetry is essential for the 
function of ACs. The interface occupies the active site at one end and the binding sites of 
forskolin and Gαs at the other (Figure 1.5). Forskolin and Gαs · GTP appear to be responsible for 
the orientation of the C1 and C2 domains and thereby the formation of the activated state. Upon 
binding of Gαs and forskolin the C1 domain is rotated 7° around the C2 domain, believed to 
position the active site for catalysis (Tesmer et al., 1997; Tesmer et al., 1999; Zhang et al., 1997 ). 
The active site (Figure 1.8) includes the α4, α5 helices of the C2 domain and β1, α1, β2-β3 turn 
of the C1 domain. The catalytic residues are conserved in mammalian AC isoforms. Lys938 and 
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Asp1018 are binding to the adenine ring and correspond to Glu and Cys respectively in guanylyl 
cyclases. With site-directed mutagenesis the substrate specificity for ACs can be changed from 
ATP to GTP (Sunahara et al., 1998), although GTP cannot be converted to cGMP. Due to a 
contact of the main chain carbonyl of Ile1019 to adenine–N6 which disfavours guanine. In 
contrast, the conversion of GC to AC has been demonstrated, with mutagenesis leading to 
successful conversion of ATP to cAMP (Sunahara et al., 1998; Tucker et al., 1998). The residues 
coordinating the binding of the ribose and triphosphate of the substrate are conserved in all ACs 
and GCs. Cyclase activity is severely impaired when these are substituted to non-conserved 
residues. The α-, β-, and γ-phosphate of the nucleotide are coordinated by Arg1029, Lys1065 in 
AC type IIC2 and Arg484 in AC type VC1. The residues Asp440 and Asp396 in AC type VC1 
are highly conserved and assist in coordinating the phosphates by coupling to Mg2+ and Mn2+ that 
stabilise the α-phosphate during catalysis (Tesmer et al., 1999). 
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Figure 1.7: Topology of the adenylyl cyclase homology domain, consisting of a central β-sheet enclosed by five 
α-helices. This picture is based on the PDB entry code: 1AB8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
___________________________________________________________________________ 
26
 
 
 
 
 
 
Figure 1.8: The nucleotide binding site in mammalian AC. An ATP analog rendered in yellow is located in the interface 
of canine V C1 (grey) and rat II C2 (slate)  (PDB:1CJK). Lys938, Asp1018 and main chain of Ile1019 belong to C2 and 
are specific adenine binding residues. Asn1025 C2 and Arg1029 C2 stabilise the transition state and the two divalent 
metals (spheres in green; Mg2+ and violet; Mn2+) are coordinated by Asp440 C1, Asp396 C1, main chain of Ile397 C1 and 
water (sphere in blue). Additionally, Lys1065 C2 and Arg484 C1 bind and stabilise the γ-phosphate. The 3´ hydroxyl of 
ribose is depicted in red and named 3´. 
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Catalytic Mechanism 
From the first heterodimeric AC crystal structure (Gαs · VC1 · IIC2 · 2’-deoxy-3’-AMP · PPi) 
the catalytic mechanism for the synthesis of cAMP was not obvious. Therefore, Sprang and 
co-workers decided to determine four crystal structures of the AC catalytic core with two 
different ATP analogs and various divalent metal ions (Tesmer et al., 1999).  
 
The active site of ACs resembles the active site of DNA polymerases, and it was therefore 
initiative to propose the same two-metal ion mechanism, based on the assumption of 
development from a common ancestor. The core of three out of four families of DNA 
polymerases contain a palm domain composed of the βαββαβ motif. This motif is present in 
the AC C1 and C2 domains (Artymiuk et al., 1997; Steitz et al., 1993; Steitz et al., 1994). 
Based on the various activated AC structures and a comparison with DNA polymerases, a 
model of the catalytic mechanism of adenylyl cyclases was established. 
 
A hydrogen bond is expected to be established between Asn1025 and the O4’ oxygen of ATP 
(Figure 1.8). The nucleophilicity of the 3’ hydroxyl ATP is increased by Mg2+, acting as a 
Lewis acid. The distance between Mg2+ and the 3’ hydroxyl of ribose is 2 Å. Then, the 3’ 
hydroxyl group is positioned for an in-line attack on the α-phosphate. This reaction generates 
cAMP and PPi. In Figure 1.8 the 3´hydroxyl of ribose is positioned away from Mg2+, but in 
the nucleotide bound state the 3´hydroxyl would be positioned towards Mg2+ and result in 
catalysis. Upon substrate binding, both ACs and DNA polymerases induce a transition from 
an open to closed conformation (Doublie et al., 1999; Tesmer and Sprang, 1998). The 
transition causes the breakdown of the fingers on the palm domain of DNA polymerases. For 
ACs, it has been noted that the α1 helix shifts 2 Å into the active site, upon substrate binding. 
A number of loops around ATP are as well broken down in ACs, to form the active site. The 
break down of these loops brings basic residues into the active site which stabilise the 
triphosphate of the substrate, the pentavalent phosphate transition state of the reaction, and the 
pyrophosphate leaving group. It has been suggested that Gsα induces the break down of loops 
around ATP to form a proper active site. Giα should on the other hand hinder the break down 
and stabilises thereby an open, inactive conformation (Tesmer et al., 1999). 
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1.4.b AC Structures from Trypanosoma brucei 
Cyclase homology domains from Trypanosoma brucei have been structurally determined in a 
monomeric state. Since the AC catalytic centres are situated at the interface of two monomers, 
T. brucei ACs cannot perform catalysis and therefore are in an inactive state. The structure 
has a high structural similarity to other CHDs, with the exception of an inserted ∆-subdomain 
positioned close to the active site. The ∆-subdomain comprises 36 residues, is inserted in the 
α3-β4 loop and might be an allosterically regulatory protein binding site. It is proposed that 
activation of these monomeric ACs occurs with a ligand-induced dimerisation, similar to 
membrane bound guanylyl cyclases (Bieger and Essen, 2001).   
  
 
 
1.5 AC Rv0386 from M. tuberculosis 
 
 
1.5.a Overview and Domain Organisation 
In 1998 Cole and co-workers published the whole genome of the aetiological agent, 
Mycobacterium tuberculosis H37Rv. Five genes were annotated as putative ACs including 
Rv1625c, Rv1318c, Rv1319c, Rv1320c and Rv1264. The name of the gene Rv0386 was for 
the first time noted in this genome project and assigned as a transcriptional regulator (Cole et 
al., 1998). Later, 15 putative ACs were detected with computational methods, among those 
Rv0386 (McCue et al., 2000). Rv0386 is characterised as a cytoplasmic class IIIc AC, with 
shortened dimerisation arm in the cyclase homology domain and acting as a guanylyl cyclase 
converting GTP to cGMP (Castro et al., 2005).   
 
In (Gamieldien et al., 2002) Rv0386 is placed between 19 other genes from M. tuberculosis 
that may have been acquired by horizontal gene transfer from eukaryotes. This possibly had 
survival advantages for the ancient mycobacterium, before it developed into an eukaryotic 
pathogen (McCue et al., 2000). 
 
Rv0386 comprises four domains with the molecular weight of 117 kD. The AC CHD domain 
is found at the N-terminus of the protein, followed by an AAA-ATPase domain, a 
tetratricopeptide repeat (TPR) domain and a luxR helix-turn-helix (HTH) DNA binding 
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domain at the C-terminus (Figure 1.9). Interestingly, the putative AC genes Rv1358 and 
Rv2488 from M. tuberculosis show an identical domain organisation as Rv0386.  
 
 
 
 
 
 
The AAA-ATPase domain is responsible for ATP binding and hydrolysis and has 40 % 
similarity to several prokaryotic transcriptional regulators, like AfsR from Streptomyces 
coelicolor (Horinouchi et al., 1990). The TPR domain functions as protein-protein recognition 
module in e.g. intracellular signalling and transcription control (Cliff et al., 2005). The HTH 
DNA binding domain is involved in transcriptional regulation and present in most prokaryotic 
and some eukaryotic transcription factors (Aravind et al., 2005). The regulatory domains of 
AC Rv0386 are suggested to participate in transcription (Castro, 2004). The presence of the 
helix-turn-helix DNA binding domain strongly proposes that the adenylyl cyclase Rv0386 is 
connected to a transcriptional effector.  
 
The regulatory function has not been tested in vitro due to folding problems of the 
holoenzymes, including Rv0386. How the AC domain is regulated via the additional domains 
is something that needs to be elucidated in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Domain organisation of Rv0386. The cyclase homology domain (CHD) in dark blue, the AAA-ATPase 
domain in light blue, the TPR-like domain in green and the luxR helix-turn-helix (HTH) DNA binding domain in 
violet. 
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1.6 Tuberculosis 
 
 
1.6.a History and Epidemiology 
 
Tuberculosis (TB) is accounted for about 1.7 million deaths in 2004 (World Health 
Organisation Tuberculosis Fact Sheet; http://www.who.int/topics/tuberculosis/en/,  #168). 
This life threatening disease is claiming more lives than acquired immune deficiency 
syndrome (AIDS) and malaria combined. The fear is that TB will kill 40 million people 
within the next 20 years, if a vaccine is not found (Carrington, 1999). The disease is caused 
by the pathogen Mycobacterium tuberculosis. The pathogen is latent for a couple of years and 
the risk of developing TB is highest up to two years after infection. AIDS and human 
immunodeficiency virus (HIV) increase the risk more than 100 times for developing the 
active state of TB. One third of the world’s population has latent TB, but only 5-10 % 
develops the active disease and can transmit the bacteria.  
 
Tuberculosis is also known as wasting disease, consumption and the white plague (Cole et al., 
1998). Until the mid of the 19th century, it was believed that TB was hereditary. The finding 
that TB is contagious came in 1865, and was discovered by the French surgeon Jean-Antoine 
Villemin. In 1882 the German scientist Robert Koch discovered the gram positive bacteria 
causing the disease, subsequently receiving the Nobel Prize in physiology or medicine in 
1905 for his discovery. But, it would take until 1943 for the first drug, streptomycin to be 
identified, by the American scientist Selman Waksman. Within the next ten years two further 
drugs against M. tuberculosis were discovered. This lead to an increased rate of people cured 
from TB and a decrease in mortality rates. However, in the 1980s it was noticed that the rate 
of TB infected people was rising. TB is a life threatening disease if not treated. 
 
Today, the highest TB mortality regions are in Africa. This is correlated with the high rate of 
HIV, which increases the risk of infection and death by TB. South-East Asia also has high TB 
mortality rates. The former Soviet Union countries had a rise in TB in the beginning of the 
1990s, but after 2001 it declined 
{http://www.who.int/mediacentre/factsheets/fs104/en/index.html,  #168}.  
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1.6.b Treatment 
Tuberculosis was until the 1940s untreatable and people with TB were sent to sanatoriums, 
special rest homes for treatment. Later, it was discovered that antibiotics such as isoniazid, 
rifampicin, pyrazinamid, ethambutol and streptomycin were very efficient in curing TB. In 
many countries, a vaccine program included the Bacillus Calmette-Guerin (BCG) vaccine, 
with 80% protection of TB. Tuberculosis is usually treated with a standard six months 
therapy, despite of HIV-infection using a combination cocktail of four drugs. Rifampicin and 
isoniazid are the most potent antibiotics. The standard therapy is two months medication of 
isoniazid, rifampicin, pyrazinamid and ethambutol with additional four months of isoniazid 
and rifampicin. Streptomycin is only used in case of antibiotic resistance or toxic/negative 
side effects using the other antibiotics. During the therapy, sputum is weekly controlled for 
presence of acid-fast staining bacilli by microscopy and cultural identification of M. 
tuberculosis in media. If the sputum cultures are positive after two months treatment, the 
therapy is extended to duration of nine months or more (Lange et al., 2005).   
 
It is essential that the patient makes a complete therapy, with all four antibiotics taken 
regularly, once per day for a period of at least six months. If not, the risk of developing 
multidrug resistant tuberculosis is increased. Recently, it was discovered that the former 
Soviet Union countries have new multidrug-resistant (MDR) M. tuberculosis strains resistant 
to the most powerful anti-TB drugs i.e. isoniazid and rifampicin. More than 50 million people 
worldwide are infected with MDR strains and 15% of all TB cases are caused by MDR strains 
of M. tuberculosis (Kaufmann, 2002). Drug resistant TB can be treated with chemotherapy, 
but this is an expensive therapy. Therefore, the development of new drugs is of high 
importance. 
 
 
1.6.c Pathogenesis 
 
Tuberculosis is transferred from person to person through air. Only persons with active TB 
can spread the disease, but not all exposed to M. tuberculosis become infected. There are 
three factors that determine if TB is transmitted: 1) How contagious the TB patient is. 2) The 
length of the exposure to M. tuberculosis. 3) The environment in which the exposure took 
place. 
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The main port of the entry of M. tuberculosis and the importance of disease manifestation is 
represented by the lung. The pathogen is inhaled into the lungs and travel to the alveolar 
(small air sacs of the lung) macrophages, where it is engulfed but not eliminated. In the 
draining lymph nodes specific T cells are stimulated, which induce the bacterial control in 
small granulomatous lesions of the lung. Here, M. tuberculosis is not completely eradicated 
(Figure 1.10). Instead, a balance between the host defence and the bacterial persistence 
develops, that might be lifelong. This represents the latent state of TB and does not have to 
develop into the active state of the disease (Kaufmann, 2001; Manabe and Bishai, 2000). 
Drugs cannot eliminate the pathogen in the latent state, but can decrease the risk of 
developing the active state (http://www.infektionsbiologie.ch). Once the active state of TB 
develops and remains untreated, 50% of the patients have a fatal outcome (Kaufmann, 2001; 
Manabe and Bishai, 2000). The active state of the disease develops from the latent state when 
the hosts’ immune system is weakened due to HIV infection, immune suppressive medication 
through cancer, diabetes, rheumatoid arthritis, malnourishment or great age. A person with the 
active disease infects up to 15 persons per year (Kaufmann, 2000). 
 
 
1.6.d Intracellular Lifestyle of M. tuberculosis 
Macrophages are used as a residence for M. tuberculosis which has two important 
implications for the survival of the pathogen (Schaible et al., 1999). Firstly, cholesterol is 
used by the bacteria as a docking site, promoting receptor-ligand interactions (Gatfield and 
Pieters, 2000). The primary interaction of the surface receptors influences the fate of the 
pathogen in the macrophages. The interaction with toll-like receptors and immunoglobulin 
receptors (FcRs) stimulate host-defence mechanisms. In contrast, interaction with 
complement receptors promotes the survival of the pathogen (Armstrong and Hart, 1975; 
Brightbill et al., 1999; Schorey et al., 1997; Thoma-Uszynski et al., 2001). The second 
implication is the survival mechanism of M. tuberculosis within the phagosome. Other 
microbes are eliminated within phagosomes harsh environment (Schaible et al., 1999) but M. 
tuberculosis survives, as it is able to arrest the maturation of the phagosome at an early stage 
to prevent fusion of the phagosome with the lysosomes (Figure 1.11) (Armstrong and Hart, 
1975; Ferrari et al., 1999; Harth and Horwitz, 1999; Russell et al., 1996).  
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It has been noted that the macrophage ingestion of M. tuberculosis results in an increase in 
cAMP levels and the fusion of lysosomes with the bacterium-containing phagosomes was 
impaired. The explanation is that the bacterium is defending itself from destruction by 
producing cAMP in the phagosomes (Lowrie et al., 1979; Lowrie et al., 1975). Recently, AC 
Rv1264 has been found to be active at pH 5.5 and inhibited at pH 7.5 in vitro. A suggested 
explanation is that Rv1264 is a pH sensor important for M. tuberculosis survival in the 
macrophages (Tews et al., 2005). 
 
 
 
 
 
Figure 1.10: Infection of tuberculosis and host defence. A) Abortive infection of M. tuberculosis resulting in 
spontaneous healing. B) TB develops directly after infection. C) In most cases the pathogen is contained in 
the granulomas in a latent state, and later <10% of the infected, develop the active state of TB as a result of 
reactivation. Effector T cells including CD4+, CD8+, γδ+ and macrophages participate in the control of TB. T 
cells produce the important macrophage activators: tumour-necrosis factor-α (TNF-α) and interferon-γ (IFN-
γ). This results in phagosomal maturation and production of reactive oxygen intermediates (ROI), reactive 
nitrogen intermediates (RNI), lymphotoxin-α3 (LT-α3) involved in antimicrobial defence. Recently, it was 
shown that granulysin and perforin produced from T cells, directly kills M. tuberculosis. Picture taken from 
(Kaufmann, 2001) 
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Figure 1.11: Mycobacterium tuberculosis intracellular lifestyle. This picture illustrates M. tuberculosis influence 
of the phagosome and endosome maturation process. At the early encounter between M. tuberculosis and 
macrophages a number of surface receptors are involved. The docking site between the pathogen and surface 
receptors is facilitated by cholesterol. Subsequently, the bacteria are engulfed and end up in the phagosome. The 
phagosome maturation is arrested at an early stage, caused by TACO.  The phagosomal acidification and the 
fusion with the endosomal pathway are hindered by M. tuberculosis. In some cases, the phagosomes mature to 
form phagolysosomes. This occurs in activated macrophages, especially after stimulation by INF-γ. Then, the 
phagosomal and endosomal pathways mature until the last stage is reached where the phagosome and endosome 
merge with the lysosome. MR, mannose receptor; CR, complement receptor; FcR, receptor for the constant 
fragment of immunoglobulin; SPR, surfactant protein receptor; TLR, Toll-like receptor; TACO, tryptophane, 
aspartate-containing coat protein; LAMP-1, lysosomal-associated membrane protein 1; V–H+ATPase, vacuolar 
ATP-dependent proton pump; Rab7, member of the small GTPase family;LBPA, lysobiphosphatic acid. Taken 
from (Kaufmann, 2001). 
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1.7 Goal of this Study 
 
 
15 adenylyl cyclases from M. tuberculosis are of high importance for survival of the pathogen 
in the human host. Biophysical and structural approach of mycobacterial ACs would result in 
a better understanding of this microbe causing the life threatening disease of tuberculosis and 
could consequently lead to new treatment. In the beginning of these studies the only available 
X-ray structures of AC class III cyclase homology domains were from mammals and 
Trypanosoma brucei. Rv0386 from M. tuberculosis is a multidomain protein, comprising an 
AC catalytic domain at the N-terminus, followed by an AAA-ATPase domain, TPR domain 
and a HTH DNA binding domain at the C-terminus. The dissimilarity of the substrate binding 
residues of Rv0386 compared to other ACs, and the promiscuous role choosing ATP and GTP 
as a substrate made this protein of high interest. Subsequently, this work was focussed on the 
class III cyclase homology domain of AC Rv0386 from M. tuberculosis. 
 
 
The goals of this study were: 
o Determination of the X-ray structure of the catalytic core of Rv0386. 
o Examination of the modes of substrate binding and the catalytic mechanism. 
o Comparison of the crystal structures of the catalytic domain of Rv0386 with 
homologous ACs.  
o Validation of a newly found interface, (which became available during this thesis) 
with analytical ultracentrifugation, small angle X-ray scattering and site-directed 
mutagenesis. 
o Understanding the regulation of AC Rv0386. 
o Establishing buffer conditions to define the mode of oligomerisation for probing of 
different conformations of cyclase homology domain Rv0386. 
o Characterisation and crystallisation of the CHD Rv0386 including the cofactor 
manganese and substrate analogs, hence this divalent cation probably improves the 
activity of the protein.   
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Chapter 2 
 
 
 
MATERIALS AND METHODS 
 
 
_________________________________________________________________________ 
 
 
2.1 Cloning of the Catalytic Domain of Rv0386 
 
 
2.1.a N-His CHD of Rv0386 
The catalytic domain of Rv0386 (residue 1-175) from Mycobacterium tuberculosis (GenBank 
Accession Number BX842573) is cloned between the 5´BamHI and 3´HindIII cleavage sites 
in the vector pQE30 (Qiagen) adding a N-terminal Met-Arg-Gly-Ser-His6-Gly-Ser tag. The 
amino acid sequence of this construct is shown below (Figure 2.1).  
            
  1  11 21  31  
MRGSHHHHHHGS  MSKLLPRG TV  TLLLADVEGS TWLWETHPDD  MGAAVARLDK  
41   51   61 71  81   
AVSGVIAA HD  GVRPVEQG EG DSFVLAFACA  SDAVAAALDL   QRARLAPIRL  
91  101  111 121  131 
RIGVHTGE VA  LRDEGNYA GP TINRTARLRD  LAHGGQTV LS GVTESLVIDR 
141  151  161 171 
LPDKAWLV DL  GTHALRDLSR   PERVMQLC HP  ELRID* 
 
Figure 2.1: The amino acid sequence of the N-His CHD of Rv0386 construct. The pQE30 vector and the 
residues of the catalytic domain of Rv0386 are depicted in black and blue respectively. The star is assigned for a 
stopcodon. 
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2.1.b C-His CHD of Rv0386 
The catalytic domain (1-175) is cloned into the 5´BamHI and 3´BglII restriction sites of 
vector pQE60 (Qiagen) containing a N-terminal elongation of Met-Gly-Gly-Ser and a C-
terminal Arg-Ser-His6 tag (Figure 2.2 and Figure 2.3). Both constructs (C-His CHD of 
Rv0386 and N-His CHD of Rv0386) were made by Lucila I. Castro (Castro, 2004). These two 
constructs were available through collaboration with the group of Prof. J.E Schultz, 
Universität Tübingen, Germany.  
 
 
 
 
                    BamHI 
       ~~~~~~~ 
  M  G  G  S   M  S  K   L  L  P   R  G  T  V   T  L  L   L  A  D   V  E  G  S   T  W  L   W  E  T   H  P  D  D · 
 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
       1 ATGGGAGGAT CCATGAGCAA GTTGCTGCCA CGGGGCACAG TGACATTGCT GTTGGCCGAC GTCGAGGGTT CCACCTGGCT GTGGGAGACC CATCCAGACG 
 TACCCTCCTA GGTACTCGTT CAACGACGGT GCCCCGTGTC ACTGTAACGA CAACCGGCTG CAGCTCCCAA GGTGGACCGA CACCCTCTGG GTAGGTCTGC 
 
 ·  M  G  A   A  V  A   R  L  D  K   A  V  S   G  V  I   A  A  H  D   G  V  R   P  V  E   Q  G  E  G   D  S  F · 
 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 ACATGGGTGC TGCCGTGGCG CGCCTCGACA AAGCCGTGTC TGGTGTGATT GCCGCCCATG ACGGCGTACG CCCAGTCGAG CAGGGTGAGG GTGATAGCTT 
 TGTACCCACG ACGGCACCGC GCGGAGCTGT TTCGGCACAG ACCACACTAA CGGCGGGTAC TGCCGCATGC GGGTCAGCTC GTCCCACTCC CACTATCGAA 
    101 
 
 · V  L  A   F  A  C  A   S  D  A   V  A  A   A  L  D  L   Q  R  A   R  L  A   P  I  R  L   R  I  G   V  H  T 
 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
     201 TGTCCTCGCG TTCGCCTGCG CGTCGGATGC CGTGGCCGCC GCGTTGGACT TGCAGCGAGC GCGGCTCGCA CCGATCCGGT TGCGCATAGG CGTGCACACC 
 ACAGGAGCGC AAGCGGACGC GCAGCCTACG GCACCGGCGG CGCAACCTGA ACGTCGCTCG CGCCGAGCGT GGCTAGGCCA ACGCGTATCC GCACGTGTGG 
 
  G  E  V  A   L  R  D   E  G  N   Y  A  G  P   T  I  N   R  T  A   R  L  R  D   L  A  H   G  G  Q   T  V  L  S · 
 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
     301 GGGGAGGTCG CGCTCCGCGA CGAAGGCAAC TATGCCGGTC CGACCATCAA CCGGACCGCG CGCCTGCGTG ACTTGGCGCA TGGGGGCCAG ACGGTGCTCT 
 CCCCTCCAGC GCGAGGCGCT GCTTCCGTTG ATACGGCCAG GCTGGTAGTT GGCCTGGCGC GCGGACGCAC TGAACCGCGT ACCCCCGGTC TGCCACGAGA 
 
 ·  G  V  T   E  S  L   V  I  D  R   L  P  D   K  A  W   L  V  D  L   G  T  H   A  L  R   D  L  S  R   P  E  R · 
 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
     401 CGGGCGTGAC CGAAAGCCTG GTCATCGATC GCCTCCCGGA CAAAGCATGG CTGGTTGACC TGGGGACGCA CGCGCTGCGG GATCTGTCGC GTCCGGAGCG 
 GCCCGCACTG GCTTTCGGAC CAGTAGCTAG CGGAGGGCCT GTTTCGTACC GACCAACTGG ACCCCTGCGT GCGCGACGCC CTAGACAGCG CAGGCCTCGC 
                                          BglII 
                                         ~~~~~~~ 
 · V  M  Q   L  C  H  P   E  L  R   I  D  R   S  H  H  H   H  H  H   * 
 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
     501 GGTAATGCAG CTGTGTCATC CCGAATTGCG TATCGATAGA TCTCATCACC ATCACCATCA CTAA 
 
 
CCATTACGTC GACACAGTAG GGCTTAACGC ATAGCTATCT AGAGTAGTGG TAGTGGTAGT GATT 
 
 
 
Figure 2.2: Nucleotide and translated protein sequence of the C-His CHD of Rv0386 construct are colored in 
blue. The vector sequence is depicted in black. The catalytic domain of Rv0386 has been cloned into the pQE60 
vector between the BamHI and BglII restriction sites. The figure has been created in Vector NTI.  
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pQE60/C-His CHD Rv0386
3957 bp
Ampicillin
C-His CHD Rv0386
Bam HI (123)
Bgl II (654)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Overview of the circular plasmid map of the construct pQE60/C-His CHD Rv0386 
residue 1-175. Vector NTI has been used for making the picture. 
 
 
2.1.c Rv0386 CHD(1-168) C168S 
In order to identify a construct suitable for crystallisation, the sequence of the catalytic 
domain of Rv0386 was aligned against the sequence of the crystallised catalytic domain of 
Rv1900c, both from Mycobacterium tuberculosis. The sequence of the catalytic domain of 
Rv1900c represents the resolved structure and therefore the construct of the catalytic domain 
of Rv0386 was designed accordingly. Mutation Cys168Ser was introduced to avoid possible 
formation of non native disulphide bridges.   
The shorter construct containing residue 1-168 and the point mutation Cys168Ser was 
generated by the QuickChange XL site-directed mutagenesis kit (Stratagene, Germany). The 
DNA of the holoenzyme of Rv0386(1-1085) in pQE30 (kindly provided by Lucila I. Castro, 
Tübingen Universität, Germany) was used as a template and primers carrying the desired 
mutation (Table 2.1 and 2.3) were used for the PCR. 18 cycles of PCR were performed with 
the Pfu Turbo DNA Polymerase at the annealing temperature 60 °C. The elongation 
temperature was carried out at 68 °C for 14 minutes in order to amplify the ca 7 kb DNA 
template (Table 2.2). As a negative control a sample of all components added for the PCR 
was mixed, but was not used for PCR.  
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5 µl 10 x reaction buffer 
10 ng dsDNA template 
1 µl (125 ng) Oligonucleotide primer #1 
1 µl (125 ng) Oligonucleotide primer #2 
1 µl dNTP mix 
3 µl Quicksolution 
Double destilled H2O up to a final volume of 50 µl  
1 µl Pfu Turbo DNA Polymerase (2.5 U/µl) 
Table 2.1: Polymerase chain reaction mixture for one sample. 
 
Denaturation 95 °C 1 min 
Denaturation 95 °C 50 sec 
Primer annealing 60 °C 50 sec 
 
18 cycles 
 Extension 68 °C 14 min (2 min/kb of plasmid length) 
Fill up 68 °C 7 min 
 4 °C ∞ 
                    Table 2.2: The polymerase chain reaction program. 
 
 
 
All samples (including the control) were digested with 1 µl Dpn I for 2 h at 37 °C in order to 
digest non-mutated DNA. 5µl of the Dpn I treated DNA was used for the transformation in 
XL1-Blue Supercompetent E.coli cells. If the negative control does not have any colonies, 
then all non-mutated DNA is digested and the colonies on the other transformation plates are 
positives, containing the desired construct. The construct was confirmed by DNA sequencing 
(MWG, Germany).   
 
 
2.1.d Rv0386 CHD(1-172) and  Rv0386 CHD(1-172) Cys168Ser 
The QuickChange XL site-directed mutagenesis kit (Stratagene, Germany) was used for 
making the constructs containing residue 1-172 with and without the point mutation 
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Cys168Ser. The holoenzyme Rv0386/pQE30 was used as a template for the PCR, together 
with the primers (Table 2.3). The exact procedure of making these constructs has been 
described in 2.1.c. The correct sequence of the constructs was confirmed by DNA sequencing 
(MWG, Germany).   
 
2.1.e Interface Mutants: V132A and E98A 
Two mutants on the dimerisation interface of the CHD of Rv0386 were made. V132A  
CHD(1-175) of Rv0386 and E98A CHD(1-175) of Rv0386, both in the pQE30 vector have been 
constructed and sequenced by Dr. Jürgen U. Linder, (Prof. J.E Schultz group, Tübingen 
Universität, Germany). 
 
 
Construct Forward primer Reverse primer 
Rv0386 CHD(1-168)C168S 5´  g cgg gta atg cag ctg agt tga 
ccc gaa ttg cgt atc g 3´ 
5´  c gat acg caa ttc ggg tca 
act cag ctg cat tac ccg c 3´ 
Rv0386 CHD(1-172)C168S 5´  g cgg gta atg cag ctg agt cat 
ccc gaa tga cgt atc gat  ttc ccg 
ccg 3´ 
5´cgg cgg gaa atc gat acg tca 
ttc ggg atg act cag ctg cat tac 
ccg c 3´ 
Rv0386 CHD(1-172)
 
5´  g cag ctg tgt cat ccc gaa tga 
cgt atc gat  ttc ccg ccg 3´ 
5´cgg cgg gaa atc gat acg tca 
ttc ggg atg aca cag ctg c 3´ 
Table 2.3: Primers used for cloning shorter constructs of the catalytic domain of Rv0386. Mutations and stop 
codons are depicted in bold. 
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2.2 Expression and Purification of the CHD of 
Rv0386 
 
 
2.2.a Overexpression   
The construct C-His CHD of Rv0386 was transformed into Escherichia coli strain 
BL21(DE3) (pREP4) (AmpR and KanR). Single cell streak out was performed on a LB agar 
plate containing Ampicillin and Kanamycin. A pre-culture was set up with Luria Broth (LB) 
medium containing 100 µg/ml Amp and 30 µg/ml Kan and a single colony from the single 
colony  streak out, grown at 37 °C ON. The pre-culture was inoculated into 10-20 L of LB 
medium in the presence of 50 µg/ml Carbenicillin and 30 µg/ml Kanamycin. Cells were 
grown at 37 °C until an OD600 = 0.4, then the temperature was decreased to 23 °C and the 
cells were grown to OD600 = 0.6-0.8. Prior to induction a glycerol stock was made containing 
750 µl cells and 250 µl glycerol, stored at -80 °C. The cells were induced with 100 µM 
isopropyl-β-D-thiogalactosid (IPTG), at 23 °C for 4-16 h.  
The cells were harvested by centrifugation at 5300 g (Sorvall RC12BP, rotor: Sorvall H 
12000), for 20 minutes, at 4 °C. The pellet was resuspended in cold PBS (phosphor-buffered 
saline: 150 mM NaCl, 10 mM Na/K phosphate pH 7.4) and transferred in 50 ml Falcon tubes, 
re-pelleted by centrifugation at 6500 g (Heraeus Multifuge 35-R) at 4 °C, for 60 min, flash 
frozen in liquid nitrogen and stored at -80 °C.  
The construct C-His CHD of Rv0386 has also been overexpressed in Escherichia coli strain 
B834(DE3) with LB medium, identical to the description in 2.2.a.  
 
 
2.2.b Over expression of Rv0386 CHD(1-172), Rv0386 CHD(1-172) Cys168Ser 
and  Rv0386 CHD(1-168) Cys168Ser 
Over expression was carried out with the constructs of Rv0386 CHD(1-172), Rv0386 CHD(1-172) 
Cys168Ser and  Rv0386 CHD(1-168) Cys168Ser. The constructs were transformed into the 
Escherichia coli strains Rosetta(DE3) pLysS (AmpR and CmR) and BL21(DE3) (pREP4) 
(AmpR and KanR).  
Pre-cultures were prepared with LB medium containing 100 µg/ml Amp and 30 µg/ml Kan 
for BL21(DE3) (pREP4) cells and 100 µg/ml Amp and 50 µg/ml Chloramphenicol for 
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Rosetta(DE3) pLysS cells. Additionally, a single colony was inoculated and grown at 37 °C 
ON. The pre-culture was inoculated into LB medium in the presence of antibiotics. Cells were 
grown at 37 °C until an OD600 = 0.4, then the temperature was decreased to 23 °C and 16 °C 
and the cells were grown to OD600 = 0.6-0.8. A glycerol stock was made prior to induction, 
containing 250 µl glycerol and 750 µl cells, stored at -80 °C. The cells were induced with 60 
µM isopropyl-β-D-thiogalactosid (IPTG), at 23 °C for 4 h or 16 °C, ON.  
Afterwards, the cells were harvested by centrifugation at 5300 g (Sorvall RC12BP, rotor: 
Sorvall H 12000), for 20 minutes, at 4 °C. Cold PBS (phosphor-buffered saline: 150 mM 
NaCl, 10 mM Na/K phosphate pH 7.4) was used for resuspending the pellet. The suspention 
was transferred to 50 ml Falcon tubes, centrifugated at 6500 g (Heraeus Multifuge 35-R) at 4 
°C, for 60 min, frozen in liquid nitrogen and stored at -80 °C.  
 
 
2.2.c Purification of C-His CHD of Rv0386 
10-15 grams of cells were thawn on ice and suspended in 100-150 ml lysis buffer (50 mM 
Tris-HCl pH 8.0, 50 mM NaCl, 20 mM imidazole, 5% glycerol, 5mM  β-mercaptoethanol) 
supplemented with one tablet complete protease inhibitor (EDTA free, Boehringer Ingelheim) 
per 50 ml lysis buffer. The pellet was lysed on ice with a Sonicator (Branson sonifier 250) at 
50 % duty cycle, 25 sec pulse, 25 sec pause in total 20 minutes. Cellular debris was separated 
by ultracentrifugation (Sorvall Discovery 100, rotor: Ti647.5) at 120 000 g for 40 minutes at 4 
°C. The protein was filtered over a 0.22 µm sterile PVDF filter (Millipore) and loaded on a 
Chelating Sepharose column (Pharmacia) loaded with Ni2+ ions, pre equilibrated with Buffer 
A (50 mM Tris-HCl pH 8.0, 10 mM imidazole, 10 mM NaCl, 5% glycerol, 2 mM MgCl2, 
5mM β-mercaptoethanol). The protein was washed to baseline with 40 mM, 60 mM and 80 
mM imidazole B buffer (50 mM Tris-HCl pH 8.0, 10 mM NaCl, 500 mM imidazole, 5% 
glycerol, 2 mM MgCl2, 5 mM β-mercaptoethanol). The protein eluted over a linear gradient, 
with an increasing imidazole concentration of 80 to 500 mM. The fractions of the catalytic 
domain of Rv0386 were collected, pooled and subjected to Size Exclusion Chromatography 
on Superdex 75 26/60 (Pharmacia Biotech) at 4 °C. The gel filtration was carried out in 20 
mM Tris-HCl pH 8.5, 10 mM NaCl, 5 % glycerol and 2mM β-ME. The protein containing 
fractions were analysed by SDS-PAGE followed by Comassie brilliant blue staining. The 
fractions containing the dimer were collected, pooled and concentrated to 10-20 mg/ml using 
Amicon Ultra centrifugal devices (Millipore) with a cut-off of 10 kD. An aliquot of the 
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protein was incubated with 1 mM of the potent inhibitor α1βCH2ATP at 4 °C, 16-19 h. The 
protein was ultracentrifuged at 100 000 g (Optima Max , Beckman Coulter) for 45 minutes at 
4 °C, to remove aggregates before crystallisation. 
 
2.2.d Purification of C-His CHD of Rv0386 as Monomer 
C-His CHD of Rv0386 was transformed in BL21(DE3) (pREP4) or B834(DE3) E.coli strains. 
The over-expression was performed as described in section 2.2.a. The cell disruption and 
nickel affinity purification was carried out according to section 2.2.c. The protein was 
dialysed in 20 mM Tris-HCl pH 8.5, 500 mM NaCl, 10 % glycerol, 2 mM β-ME, 0.5 mM 
MnCl2 ON in 4 °C and run on a gelfiltration column Superdex 75 26/60 (Pharmacia Biotech) 
in a buffer containing the same components as the dialysis buffer. The protein in the 
monomeric peak was collected and concentrated using Amicon Ultra centrifugal devices 
(Millipore) with a cut-off of 10 kD to ca 1 mg/ml. The protein was incubated with 1 mM 
α1βCH2ATP at 4 °C, ON. Prior to crystallisation the protein was ultracentrifuged at 100 000 g 
(Optima Max, Beckman Coulter) for 45 minutes at 4 °C, in order to remove aggregates. 
 
 
2.2.e Purification of N-His CHD of Rv0386 
N-His CHD of Rv0386 was transformed in BL21(DE3) (pREP4) or BL21(DE3) E.coli 
strains. The over-expression was carried out according to section 2.2.a.  
10 grams of cells corresponding to 4 L of cell culture were thawn on ice and suspended in 200 
ml lysis buffer (50 mM Tris-HCl pH 8.5, 300 mM NaCl, 10% glycerol, 2 mM β-ME, 1.0 mM 
MnCl2) supplemented with one tablet complete protease inhibitor (EDTA free, Boehringer 
Ingelheim) per 50 ml lysis buffer. The cells were disrupted on ice with a Sonicator (Branson 
sonifier 250) at 50 % duty cycle, 25 sec pulse, 25 sec pause in total 40 minutes. Cellular 
debris was separated by ultracentrifugation (Sorvall Discovery 100, rotor: Ti647.5) at 120 000 
g for 40 minutes at 4 °C. The protein was purified over a Chelating Sepharose column 
(Pharmacia) loaded with Ni2+ ions, pre equilibrated with Buffer A (50 mM Tris-HCl pH 8.5, 
10 mM imidazole, 10 mM NaCl, 10% glycerol, 2 mM β-ME, 1.0 mM MnCl2 ). The protein 
was washed to baseline with 50 mM imidazole B buffer (50 mM Tris-HCl pH 8.5, 10 mM 
NaCl, 500 mM imidazole, 10% glycerol, 2 mM β-ME, 1.0 mM MnCl2). The protein eluted 
over a linear gradient of 10 to 100 % corresponding to 50 to 500 mM imidazole. The fractions 
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of the catalytic domain of Rv0386 were collected, pooled and concentrated. One part of the 
protein was used for crystallisation, while the other was polished on Superdex 75 26/60 
(Pharmacia Biotech) at 4 °C. The gel filtration was carried out in 50 mM Tris-HCl pH 8.0, 
300 mM NaCl, 10 % glycerol, 2 mM β-ME, 1.0 mM MnCl2. The protein containing fractions 
were analysed by SDS-PAGE followed by Comassie brilliant blue staining. The fractions 
containing the dimer were collected, pooled and concentrated to 10 mg/ml using Amicon 
Ultra centrifugal devices (Millipore) with a cut-off of 10 kD. Aggregates were removed by 
ultracentrifugation at 100 000 g (Optima Max, Beckman Coulter) for 45 minutes at 4 °C. 
Drops were set up for crystallisation, by the hanging drop method. 
 
 
2.2.f Purification of Rv0386 CHD(1-172) Cys168Ser and  Rv0386 CHD(1-168) 
Cys168Ser 
Four grams of cells were thawn on ice and suspended in 50 ml lysis buffer (50 mM Tris-HCl 
pH 8.0, 500 mM NaCl, 10 mM imidazole, 10% glycerol, 0.02% MTG) added with one tablet 
complete protease inhibitor (EDTA free, Boehringer Ingelheim) per 50 ml lysis buffer. 
Disruption of the cells was accomplished on ice with a Sonicator (Branson sonifier 250) at 50 
% duty cycle, 25 sec pulse, 25 sec pause in total 20 minutes. Ultracentrifugation (Sorvall 
Discovery 100, rotor: Ti647.5) at 120 000 g for 40 minutes at 4 °C was carried out to separate 
the cellular debris. The protein was loaded on a dripping column comprising 1 ml Chelating 
Sepharose (Pharmacia) resin loaded with Ni2+ ions, pre equilibrated with 5 column volumes 
of lysis buffer. The protein was washed with 50 mM imidazole B buffer (buffer A: 50 mM 
Tris-HCl pH 8.0, 500 mM NaCl, 10% glycerol, 0.02% MTG, buffer B: 50 mM Tris-HCl pH 
8.0, 500 mM NaCl, 500 mM imidazole, 10% glycerol, 0.02% MTG). The protein was step 
eluted with 150 mM and 500 mM imidazole B buffer. The catalytic domain of Rv0386 was 
collected in eight fractions, one ml each, pooled and concentrated. An aliquot was dialysed at 
4 °C and used for crystallisation, while the remainder was purified further on a Superdex 75 
26/60 (Pharmacia Biotech) at 4 °C in 50 mM Tris-HCl pH 8.5, 500 mM NaCl, 10 % glycerol 
and 2mM β-mercaptoethanol. The protein containing fractions were analysed by SDS-PAGE 
followed by Comassie brilliant blue staining. The fractions containing the protein were 
collected, pooled and concentrated to 5-10 mg/ml with a cut-off of 10 kD using Amicon Ultra 
centrifugal devices (Millipore). Aggregates were removed by ultracentrifugation at 100 000 g 
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(Optima Max, Beckman Coulter) for 45 minutes at 4 °C. The protein was used for 
crystallisation.  
 
 
2.2.g Production of Selenomethionine Substituted Protein 
The C-His CHD of Rv0386 construct was transformed into methionine requiring auxotroph 
Escherichia coli strain B834(DE3) and plated out on a LB agar plate containing Ampicillin. 
Pre-culture: a single colony was spread on a LB agar plate containing Amp, incubated in 37 
°C ON. The overgrown agar plate was harvested and used for inoculation of 1 L minimal 
media (2xM9, 0.4 % glucose, 19 amino acids (-Met) at 40 µg/ml, Seleno-L-methionine at 40 
µg/ml and vitamins: riboflavin, niacinamide, pyridoxine monohydrochloride, thiamine at 
1µg/ml) (Table 2.4-2.6) (Ramakrishnan et al., 1993) with 50 µg/ml Carbenicillin. The culture 
was grown for 4h, at 37 °C until the OD600 reached a value of 0.7. As a control to see if the 
plasmid was still inside the cells, a small sample of the culture was spread on a LB-agar plate 
containing Amp and left in 37 °C, ON. The cells were induced with 100 µM IPTG, for 5h at 
23 °C. The cells were harvested and stored in -80 °C, as described in section 2.2.a. The 
buffers used for the protein purification were extensively degassed, to avoid oxidation of the 
SeMet protein. Purification was performed according to section 2.2.c.  
 
 
20 x M9 
10 g NH4Cl 
30 g KH2PO4
68 g Na2HPO4 (or 128g Na2HPO4 x 7 H2O) 
Add water to make 500 ml and autoclave. 
Table 2.4: The components of the 20 x M9 media. 
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Amino acid mix I: all amino acids except Met, Phe, Trp, Tyr.  
Concentration of each amino acid: 4mg/ml. Filter sterilise and store at -20 °C.  
Amino acid mix II: Phe, Trp, Tyr. Concentration of each amino acid: 4mg/ml. The solution 
is adjusted to pH 8.0 with NaOH to improve solubility before bringing it up to volume. The 
mixture could be turbid. Filter sterilise and store at +20 °C. 
Vitamins: riboflavin (= lactoflavin, vit B2), niacinamide (= nicotinamide, vit PP), thiamine 
(= vit B1), pyridoxine monohydrochloride (= vit B6). Concentration of each: 1mg/ml. Make 
a vitamin mix of niacinamide, thiamine and pyridoxine monohydrochloride. Riboflavin does 
not dissolve completely. Filter sterilise the vitamin mix and riboflavin and store at -20 °C. 
Table 2.5: The mixtures, concentrations and storage temperatures of the vitamins, amino acid mix I, amino acid 
mix II.  
 
 
 
1L of minimal media supplemented with SeMet 
2 ml 1 M MgSO4
100 ml 20 x M9 
2 ml FeSO4  x 7 H2O at 12.5 mg/ml 
10 ml 40% Glucose 
10 ml Amino acid mix I at 4mg/ml (all residues except Met, Phe,  
Trp, Tyr) 
10 ml Amino acid mix II at 4mg/ml includes Phe, Trp, Tyr 
1 ml Vitamins at 1 mg/ml includes riboflavin, niacinamide, 
thiamine, pyridoxine monohydrochloride 
4 ml Seleno-L-Methionine at 10 mg/ml 
Add water to make 1L and make sure that pH is about 7.4 
Autoclaved components: 40% Glucose, 1M MgSO4, 20 x M9 
The other solutions were filter sterilised (vitamins, aa mix I, aa mix II, SeMet) 
Table 2.6: Minimal media supplemented with SeMet. Full description of the media can be found on 
(http://alf1.mrc-lmb.cam.ac.uk/~ramak/madms/segrowth.html) 
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2.3 Activity Studies of the Catalytic Domain of 
Rv0386 
 
 
 
The activity of the AC has been determined in a volume of 100 µl at 30 °C for 20 minutes 
(Salomon et al., 1974). The catalytic domain of Rv0386 was incubated with 50 mM 3-(N-
morpholino)-propanesulfonic acid pH 7.5, 22 % glycerol, 5 mM MnCl2, 850 µM [α-32P]ATP 
and 2 mM [2,8-3H]cAMP. The kinetic analysis was conducted from 10 µM to 2.3 mM ATP. 
From the Lineweaver-Burk plot the kinetic constants have been derived (Lineweaver and 
Burk, 1934). Standard errors of the mean of the multiple assays were usually <10 %. In order 
to determine the GC activity, the guanine nucleotides were used instead of the adenine 
nucleotides(Klumpp and Schultz, 1982). The activity assays have been performed by Lucila I. 
Castro in the laboratory of J.E Schultz (Tübingen Universität, Germany) (Castro, 2004). 
 
 
2.4 Biophysical Characterisation  
 
2.4.a Dynamic Light Scattering 
In order to determine if the catalytic domain of Rv0386 from Mycobacterium tuberculosis is 
monodisperse or polydisperse, the protein was measured in different concentrations, buffers 
and temperatures in a 12 µl quartz cuvette in a Protein Solutions DynaPro temperature 
controlled Microsampler. 
 
 
2.4.b Mass Spectrometry 
Electrospray ionisation mass spectrometry (ESI-MS) was performed by Dr. Jens Pfannstiel, 
member of the group of Prof. Johannes Lechner, Biochemie-Zentrum Heidelberg, Universität 
Heidelberg. 
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2.4.c Analytical Ultracentrifugation  
In order to determine shape and oligomeric state of the catalytic domain of Rv0386 in solution 
analytical ultracentrifugation (AUC) was performed. Since the reducing agent β-
mercaptoethanol absorbs, the protein was purified according to section 2.2.c and 2.2.d and 
then dialysed into the buffer containing 20 mM Tris-HCl pH 8.5, 10 mM NaCl, 5 % glycerol 
and 0.5 mM DTT at 4 °C ON. 5% glycerol is the maximal amount compatible with AUC. 
Additionaly, the Mn2+ purified sample was dialysed into 50 mM Tris-HCl pH 8.5, 500 mM 
NaCl, 5 % glycerol, 0.5 mM DTT and 50 mM Tris-HCl pH 8.5, 10 mM NaCl, 5 % glycerol, 
0.5 mM DTT, 0.5 mM MgCl2. Protein concentration was measured at Abs280 and the protein 
concentration used for the experiment was 1 mg/ml. The volume used for each protein sample 
was 500 µl, with dialysis buffer as reference. The rotor A N60 Ti contained three cells and 
each cell had two compartments, one for the buffer and the other for the protein. 
Sedimentation velocity run was conducted in a Beckman Coulter Optima XLA analytical 
ultracentrifuge, 200 000 g, 2.5 h, at 20 °C. The software SEDNTERP (Laue et al., 1992) was 
used for calculating the partial volume, Hydropro (Garcia De La Torre et al., 2000) for 
determining the theoretical s-values and Sedfit (Schuck, 2000) for calculating the actual s-
values. The analytical ultracentrifugation run was performed by Jacek Mazurkiewicz, in the 
group of PD Karsten Rippe, Kirchhoff Institut für Physik, Universität Heidelberg. 
 
2.5 Crystallisation, Data Collection and Structure 
Determination 
 
2.5.a Crystallisation 
Formation of macromolecular crystals are influenced by many variables, such as homogeneity 
of the protein, protein purity, concentration of the protein and precipitant, temperature, pH, 
vibrations, age of protein, source, and presence of ligands. In the most common methods of 
growing protein crystals, pure and homogeneous protein is dissolved in an aqueous buffer 
containing a precipitant (e.g. ammonium sulfate or polyethylene glycol) at a concentration 
where the protein is still soluble and does not precipitate. The precipitating conditions are then 
reached by controlled evaporation of water allowing for crystal growth. 
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 In the hanging drop vapour diffusion method the protein/precipitant solution is equilibrated in 
a closed container with a larger reservoir, where the precipitant concentration is in the 
appropriate range to produce crystals. Vapor diffusion in this closed system results in net 
transfer of water from the protein solution to the reservoir, until the precipitant concentration 
is the same in both solutions. The volume of the protein droplet is much smaller than the 
reservoir. The final concentration of the precipitant in the protein solution is approximately 
the same as in the reservoir. The net transfer of water terminates at system equilibrium and the 
protein solution is sustained at the highest precipitant concentration. Amorphous precipitation 
usually occurs when protein-and precipitant concentrations are too high. In case of no 
precipitation, protein-and precipitant concentrations would have to be adjusted. 
 
In order to find a proper crystallisation condition, different commercial sparse-matrix and grid 
screens were tested. 500 μl of precipitant solution is filled into a crystallisation plate 
containing 24 wells (Molecular Dimensions Limited). 1.5 μl of precipitant is mixed with 1.5 
μl of protein solution on a siliconised cover slide (Hampton Research). The cover slide 
containing the drop hanging up-side down was sealed with grease (hanging drop vapour 
diffusion method). For initial crystallisation conditions crystallisation screens Wizard I and II, 
Cryo I and II (Emerald Biostructures) MembFac, Crystal Screen I and II, Index Screen, 
Peg/Ion Grid Screen (Hampton Research) were used. Conditions containing crystals were 
optimised by individually devised screens around the initial condition by altering buffer, 
precipitant, and additive concentrations and identities, as well as altering the temperature of 
crystallisation (19 °C and 4°C) and protein concentration. Crystals grew ON, but the biggest 
and best diffracting crystals took from a few days to 2 weeks to grow. Rod shaped crystals of 
the catalytic domain of Rv0386 grew in hanging drops using vapour diffusion at 19 °C by 
mixing 1.5 µl protein solution (10-20 mg/ml) with 1.5 µl of 0.1 M Hepes pH 7.5 and 0.7 M 
sodium acetate. The selenomethionine crystals were grown in order to perform a single 
anomalous dispersion experiment (SAD). The SeMet crystals grew as thick rods. 1.5 µl Se-
Met protein (10-20 mg/ml) was crystallised in 1.5 µl of 5% (w/v) PEG2000, 0.1 M Hepes pH 
7.5 and 0.2 M KCl. After 2-4 days native and Se-Met crystals grew to a size of 30 x 30 x 250 
µm. Rv0386 catalytic domain crystallised in the tetragonal space group P4122. The first non-
diffracting crystals of Rv0386 CHD were originally grown by Lucila I. Castro (Universität 
Tübingen, Germany) (Castro, 2004). 
 
 
MATERIALS and METHODS 
___________________________________________________________________________ 
50
 
2.5.b Crystal Freezing and Data Collection 
For most crystals the cryo-solution, i.e. a solution which avoids the formation of ice upon 
freezing, is the same as the crystallisation conditions with an additional 20-25 % (w/v) 
glycerol, polyethylenglycol or ethylenglycol (Garman and Schneider, 1997). A protein crystal 
is moved to a cryo-solution for a few seconds. Thereafter the crystal is transferred into liquid 
nitrogen using a nylon loop of size 0.05 mm to 0.5 mm (depending on the size of the crystal) 
and stored frozen at 100 °K until data collection. At 100 °K crystals are exposed to X-rays, 
because at this temperature radiation damage is lower than at room temperature, 
conformational disorder and thermal vibrations are reduced.  
 
In the year 1895 X-rays were discovered by Röntgen. X-rays are electromagnetic radiation of 
wavelength 0.1-100 Å and can be described by three parameters, wavelength, amplitude and 
phase. X-rays are not affected by magnetic fields and cannot be focused by optical lenses. The 
images are therefore derived indirectly by recording the diffraction pattern of X-rays. The 
wavelength of X-rays emitted by the X-ray source and the wavelength of all recorded X-rays 
are the same, which means that the diffraction is inelastic and that the wavelength is known. 
Diffraction of a single molecule cannot be detected with present technology, since X-rays are 
scattered very weakly. Usually, diffraction from multiple proteins is erased by each other but 
in proteins that form a crystal diffraction is enhanced and can be detected if it fulfils a 
criterion known as Bragg’s law. Bragg´s law of diffraction was established in the year of 1912 
by W.H Bragg and W.L Bragg and it demonstrates the conditions that produce diffraction. 
The first structure was determined in 1912 from NaCl. The 17 kD sized protein Myoglobin 
was the first protein structure, solved by Max Perutz in 1958.  
 
 
Bragg´s law: 2 dhkl sinθ = n λ 
dhkl: spacing between two lattice planes 
hkl: miller indices, identifies equivalent, parallel planes 
θ: diffraction angle 
n: an integer 
λ: wavelength of x-ray (copper target emits at 1.5418Å, CuKα) 
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X-rays are produced by two methods. The first method is that rotating anodes or sealed tubes 
generate X-rays by accelerating electrons at high voltage against a metal target (most common 
is copper or molybdenum) and the second method is to use synchrotron radiation, where the 
electrons emit energy in the curved motion and the energy is emitted as X-rays. Protein 
crystals are exposed to a strong X-ray source, resulting in a diffraction pattern (reflections) 
that is recorded by a X-ray detector. In order to test diffraction of crystals and heavy-atom 
derivatives an in-house Bruker Nonius X-ray generator was used with a MAR345 imaging 
system (Marresearch). The crystals were diffracting to ca 8-10 Å in-house. All data used for 
structure determination was recorded on CCD image plates (ADSC) at the European 
synchrotron radiation facility (ESRF) in Grenoble, France. The beamlines used for data 
collection were ID14-4 (native) and ID14-1 (SeMet).  
 
2.5.c Data Processing 
Autoindexing can be done in two ways. One is to autoindex the collected data by entering the 
unit cell in the program and all possible orientations of this cell are searched until a match is 
found. In the second, the reciprocal space is searched for vectors, three non-coplanar groups 
are searched for, and the shortest reciprocal space distance (the largest in real space) is taken 
to be the cell edges. The correct cell is usually the one that has the longest axes (in real space) 
and highest symmetry.  
 
Crystals are constructed from unit cells, repeated by translation in all three directions. The 
unit cell edges are assigned a, b, c and the angles between them are α, β and γ. The unit cell 
edges a, b, c in real space corresponds to the coordinate system h, k, l (Miller indices) in 
reciprocal space, respectively, giving rise to the reflection spot (h k l). The program DENZO 
(Otwinowski and Minor, 1997) determinates parameters from the pattern of recorded 
diffraction spots and allocates the spots to lattice planes: called indexing. The intensities of 
the spots by integration and profile fitting is measured by DENZO. Scalepack (Otwinowski 
and Minor, 1997) was used for scaling images from different images, since intensities on 
different images vary in strength due to the thickness of the crystal in the beam or due to 
crystal decay. Reflections that diverge above a threshold from the mean are assumed to be 
incorrectly measured and can be rejected by Scaling programs. The Rsym value is an 
important parameter of the accuracy of a data set. In Rsym the differences between symmetry 
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related spots that in the ideal case would be identical in intensity is compared. Data with 
Rsym < 0.05 are good data, Rsym < 0.10 probably usable data, Rsym > 0.20 are doubtful 
data. Two datasets scaled together with a Rsym of 0.57 do not have any relationship to each 
other. Rsym of 0.35 can be reached with random data scaled in bins with multiple scale 
factors. The reflections are calculated as: 
 
( ) ( )
( )∑ ∑
∑ ∑ −=
ihiIh
ihIhIih
Rsym  
                                    
I(h) is the mean intensity after scaling 
I(h)i is the intensity of a recorded diffraction spot 
 
 
2.5.d Molecular Replacement 
The phase of each reflection is the only parameter not known, so far. There are several 
possibilities to determine this. A homologous structure with sequence identity of ca 50 %, can 
be used as a model in molecular replacement. With this high sequence identity it should be 
straightforward, since the structures are most likely very similar. In molecular replacement, 
firstly introduced by Michael Rossmann (Rossmann, 1972), the phases from structure factors 
of a related, known protein are used as an initial guess of the unknown structure phases. The 
known protein is called the phasing model and it is fitted into the unit cell of the unknown 
structure. By calculating a Patterson function in a random P1 cell and then superimposing 
them (cross rotation matrix) the orientation of the two molecules are determined. Thereafter, 
the translation function in the real cell is determined. This method assumes as that the phases 
of the phasing model are the same as that of the unknown protein. R-factor calculation and 
correlation functions estimate the quality of the solutions. Molecular replacement failed for 
CHD of Rv0386. Monomeric, dimeric and truncated models from different homologous 
proteins were used, unsuccessfully. The advantage of molecular replacement is that it is the 
fastest method of solving a structure, from a single native data set when a homologous model 
is available. However, initial phases are biased towards the phasing model, making it difficult 
to align the correct structure.  
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2.5.e Single Anomalous Dispersion (SAD) 
Another possibility to determine phases is to take advantage of the heavy atom´s (selenium) 
capacity to absorb X-rays of specific wavelength. Due to this absorption, breakdown of 
Friedel´s law occurs and the reflections h k l and -h -k –l (Bijvoet pairs) do not have equal 
intensity anymore (Figure 2.4). This effect is called anomalous dispersion or anomalous 
scattering. Elements absorb and emit X-rays, and at wavelengths just below their emission 
wavelength the absorption drops sharply. This abrupt change in absorption at a specific 
wavelength is called the absorption edge. Anomalous scattering occurs when the X-ray 
wavelength is near the heavy atom´s (selenium) absorption edge, the heavy atom absorbs a 
fraction of the radiation and is reemitted with altered phase.  The highest signal of anomalous 
scattering is obtained when the wavelength of the heavy atom´s absorption edge is used for 
data collection. Carbon, oxygen and nitrogen, do not contribute to anomalous scattering, since 
the absorption edge for these elements are not near the wavelength of the X-rays used in 
crystallography. 
 
Differences in intensity are usually very small, so data are collected with a high redundancy to 
improve the signal to noise ratio and allow more accurate estimates of the intensities. It is 
necessary to use one crystal where the Friedel pairs are collected under similar conditions. 
Data for SeMet substituted CHD of Rv0386 crystals were collected at ID 14-1 at ESRF, 
Grenoble, France which is a beamline with a fixed wavelength at λ = 0.934 Å. Prior to the 
data collection, a wavelength scan was performed of SeMet substituted crystals at ID 14-4 and 
revealed a peak wavelength of λ = 0.9793 Å for selenium. Therefore the wavelength at ID 14-
1 was sub optimal for the anomalous signal. The structure of the catalytic domain of Rv0386 
was solved using single anomalous dispersion (SAD). SAD data can be collected at 
synchrotron beamlines whose wavelength cannot be altered (ESRF, ID 14-1, ID 14-2 etc). 
Multiple anomalous dispersion (MAD) on the other hand, uses the anomalous dispersion at 
multiple wavelengths and therefore data has to be collected at synchrotron beamlines whose 
wavelength can be altered. MAD was not tried, since the method SAD was successful. The 
substructure solution of anomalous scatterers are determined, by an anomalous Patterson map 
that calculates the position of the anomalous scatterers. The substructure of the Se-Met 
derivatised CHD of Rv0386 was found with either of the programs SHAKE ‘n’ BAKE (SnB) 
(Miller et al., 1994) or SOLVE (Terwilliger and Berendzen, 1999). Phasing was carried out 
with the program SHARP (de la Fortelle and Bricogne, 1997), and phases were improved by 
solvent flattening with Solomon (Abrahams and Leslie, 1996). Solvent flattening improves 
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the signal to noise ratio in electron density maps. Usually 30-70 % of the crystal volume is 
occupied by protein. The rest is comprised of solvent, that adds random noise to the 
diffraction. With the program Solomon a clear electron density map was obtained. 
 
By replacing the sulphur atoms to selenium atoms in methionines, centres are created that are 
more electron dense in the SeMet substituted protein compared to the native protein. The 
reflection intensities are therefore altered. The difference between the structure factor of the 
native protein (FP) and the derivatised protein crystal (FPH) is defined as FH. The 
substructure solutions of heavy atom centres can be defined from Patterson maps, and phases 
are determined (Figure 2.5) for structure determination. 
 
 
 
 
 
Figure 2.4: Breakdown of Friedel's law. Friedel's law states that the amplitude of FP (+) and FP (-) are the same. 
The amplitude of FP (+) and FP (-) is equal for the native protein but the phase is reversed. The protein with an 
anomalous scatterer has both a different phase and amplitude between FPH (+) and FPH (-). Figure taken from 
(Drenth, 1994). 
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Figure 2.5: Phase determination using isomorphous replacement. The structure factor of the native protein is FP. 
When the substructure of the heavy atoms has been determined, phase and magnitude of FH can be calculated. 
With FPH measured experimentally, there are two possible phase values for FP, FP1 and FP2. Which of these is 
correct can be determined by a second derivative, which intersects with either FP1 or FP2. Figure taken from 
(Drenth, 1994). 
 
 
 
2.5.f Refinement 
The electron density of the unit cell can be calculated and represented in a map. The electron 
density is the primary experimental result, in which a protein model is built. The following 
formula is used to calculate the electron density at any point within the unit cell. This is the 
Fourier series that gives the first electron density map: 
 
Fourier synthesis: 
( ) ( ) ( )( )calchkllzkyhxiobs
h k l
hkl ehklFw
V
xyz ´21 απρ −++−= ∑ ∑ ∑  
  
ρ (x y z) is the value of electron density at position x, y, z 
F (h k l) obs is the structure factor of reflection h k l from the native intensities of the new 
protein 
W hkl  is the weight factor, which is close to 1.0 if α ´ (h k l) is among the most reliable phases 
α ´ (h k l) calc is the phase of reflection h k l from the anomalous dispersion or phasing model 
 
 
The maps were visualised by Program O (Jones et al., 1991). The Cα chain of Rv0386 
catalytic domain was traced by using a poly-alanine model. In order to make the protein 
 
MATERIALS and METHODS 
___________________________________________________________________________ 
56
model to refine, the start with a poly-alanine model was very useful. If the first protein model 
is derived from molecular replacement, the protein model will contain errors because the 
protein could be in another conformation. In order to improve the protein model, manual 
building is done in O. R-factor is a reliability factor that is used for estimating the error of the 
protein model. R-factor is the difference between the experimentally derived structure factors 
and the calculated structure factors that would be obtained if the protein model was correct. 
 
( ) ( )
( )∑
∑ −=−
hF
hFhF
factorR
o
co  
 
Fo experimentally observed structure factor of reflection h 
Fc calculated structure factor of reflection h 
 
A completely random model would have a R-factor about 55 %. R-factor of refined structures 
are between 20 and 30 percent, depending on the resolution of the diffraction. In Table 3.4 the 
refined structure of the CHD of Rv0386 is presented. Higher resolution structures tend to have 
lower R-factor values. The R-factor alone is influenced by the changes made and therefore not 
free of model bias, i.e. it can lead to over-refinement. Approximately 5% of reflections are left 
out from refinement and therefore independent of any manipulation. A Rfree value (Brunger, 
1993) is calculated from these reflections, using the same formula as for calculating the R-
factor. Typically the R-factor should be about the resolution × 10 and the Rfree should be a 
few % higher. At a resultion of 1.6 Å a good structure may have R-factor = 17 %  and Rfree = 
20 %. If the difference between R-factor and Rfree is ca 10 % there is a risk that the protein 
model has been over-refined. If the R-factor falls during refinement and Rfree do not 
decrease, then there is a risk that the model is wrong. It is important that both Rfree and 
Rfactor decline. 
 
Refinement programs can refine the atomic coordinates of atomic positions as well as their B-
factors that represent the level of dynamic disorder of individual atoms. Iterative model 
building and refinement using the program REFMAC 5 (Murshudov et al., 1999) was done. 
As the model improves, the restraints can be relaxed. Waters were placed by the program 
ARP/wARP (Perrakis et al., 1999). In the final refinement a few cycles of TLS (Winn et al., 
2001) was used. The quality of the refined model was evaluated using WHAT IF (Vriend, 
1990) and PROCHECK (Laskowski et al., 1993). These programs validate the quality of the 
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Ramachandran plot, as well as errors like atoms that are unlikely near to each other, 
improbable hydrogen bond arrangements. The Ramachandran plot compares the mainchain 
angles of proteins (ψ and φ) with those from known structures at high resolution and on this 
basis defines allowed, generously allowed and disallowed regions. The program SFCHECK 
(Vaguine et al., 1999) checks the quality of the structure-factor data and compares it to the 
structure factos deposited in the Nucleic Acid Database (Berman et al., 1992). 
 
 
2.5.g Data Analysis and Interpretation 
The residues of the protein model into secondary structure elements were assiged with the 
program DSSP(Kabsch and Sander, 1983). PYMOL (DeLano, 2002) has been used in 
drawing all figures of the protein structure. A sequence alignment was generated using the 
program CLUSTALX (Thompson et al., 1997). The topology of the cyclase homology 
domain was designed with TopDraw (Bond, 2003). DynDom (Hayward and Berendsen, 1998) 
generated the domain movements between the inhibited and modeled active state. Corel 
Photo-Paint 12 was utilised for photo editing purposes.  
 
 
 
2.6 Small Angle X-ray Scattering (SAXS) 
 
 
 
2.6.a Introduction to SAXS  
In the end of the 19th century, Röntgen discovered radiation with wavelength much smaller 
than that of visible light. Because of their unknown nature, Röntgen named this high-energy 
radiation “X-rays”. Soon after this discovery, von Laue and his associates discovered that 
crystals scatter X-rays in distinct patterns. It was quickly recognized that these patterns give 
direct insight into the structure of the materials that caused the scattering. Since these early 
discoveries, many technical advances made X-ray scattering one of the most powerful 
characterization tools available for both homogeneous and heterogeneous materials. Today, 
 
MATERIALS and METHODS 
___________________________________________________________________________ 
58
scattering from X-rays, neutrons and light is used by scientists in many different disciplines to 
study an extensive range of materials ranging from polymers to proteins. 
 
The method small angle X-ray scattering (SAXS) makes it possible to study individual 
proteins and large complexes, under nearly physiological conditions and in solution. It is 
applicable to study the shape of low resolution three-dimensional particles, oligomeric 
mixtures, complex formation, quaternary structure and kinetics of assembly/dissociation or 
folding/unfolding processes. Analysis of structural changes upon variation in ionic strength, 
pH, temperature etc. is also eligible. SAXS can be assigned for molecules with the molecular 
weight of 5 kDa to 100 MDa in a resolution from 15 to 10 000 Å. SAXS is the only 
successful method to obtain the shape of macromolecules with molecular masses of a few 
hundred kDa in their native condition, hence too small for cryo electron microscopy (EM) and 
too large for nuclear magnetic resonance (NMR). The disadvantage with SAXS is that it 
cannot (easily) be applied to study viscous samples. 
 
Monodisperse samples (>90 % is desired) are required for structure analysis, i.e determining 
shape and quaternary structure. The monodispersity of the sample can be determined by 
native gel filtration, analytical ultracentrifugation (AUC), dynamic light scattering (DLS) etc. 
For a complete study 2 to 5 mg of protein is required. A concentration range from 1 to 20 
mg/ml (1, 3, 5, 10, 15, 20 mg/ml) in a sample volume of ca 100 µl per measurement is 
necessary. In order to decrease the aggregation/damage during the data collection the reducing 
agent DTT (2mM) was added to the sample and the buffer before the experiment. If the 
sample is aggregated, the scattering data will be difficult or even impossible to interpret. The 
corresponding buffer is measured before and after each sample of the macromolecular 
solution. Buffers containing high amounts of salts and glycerol (>0.5 M) should be avoided, 
since the signal of the sample with low protein concentrations is difficult to detect because of 
the limited contrast. The cell is cleaned and refilled manually after each measurement. The 
buffers should be in sufficient amount (> 10 ml) to clean the cell and dilute the samples. The 
SAXS measurement was performed at the X33 SAXS-beamline, EMBL, Hamburg, Germany. 
The collection, processing and the analysis of the SAXS data was done with the help of Dr. 
Dmitri Sverguns group. 
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2.6.b Theory of SAXS 
Small angle X-ray scattering (SAXS) uses a small diffraction angle when a sample in solution 
is irradiated with X-rays and the resulting scattering pattern is measured (Figure 2.6). A low 
resolution structure is thereafter determined from the observed reflections on the detector. 
Scattering patterns are caused by the interference of secondary waves that are emitted from 
various structures (electrons for X-rays) when irradiated. Scattering of X-rays is caused by 
differences in electron density. Unlike an electron micrograph, small angle X-ray scattering 
patterns do not give morphological information directly. The result of a SAXS experiment 
gives rise to a scattering curve and it is essentially the intensity of the Fourier transform of the 
electron density and must be interpreted in order to determine morphology. One fundamental 
problem with any scattering experiment is that two different morphologies can, in theory, give 
identical scattering patterns. Generally, one cannot reconstruct the exact microstructure 
uniquely from a SAXS pattern because in a scattering experiment only the scattered radiation 
intensity can be measured and all phase information is lost. Therefore, one cannot be 
absolutely sure that a scattering pattern is due to a particular morphology. However, 
something usually is known about the system in question, so that it is often (but not always) 
reasonable to assume that if a particular model is shown to fit the scattering pattern, then the 
model is a correct description of the morphology. Nevertheless, many different approaches 
exist to extract morphological information from a SAXS pattern. Interpreting the SAXS data 
can be a very difficult task. Models can be fitted to give information about the radius of 
gyration, shape of the particles, surface-to-volume ratio of the scattering objects, 
crystallisation of polymer materials. 
 
 
 
 
Figure 2.6: Instrumentation of SAXS. Picure taken from (Koch et al., 2003). 
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Scattering of a protein in solution allows the determination of the radius of gyration of the 
macromolecule, which yields the shape, and the correlation, which depends on the distance 
between clusters. The scattering sample can give various information, i.e the decline of the 
scattering curve and from features in the curve such as peaks that correspond to a correlation 
function between the particles. During the SAXS measurement there are three components 
that are measured, i.e the scattering of the sample (signal that we require), background 
scattering (water) and noise i.e. X-rays scattered from secondary objects like slits.   
 
( ) ( ) ( ) ( ) qSqPV
V
N
d
qdq particle 221
2 ρρ −=Ω∝Ι
∑ ( ) 
 
I (q): intensity of scattering 
N :    number of scatterers in the volume V of sample 
Vparticle: volume of the individual scattering item 
ρ:      density of the particle (ρ 1) or the matrix (ρ 2) 
P(q): form factor 
S(q): structure factor 
 
In a diluted system the clusters in solution scatter independently, and thereby there are no  
interparticle effects. Due to this, the sum of independent particle scattering is equal to the total 
scattering intensity I(q). Since there are no interactions between particles, there are no 
correlation effects and therefore the structure factor S(q) has no affect on the scattering. 
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The size and shape about the scatterers can be calculated by the form factor P(q). 
 
 
Monodisperse Spheres 
It can be difficult or even impossible to interpret the SAXS data if the sample (scattering 
spheres) is not monodisperse. In Figure 2.7 measured data of silica spheres are shown in 
orange and the size and shape can be determined from the form factor P(q) in blue.  
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 Porod region      
 
 
 
Figure 2.7: From the scattering curve the form factor P(Q) of silica spheres is determined.  
 
 
Particles Interacting 
With increased density for the silica spheres, the correlation effect becomes important, since it 
changes the scattering features (especially at low q values). The interparticle structure can be 
determined by interpreting the correlation effect, appearing as additional peaks in the 
scattering (Figure 2.8).  
 
 
 
Figure 2.8: Experimental data on interacting charged Silica spheres. The intensity scattering signal I(q) is 
devided into two terms: the structure factor S(Q) and the form factor P(Q).  
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Form factors for Spheres 
e form factor P(q) for a spherical scatterer of density contrast ρ0 Below is the formula for th
and radius R. The expected scattering intensity can be calculated and through the Guinier and 
the Porod approximations the scattering curve can be fully investigated.  
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uinier Approximation 
 of the scattering is proportional to the 
G
From the text above we know that the intensity
structure factor and the form factor.  
 
( ) ( ) ( )qSqPqI ∝  
 
 this case there are no particles interacting (diluted system) and therefore the structure factor 
igure 2.7.  The Guinier region is 
 
In
does not have any effect on the scattering, and thus S(q)=1. 
The Guinier region is marked in the scattering curve in F
referred to a very low angle range of the scattering plot, where q < 1/R. In the Guinier area a 
plotted graph of ln I(q) against q2 should give a straight line. 
 
( ) 5202
22Rq
eVqI
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5
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22
 
 
he size of the particles (assuming spherical scatterers) can be determined from the gradient T
of the line. The equation above is applicable on spherical particles, but the equation can be 
adopted to fit an arbitrary shaped particle, by using the radius of gyration, which is the centre 
of electron mass. In conclusion, from the Guinier region of the scattering curve both shape 
and size can be extracted.  
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Porod´s law 
ion (Figure 2.7) is an area of the scattering curve with higher q and it is applied The Porod reg
on the surface properties of the particle. 
 
( ) ( ) ( )
2
20 cos
sin3
⎟⎟⎠
⎞
⎜⎜⎝
⎛
⎥⎦
⎤⎢⎣
⎡ −=∝ qR
qR
qR
qR
VqPqI ρ  
 
 the Porod region, qR>>1, when the cos2(qR) = 1/2 and sin (qR)/qR→0, the equation is In
simplified to: 
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owards larger angles there is a decrease in the scattering intensity, which follows a q-4 
he experimental data is fitted by using the form factor for spherical scattering particles. 
h is 
 Programs used for Processing and Analysis of SAXS Data 
RIMUS  
ain program PRIMUS (Konarev et al., 2003) used for processing 
selected data files with different sample concentrations (no zero sample concentration). The 
 
T
dependence. An exception is though, rough or complex surfaces of the scattering particles that 
will not have a q-4 dependence at higher angles. The surface area and the unit volume are 
assigned to the V2/R4 factor, which is a measure of the particle smoothness.  
 
T
In order to fit the data correctly, the absolute scattering intensity must be known whic
related to the concentration of the scatterers. This is a difficult parameter to quantify but is 
essential in order to establish the true scattering strength of the particle. 
 
2.6.c
 
P
A program suite where the m
of the small angle scattering data, manipulates and analyses the data. PRIMUS performs 
averaging, subtraction of background and merging of the SAXS data measured in different 
angular ranges. The buffer is extracted and the data is extrapolated to zero concentration for 
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radius of gyration, Rg (for rod-type, flat and globular particles) from the Guinier plot, zero 
intensity, Porod's volume and molecular weight are evaluated. PRIMUS can via pop-up 
menus analyse characteristic functions by indirect Fourier transformation. It can also perform 
peak analysis for partially ordered systems and shape approximations in terms of three-
parametric geometrical bodies can be found. 
 
DAMMIN 
DAMMIN (Svergun, 1999) is used in order to restore ab initio low resolution shape. The 
o restores internal structure of biological macromolecules in solution from program als
isotropic scattering. DAMMIN fills densely packed particles (small spheres or dummy atoms) 
into a sphere of diameter equal to the maximun particle size. Each dummy atom should be 
assigned either to solvent or particle. Next step is the minimization, by which the program 
searches for compact dummy atoms that fits the SAXS data (Figure 2.9). Simulated annealing 
(SA) is a minimization method where the temperature is high and the changes are almost 
random, thereafter it is cooled down. In the end a configuration with nearly minimum energy 
is reached. Simulated annealing is used in order to find a configuration that fits the data while 
minimizing the interfacial area (Figure 2.10). Application of the method is to determine the 
shape of several proteins from experimental x-ray scattering data. 
 
 
Figure 2.9: An example of dummy atom configurations after minimization  
in the range of compact to disconnected arrangement. Figure taken from  
) (http://www.embl-hamburg.de/ExternalInfo/Research/Sax/dammin/sld004.htm
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         A            B 
0: The ctures resent t e shape ermi he s1 subfragment of the myosin head. The graph 
ASSHA 
Konarev et al., 2001) is applied for rigid-body refinement and 3D rendering. The 
LOBSYMM                  
 and Svergun, 2005) is applied for rigid body modelling of 
Figure 2.1  pi  p h  det nation of t
in A) presents the shape reconstruction in the beginning when the fit to the experimental data is bad (χ = 36.38) 
and the graph in B) shows a good fit (χ = 1.04) to the experimental data. The dummy atoms in orange are shown 
to be very well fitted in B) Figure taken from (http://www.embl-
hamburg.de/ExternalInfo/Research/Sax/dammin/sld006.htm) and (http://www.embl-
hamburg.de/ExternalInfo/Research/Sax/dammin/sld024.htm) 
 
M
MASSHA (
program displays and manipulates low resolution models and high resolution atomic 
structures, which are portrayed as ensembles of beads. The program allows interactive and 
automated rigid body refinement of the quaternary structure of macromolecular complexes 
against solution scattering data. Alignment of structural models of different resolution and 
origin are performed automatically. The low-or high resolution models are refined to fit the 
experimental solution scattering data. 
 
G
GLOBSYMM (Petoukhov
symmetric oligomers. The program searches for the quaternary structure of a symmetric 
oligomer built from monomers. From the high-resolution model the partial scattering 
amplitudes of the monomer Alm(s) are computed by CRYSOL (Svergun et al., 1995). The 
monomer is centered at the origin in a reference orientation. The monomer is rotated by the 
Euler angles (α, β, γ) and thereafter it is substituted by the vector r = (r, ψ, ϕ), creating a 
symmetric oligomer. The partial scattering amplitudes of the rotated and shifted monomer 
BBlm(s)=Blm(s, α, β, γ, r) are analytically expressed via the amplitudes Alm(s) and the elements 
of the finite rotation matrix. The scattering from the entire oligomer is: 
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multiples of n and all imaginary parts 
 
In order to prevent oligomeric structures with steric clashes and those with too loose contacts 
 
 
LIGOMER 
onarev et al., 2003) determines the molecular weights, radii of gyration and 
where the summation runs only over m equal to zero or 
vanish in the case of k=2. The scattering intensity from the symmetric oligomer can be 
calculated from the equation above, thereby it is possible to search for the positional 
and rotational parameters to minimize discrepancy between the experimental data and the 
calculated curve.  
between the monomers, a crude dummy atom structure of the monomer is produced. This lead
to a fast evaluation of the parameters of contacts and the overlap between monomers, thereby 
the less favorable structures were left out on in the course of minimization. 
O
OLIGOMER (K
volume fractions for each of the mixtures of proteins with known scattering intensities. The 
program uses experimental scattering curves from a mixture of proteins as input data and 
determines the form-factors for each component of these mixtures. I(s) is the experimental 
scattering intensity from a mixture of different proteins (components), and mentioned as 
contributions wi of each protein Ii(s) to resulting scattering:  
 
( ) ( )( )∑ ×= sIwsI ii  
 
wi  is the volume fraction and Ii(s) is the scattering intensity, from the i-th component. 
 
If the intensities from the proteins are known, OLIGOMER uses the algorithm of 
unconstrained or nonnegative least-squares to minimize the deviation between the 
experimental and calculated scattering curves. The program estimates molecular weights of 
the proteins (components) in order to determine the radius of gyration and volume fractions 
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from experimental or model scattering curves of components of the mixture. Therefore, it is 
important that the proper molecular weight (calculated from the primary sequence) of each 
protein (component) is entered into the program, otherwise the values of the volume fractions 
will be incorrect. 
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Chapter 3  
 
 
RESULTS 
 
 
_________________________________________________________________________ 
 
 
 
In the beginning of this thesis, no structural information was available on adenylyl cyclases 
(AC) from M. tuberculosis. AC Rv0386 from M. tuberculosis is a multidomain protein, 
comprising a catalytic AC domain at the N-terminus, followed by an AAA-ATPase domain, 
TPR domain and a helix-turn-helix DNA binding domain at the C-terminus. The catalytic 
core of AC Rv0386 converts ATP to cAMP and GTP to cGMP, which is extraordinary.  
Structural studies were applied to increase our understanding of the molecular mechanism of 
the catalytic core of Rv0386. Several constructs were designed, for overexpression, 
purification and biophysical characterisation, presented in the first section of this chapter. 
Crystallisation with native and selenomethionine substituted protein and structure 
determination with SAD is described in the second part. Small angle X-ray scattering, 
analytical ultracentrifugation and mutagenesis was applied to verify a unique inhibited 
conformation of the X-ray structure, presented in the successive section. Additionally, crystals 
of the catalytic core in the probably active state were included.  
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3.1  Purification and Biophysical Characterisation of 
the Catalytic Domain of Rv0386 
 
 
3.1.a Purification of C-His CHD of Rv0386 
The cyclase homology domain of Rv0386 comprising an uncleavable C-terminal histidine tag 
was expressed in the Escherichia coli strains BL21(DE3), BL21(DE3)pREP4 and B834(DE3) 
as described in section 2.2.a. The highest yield of over expressed protein was obtained with 
B834(DE3) (not shown). The catalytic domain was purified in two steps, using first affinity 
chromatography and then size exclusion chromatography. The histidine tag was well exposed 
and the protein bound with high affinity to the nickel column. After the washing step of 80 
mM imidazole, the protein was eluted over a linear gradient (80-500 mM imidazole) with the 
elution peak at 125 mM imidazole in a pure form, without visible Coomassie stained 
contaminations (Figure 3.1). The second purification step, size exclusion chromatography was 
introduced to remove aggregation. Molecular weights given from gel filtration runs are 
derived from a calibration run with protein standards (Sigma). For Superdex 75 10/30, the 
aggregated protein gives a peak at the void volume (8.08 ml) and the catalytic domain elutes 
as a dimer at retention volume VE = 10.48 ml, corresponding to a molecular weight of 45 kD 
(Figure 3.2). Using a Superdex 75 26/60, the aggregated protein elutes at 126 ml (void 
volume) and the CHD at the retention volume VE = 174 ml, corresponding to 45 kD. These 
values are compatible with the calculated molecular weight of 40.4 kD of the dimer of the 
catalytic domain of Rv0386. The protein yield after gel filtration corresponds to 1 mg per liter 
bacterial culture, which is sufficient for crystallisation. 
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Figure 3.1: Affinity purification of C-His CHD of Rv0386. The 12% 
Coomassie stained SDS-PAGE shows a protein band at 20 kD, which 
corresponds to the expected molecular weight of 20 kD of the histidine 
tagged catalytic domain of Rv0386.  
 
Figure 3.2: Size exclusion chromatography chromatogram of C-His CHD Rv0386. A) The main peak 
at retention volume, VE = 10.48 ml, corresponds to a molecular weight of 45 kD (calculated Mw of the 
CHD dimer = 40.4 kD). The aggregation peak is visible at the void volume of 8.08 ml.  B) Samples 
from the elution peaks in A are visible on the Coomassie stained SDS-PAGE. C-His CHD Rv0386 is 
observed as a band at a molecular weight of 20 kD. 
RESULTS 
___________________________________________________________________________ 
71
3.1.b Purification of N-His CHD of Rv0386 
The protein purification was carried out in two steps using affinity chromatography and gel 
filtration. The N-terminal his tagged CHD of Rv0386 bound with high affinity to the nickel 
resin and was eluted with a gradient of 50 to 500 mM imidazole. The protein eluted in two 
peaks, the first between 150 and 250 mM imidazole and second between 250 and 500 mM 
imidazole. The second elution peak gave rise to protein that precipitated easily at low salt 
concentrations and at higher protein concentrations. The eluted catalytic domain was in a pure 
form as shown on the SDS-PAGE (Figure 3.3). The protein yield is 18 mg per liter bacterial 
culture. Size exclusion chromatography was performed to analyse the oligomeric state and to 
separate aggregated protein. The catalytic domain has a tendency to precipitate at salt 
concentrations lower than 300 mM, and it was best to keep a minimal glycerol concentration 
of 10 %. Gel filtration over Superdex 75 26/60 visualises the oligomerisation state of the N-
terminal histidine tagged catalytic domain of Rv0386 (Figure 3.4).  The aggregated protein 
eluted at the void volume 111 ml and the dimeric catalytic domain has a retention volume of 
VE=174 ml, corresponding to the molecular weight of 40 kD which is close to the theoretical 
molecular weight of 41.4 kD. Tetrameric, octameric and higher oligomeric species eluted at 
VE=150 ml corresponding to a molecular weight of 80 kD, 141 ml to 160 kD and 124 ml to 
250 kD respectively. 
 
 
 
 
 
  
 
Figure 3.3: Affinity chromatography of the N-His CHD of Rv0386. The protein was analysed by SDS-
PAGE and stained with Coomassie Brilliant Blue. Ft= flow through.  
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3.1.c Purification of SeMet Substituted Rv0386 CHD 
Over expression, purification and crystallisation of selenomethionine substituted C-His CHD 
Rv0386 was carried out in order to obtain phase information for a SAD experiment.  In most 
cases, the over expression of selenomethionine substituted protein gives a very low yield, due 
to the slow growth in minimal media. In contrast, over expression of SeMet substituted C-His 
CHD Rv0386 was very successful, producing high amount of protein in short time. The 
bacterial cells grown in SeMet substituted minimal media behaved as during native over 
expression. The cells reached an optical density of 0.7, within 4 hours. During the purification 
of the SeMet substituted C-His CHD of Rv0386 the buffers were intensely degassed, in order 
to decline the risk of oxidation of the SeMet protein. During affinity chromatography the 
protein eluted at 125 mM imidazole in an almost pure form. The catalytic domain is observed 
on the Coomassie stained SDS-PAGE with a molecular weight of approximately 20 kD 
(Figure 3.5). The size exclusion chromatography separates the aggregated protein from the 
dimeric form (Figure 3.6). The former elutes at the void volume 121 ml and the latter at 
retention volume VE= 167 ml, corresponding to a dimer of Mw of 40 kD, compatible to the 
expected molecular weight of 40.4 kD. The protein was analysed on a Coomassie stained 
SDS-PAGE, where a single band of the catalytic domain can be observed. The protein yield 
after size exclusion chromatography is 5 mg per liter bacterial culture.  
 
 
Figure 3.4: Size exclusion chromatography of the N-His CHD of Rv0386. The protein oligomerises and 
the dimeric peak is visible at retention volume, VE = 174 ml, corresponding to the Mw of 40 kD, which is 
close to the expected Mw of 41.4 kD.  
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Figure 3.5: Affinity chromatography of SeMet substituted C-His CHD of Rv0386. 
The protein is eluted in an almost pure form and in high amount observed on the 
Coomassie stained SDS-PAGE.   
 
 
Figure 3.6: Size exclusion chromatography of SeMet substituted C-His CHD Rv0386. A) The main peak is at 
retention volume VE=167 ml, corresponding to a dimer of a molecular weight of 40 kD, compatible to the expected 
value of 40.4 kD. Aggregated protein elutes at void volume 121 ml. B) SeMet substituted protein is in a pure state 
after gel filtration as observed on the Coomassie stained SDS-PAGE.  
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3.1.d Activity Studies 
AC Rv0386 is a low activity protein compared to other ACs from M. tuberculosis. 
Exceptionally, the enzyme converts ATP and GTP to cAMP and cGMP, respectively. The 
catalytic domain of Rv0386 exhibits 20 % guanylyl cyclase side-activity (Castro, 2004; 
Castro et al., 2005). 
 
The Vmax values of the Rv0386 C-His CHD and the Rv0386 holoenzyme are 5.6 and 3 nmol 
cAMP·mg-1·min-1, respectively (in the presence of 850 µM ATP). In contrast, the Vmax of 
cyclase homology domains of Rv1900c and Rv1264 is 180-fold higher compared to the 
Rv0386 C-His CHD. The Hill coefficient of 0.9 for C-His CHD of Rv0386 indicates no 
cooperativity. The low activity could possibly be stimulated by the other regulatory domains 
of Rv0386 and by an unknown external effector (Castro, 2004; Castro et al., 2005). 
 
 
Oligomerisation of the Catalytic AC Domain of Rv0386 
During the protein dependence measurement of N-His CHD Rv0386, it was noted that protein 
specific activity increased 5-fold at protein concentrations between 46.5 to 465 nM. In 
contrast, higher protein concentrations resulted in a slight decrease of the specific activity. 
This suggests a rapid construction of a homodimer with formation of oligomers induced by 
increasing protein concentrations (Figure 3.7). The catalytic domain of Rv0386 oligomerises 
in solution forming monomers, dimers, trimers, tetramers and hexamers as shown by SDS-
PAGE followed by western blot analysis. The sample of N-His CHD of Rv0386 applied for 
the western blot experiment had AC and GC activities of 3.7 and 1.1 nmol cAMP·mg-1·min-1, 
respectively. The dissociation constant (Kd) was determined to 140 nM, indicative of a high 
affinity of the catalytic domains for each other. The Kd of C-His CHD was determined to 1.5 
µM, which indicates a slower oligomerisation process of this construct compared to N-His 
CHD (Castro, 2004). 
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Activity studies of the catalytic core of Rv0386 detected low activity for all constructs (Table 
3.1). N-His CHD and C-His CHD have a Vmax of 4.8 and 3.9 nmol cAMP·mg-1·min-1, 
respectively. The C-His CHD has 81% AC activity of the N-His CHD. In order to analyse 
whether a shorter C-terminus influences the activity, constructs with truncated C-terminus 
were expressed for kinetic measurements. Measured AC activity for Rv0386 CHD(1-172) was 
30% compared to N-His CHD. The mutations are not substituting the substrate binding 
residues and should therefore not influence the activity. No AC and GC activity could be 
detected for Rv0386 CHD(1-172) Cys168Ser and Rv0386 CHD(1-168) C168S indicating that the 
C-terminus is important for the activation.  
No activation by forskolin and no inhibition by P-site inhibitors was observed, which is in 
agreement with soluble ACs from M. tuberculosis (Castro, 2004; Castro et al., ; Linder, ; 
Sinha et al., 2005). The divalent cofactors Mn2+ and Mg2+ were tested in vitro and it was 
found that Mn2+ improves the activity of the AC Rv0386 (Castro, 2004; Castro et al., 2005) 
which is in agreement with all other ACs tested from M. tuberculosis (Guo et al., 2001; 
Linder et al., 2002).  
 
 
 
Figure 3.7: Western blot analysis of the oligomeric state of the cyclic homology domain of Rv0386. The 
primary antibody applied is a specific antibody for the catalytic domain of Rv0386. Picture taken from 
(Castro, 2004). 
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3.1.e Purification of Rv0386 C-His CHD as Monomer 
The cofactor Mn2+ is important for the activity of the AC Rv0386 as shown by (Castro et al., 
2005). Therefore, the metal ion Mn2+ was included in the purification and crystallisation of C-
His CHD Rv0386. Mn2+ was added after the affinity chromatography step to the dialysis 
buffer, prior to size exclusion chromatography. When MnCl2 is added, the protein has a 
tendency to aggregate and precipitate. To prevent aggregation 10% glycerol and 500 mM 
NaCl was added which kept the protein stable. Surprisingly, when ≥0.5 mM MnCl2 is added 
to the gel filtration buffer, the catalytic domain is observed as a monomer. In comparison, 
magnesium chloride (MgCl2) does not affect the catalytic domain of Rv0386 in the same way 
and the protein stays dimeric. The protein behaves identical with MgCl2 or without any 
addition of cofactor.  
 
Affinity chromatography over a nickel column gives an almost pure protein, as evaluated by 
SDS-PAGE (Figure 3.8). The molecular weight of 24 kD corresponds to the theoretical 
molecular weight of 20 kD of the catalytic domain of Rv0386. The gel filtration column 
Superdex 75 10/30, gives a peak at the void volume (8.20 ml) of aggregated protein and the 
 
Protein µM in assay  AC activity nmol/mg/min  
C-His CHD Rv0386 0.2 
0.5 
1.4 
2.1 
3.2 
3.5 
N-His CHD Rv0386 0.2           
0.5           
1.4           
2.7 
4.0 
4.3 
Rv0386 CHD(1-172) 0.2          
0.5          
1.4          
0.00 
1.10 
1.40 
Rv0386 CHD(1-172) Cys168Ser 0.2          
0.5          
1.4          
0.00 
0.00 
0.30 
Rv0386 CHD(1-168) C168S 
 
0.2          
0.5          
1.4          
0.00 
0.00 
0.20 
Table 3.1: AC activities of AC constructs under identical conditions. Assay performed with 
MOPS buffer pH 7.5, 5 mM Mn2+, 850 µM ATP, for 20 min at 30°C. Detection limit was 0.15 
nmol/mg/min. 
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catalytic domain elutes as a monomer at retention volume VE = 11.77 ml, corresponding to a 
molecular weight of 22 kD (Figure 3.9). Aggregated protein elutes at the void volume 120 ml 
of Superdex 75 26/60 and the CHD at the retention volume VE = 195 ml, corresponding to 22 
kD. This value is compatible to the theoretical molecular weight of 20 kD of the monomer of 
the CHD of Rv0386. After gel filtration the protein yield was 2.5 mg per liter bacterial cell 
culture. In summary, the oligomeric state of the cyclase homology domain was changed upon 
addition of the cofactor Mn2+ which was unexpected.  
 
 
 
Figure 3.8: Affinity chromatography of C-His CHD of Rv0386. The catalytic domain elutes from the 
nickel column in an almost pure form. The molecular weight at the SDS-PAGE gives a strong band at 24 
kD, which corresponds to the expected Mw of 20 kD for the catalytic domain of Rv0386. sup = 
supernatant, ft = flow through. 
 
Figure 3.9: Size exclusion chromatography of C-His CHD of Rv0386 eluted as monomer. A) The 
aggregation peak is visible at the void volume of 8.2 ml of Superdex 75 10/30. The main peak at retention 
volume, VE=11.77 ml corresponds to a molecular weight of 22 kD, agreeing with an expected monomer of 
Mw of 20 kD. B) Samples were analysed on Coomassie stained SDS-PAGE. 
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3.1.f Degradation Test of CHD Rv0386 
The N-His CHD of Rv0386 was left for 5 days in 4°C. This test was carried out to analyse the 
protein stability after leaving the protein in the refrigerator a couple of days, prior to 
crystallisation. After 5 days the catalytic domain has formed degradation bands as observed 
on the Coomassie stained SDS-PAGE in (Figure 3.10). Thus, the protein is not suitable for 
crystallisation after a few days of storing at 4°C.  
 
 
  
 
3.1.g Mass Spectrometry 
In order to determine if the cyclase homology domain of Rv0386 is fully intact, electrospray 
ionisation mass spectrometry (ESI-MS) was chosen. This technique is very sensitive and 
accurate and the main species of the catalytic domain of Rv0386 was determined to the 
molecular weight of 20121±0.02 Da (Figure 3.11), which is identical to the expected value of 
the demethionised CHD Rv0386. The minor species comprising the molecular weight of 40 
242±0.02 Da, corresponds to the dimeric demethionised CHD Rv0386 with the Mw of 40 242 
Da.  
Figure 3.10: Degradation test 
of the CHD of Rv0386. The 
protein is analysed on the SDS-
PAGE after 5 days in 4 °C. 
Several degradation bands and
minor contaminations are 
detected. Lane 1: 40 µg, Lane 2: 
20 µg, Lane 3: 10 µg protein.  
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3.1.h Dynamic Light Scattering 
Dynamic light scattering was carried out as an entry test for crystallisation. For a poly 
dispersity of <20-25% the protein is regarded as mono disperse and has a good chance to 
crystallise due to homogeneity and a single species in solution. The C-His CHD of Rv0386 
was purified with affinity- and size exclusion chromatography and the measurement was 
carried out at protein concentration of 1mg/ml, in buffer comprising 50 mM Tris pH 8.5, 500 
mM NaCl, 2 mM BME, 10% glycerol, at 12 °C. Prior to the measurement aggregation was 
removed by ultra centrifugation at 100 000 g for 45 to 60 min at 4°C. The protein is mono 
disperse with a poly dispersity of 20.4 % and a molecular weight of 47 kD (Figure 3.12), 
  
Figure 3.11: Electrospray ionisation mass spectrometry of the catalytic domain of Rv0386. The main peak at 
molecular weight of 20 121 Da correspond to the theoretical value of the demethionised catalytic domain. The 
minor peak at 40242 Da, matches the expected molecular weight of the dimeric demethionised catalytic 
domain. 
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corresponding to a dimer with the theoretical molecular weight of 40 kD. The cyclase 
homology domain of Rv0386 is homogeneous and suitable for crystallisation. 
 
 
 
 
 
 
 
 
3.2 Structure Determination of the Catalytic Core of 
Rv0386 
 
3.2.a Crystallisation of the Catalytic Domain of Rv0386 
The catalytic domain of Rv0386 was crystallised in several crystal forms with the hanging 
drop vapour diffusion method, with protein comprising the N-terminal or C-terminal histidine 
tag (N-His CHD or C-His CHD). There were a number of different morphologies observed 
(Table 3.2). Generally, crystals were grown within 24 h to a couple of days. The crystals were 
tested at the synchrotron radiation source (ESRF, Grenoble, France) for diffraction quality. 
None of these initial crystals diffracted. Further screening of different morphology crystals, 
       
 
 
R(nm) PD(%) Mw(kD) Mass(%) Baseline SOS-
error 
Intensity (counts/s) 
3.1 20.4 47 100 1.000 210 79 000 
Figure 3.12: Dynamic light scattering of the catalytic core of Rv0386. The protein is mono 
disperse with a molecular weight of 34 kD, corresponding to a dimer, compatible to the expected 
Mw of 40 kD. R=hydrodynamic radius, PD=poly dispersity, Mw=molecular weight, SOS=sum 
of squares.  
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resulted in a breakthrough. Small, tiny rod-like crystals of the C-His CHD Rv0386 grown in 
the condition 0.5 M Sodium Acetate, 0.1 M imidazole pH 6.5 were tested at ESRF, Grenoble 
with the diffraction of 8 Å (Table 3.2).  
 
 
Construct Condition Diffraction in 
ESRF, Grenoble 
Crystals   
     
N His CHD Rv0386 10 % PEG 6000 
2 M NaCl 
9% Glycerol 
(Castro, 2004) 
 
 
No diffraction 
N His CHD Rv0386 10 %PEG 8000 
0.1 M CHES pH 9.5 
0.2 M NaCl 
 
 
 
No diffraction 
C His CHD Rv0386 15% PEG 4000 
0.1 M Tris HCl pH 8.5 
0.2 M Sodium Acetate 
 
 
 
No diffraction 
C His CHD Rv0386 0.5 M Sodium Acetate  
0.1 M imidazole pH 6.5 
(Castro, 2004) 
 
 
 
 
Diffraction to 8 Å 
 
 
 
 
  
 
Table 3.2: Crystals of N-His and C-His CHD Rv0386 grown in different conditions.   
 
 
Fine screening with other buffers but at identical pH, lyotropic and chaotropic precipitants of 
the Hofmeister series, most commonly used precipitants, additives and inhibitors were applied 
to improve the crystals. Additionally, the protein purification was modified where a size 
exclusion chromatography step was included. Furthermore, the complete protein purification 
procedure was carried out more rapidly. Within one day, the cells were broken up, affinity-
and size exclusion chromatography were carried out, including incubation of concentrated 
protein with ATP analogue. The following day crystallisation trials were set up. Crystals 
increased in thickness and size in several conditions. Protein solution of 1.5 µl (10-20 mg/ml) 
was mixed with 1.5 µl crystal condition of 0.1 M Hepes pH 7.5 and 0.7 M sodium acetate. 
After 2-4 days at 19 °C the rod shaped crystals grew to a size of 30 x 30 x 250 µm3 (Figure 
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3.13) and a complete native dataset was collected at ESRF, beam line ID 14-4 to a resolution 
of 2.95 Å.  
 
3.2.b  Crystallisation of the Se-Met Modified Catalytic Domain of Rv0386 
In order to obtain phase information for a SAD experiment selenomethionine substituted C-
His CHD was crystallised. The selenomethionine modified protein behaved comparable to the 
native protein and crystallised in similar conditions with the hanging drop vapour diffusion 
method. 1.5 µl of protein solution (14 mg/ml) mixed with 1.5 µl of 0.6 M NaAc, 0.1 M Hepes 
pH 7.25, set up for crystallisation at 16 °C resulted in rod shaped crystals. Initial data 
collected were insufficient to determine the structure, due to the limited size of the crystals 
obtained. Larger crystals were grown from PEG2000. Protein solution of 1.5 µl (17-20 
mg/ml) was mixed with 1.5 µl of 5% (w/v) PEG2000, 0.1 M Hepes pH 7.5 and 0.2 M KCl 
and set up for crystallisation at 19 °C. After 2-4 days the Se-Met substituted crystals grew to a 
size of 30 x 30 x 250 µm3 with sharp and distinct edges of rod shaped crystals (Figure 3.14).  
Figure 3.13: Improved rod shaped crystals of 
the C-His CHD Rv0386. A) and B) show
crystals grown in 0.1 M Hepes pH 7.1, 0.4 M 
NaAc, 0.1 M KCl, 19°C. A) Crystals 3 days 
old and B) partially degraded after 5 weeks 
time. C) Crystals grown in 0.1 M Hepes pH 
7.5 and 0.7 M sodium acetate at 19 °C.   
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3.2.c Structure Determination of the Catalytic Domain of Rv0386 
The complete dataset of the PEG2000 selenomethionine modified crystals were collected at 
ESRF, beam line ID 14-1 (Grenoble). The crystals were collected in one sweep, over the 
oscillation range of 180 °. Statistics of the data collection are given in Table 3.3. The crystals 
belong to the space group P4122 with unit cell dimensions of a* = b* = 82.90 Å and c* = 
275.18 Å. The asymmetric unit contains 4 molecules. Measured reflections were integrated 
and scaled using Denzo and Scalepack (Otwinowski and Minor, 1997). I tried to solve the 
structure of the catalytic core of Rv0386 with molecular replacement, employing monomeric, 
dimeric, and truncated models from a number of homologous models. The sequence identity 
was typically as low as 14%. The structure could not be solved with molecular replacement, 
possibly due to low sequence identity and slight differences in orientation of the α-helices. 
The crystal structure of CHD Rv0386 was finally solved with the SAD phasing technique. 8 
out of 12 selenium sites were identified in the four chains resulting in a map with the figure of 
merit (FOM) of 0.31 with the program SOLVE (Terwilliger and Berendzen, 1999). In all four 
chains the Met1 is removed due to post-translational modification, which explains the lacking 
selenium sites. Phasing was carried out with the program SHARP (de la Fortelle and 
Bricogne, 1997), and phases were improved by solvent flattening with Solomon (Abrahams 
and Leslie, 1996). The Rv0386 catalytic domain was initially built in O (Jones et al., 1991) as 
a poly-alanine model, which was necessary to start the refinement. Later on, as the phases 
Figure 3.14: Improved Se-Met modified crystals. A) Thicker crystals grown in the condition of 0.6 M 
NaAc, 0.1 M Hepes pH 7.25 at 16 °C. B) Seleno methionine containing crystals with sharp edges grown in 
5% (w/v) PEG2000, 0.1 M Hepes pH 7.5 and 0.2 M KCl at 19°C. 
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improved and R-factor converged, the side-chains were added. Iterative model building and 
refinement using the programs O (Jones et al., 1991) and Refmac 5 (Murshudov et al., 1999) 
lead to the current model comprising four chains with a few residues at the N- and C-terminus 
omitted but without gaps in the protein chain. The final map had a figure of merit of 0.8. 
Refinement statistics gave an Rfree of 30.6 % and an Rfactor of 22.1 % (Table 3.4). The quality 
of the final refined model was checked by PROCHECK (Figure 3.15), WHAT IF and 
SFCHECK (Figure 3.16). The model is shown in a well refined state. 
 
 
 
 
               
 
 
 
 
 
 
 
 
Data collection 
    Native SeMet 
Unit cell a* = b *= 82.9 Å c* = 275.2 Å α = β =  γ = 90° 
a* = b* = 82.9 Å c* = 275.2 Å 
α = β =  γ = 90° 
No of chains per AU 4 4 
Space group P4122 P4122 
Resolution (Å) 25 – 2.95 25 - 3.10 
Mosaicity 0.23 0.31 
Unique reflections 21091 18397 
Redundancy 12.8 19 
Completeness (%) 99.9 99.8 
Rmerge*(%) 10.6 6.9 
 I / σ 18.7 20 
HR shell in Å 3.06 - 2.95 3.15 - 3.10 
Rmerge* (HR) in % 47.9 26.6 
I / σ (HR) 4.5 6.3 
Table 3.3: Data collection statistics of the native and selenomethionine modified crystals of the catalytic 
domain of Rv0386. The former crystals grown in NaAc diffracted to 2.95 Å and the latter grown in 
PEG2000 diffracted to 3.1 Å. 
*Rmerge = Σhkl Σi | Ii (hkl)- <I(hkl)> | / Σhkl Σi Ii (hkl); where HR corresponds to the highest resolution shell.  
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Refinement statistics 
No. of amino acids A:  3-173     B:  3-173    C: 4-183    D: 5-175
No. of protein atoms 5259 
No. of water atoms 287 
RMSD bond (Å) 0.016 
RMSD angle (°) 1.788 
Rfree ‡(%) 30.6 
Rfactor § (%) 22.1 
Ramachandran (%)  
Residues in most favoured regions 84.0 
      Residues in additional allowed regions 15.7 
        Residues in generously allowed regions 0.3 
            Residues in disallowed regions 0.0 
Table 3.4: Refinement statistics of the catalytic domain of Rv0386.  
§Rfactor = Σ | Fo - Fc | / Σ Fo , where Fo and Fc are observed and calculated structure factors respectively.  
‡Rfree is calculated with 5 % of the data. 
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Figure 3.15: Stereochemical parameters of the final model. A) Ramachandran plot of the catalytic 
core of Rv0386 including the B) main-chain parameters and C) side-chain parameters, generated 
by PROCHECK.  
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Figure 3.16: The quality of the structure factor data of the catalytic domain of Rv0386 verified by SFCHECK. 
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3.2.d Overall Crystal Structure 
We obtained tetragonal crystals that diffracted to 2.95 Å resolution. The structure of the cyclic 
homology domain of Rv0386 (Figure 3.17 A, B, C) was solved by SAD. The asymmetric unit 
contains four molecules (A, B, C, D) forming two homodimers (AB and CD) (Figure 3.18). 
Each homodimer comprises two monomers oriented in a head-to-head arrangement, where the 
catalytic residues do not form active sites, thus this conformation is assigned here as the 
inhibited state of CHD Rv0386. The refined model (Table 3.4) of the structure included 
complete chains for residues 3-173 for chains A and B, residues 4-183 for chain C and amino 
acid 5-175 for chain D. A flexible loop region ranging from residue 99-109 is partially 
disordered in all four chains. There are two further extensive contacts between monomers that 
belong to different head-to-head dimers. Chain C contains an entirely ordered C-terminal his6-
tag (residues 178-183) and it binds between symmetry related molecule A (A’) and chain B 
where it occupies part of the conserved active site of molecule A’. Further, residues 150-173 
in chain A are exchanged towards the residues in the related symmetry molecule A’ (Figure 
3.19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: Overview of the X-ray structure of the catalytic core of Rv0386. A) Overall structure of the
CHD of Rv0386. The catalytic domain of Rv0386 as monomer in rainbow, ranging from the N-terminus 
in blue to the C-terminus in red. The secondary structure elements are labelled. All figures are created by 
PyMOL (DeLano, W.L., The PyMOL Molecular graphics System (2002), http://www.pymol.org). 
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The monomers in the asymmetric unit are very similar. The root mean square deviation 
(r.m.s.d) between corresponding Cα atoms, between A and B chain is 0.85 (unit) with 141 Cα 
atoms, between chain C and B = 0.93 with 167 Cα atoms, between chain D and  
 
 
Figure 3.17: B) Inhibited dimer in the head-to-head conformation. The elongated dimer in cartoon is
rendered in grey and rainbow. C) 90 degrees rotated compared to B). The two catalytic sites with 
corresponding residues are coloured in magenta and black. The catalytic residues do not form active sites 
and they are shown in sticks where nitrogen, blue; oxygen, red.  
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Figure 3.18: Four molecules in the asymmetric unit. Homodimers AB and CD in cartoon are rendered in 
grey-wheat and dark green-light green respectively. The edges of the asymmetric unit are depicted in 
magenta.  
 
 
 
Figure 3.19: Extended region of monomer A. Molecules AB in grey-wheat and the symmetry related 
molecule A’ in cyan are shown in cartoon.  The extended part of the A chain and A’ (residue 150-
173) are coloured in black and deepteal respectively. 
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B = 0.95 with 166 Cα atoms. The differences between the molecules are found in flexible 
loops and terminal residues. The flexible loops in all molecules are in the areas of residues 54-
59, 99-109 and 149-162. The first eight N-terminal amino acids and the C-terminal amino 
acids starting from residue 172 do not superimpose. The dimension of the catalytic domain of 
Rv0386 is 31 x 40 x 42 Å3. The extended regions at the C-terminus, residue C178-C183 and 
A150-A173 extend about 30 Å from the main protein bodies. 
 
The structure consists of a three-layer α/β sandwich. The central part consists of a mixed β-
sheet, surrounded by 4 α-helices. The β-sheet contains seven β strands in the order 2-3-1-4-6-
8-7. The β strands 2-3-1-4 and 6-8-7 are antiparallel, while β4 and β6 are parallel. The α-
helices 1-2-3 are situated on one side of the antiparallel 2-3-1-4 β-sheet and on the opposite 
side α4 is located. In contrast to the other α-helices, α5 is 90 ° rotated towards the central β-2-
3-1-4-6 sheet. The secondary structure elements are different in the four chains. The β2 
(residues 50 to 52) in chain B and β7β8 (amino acids 146-152; 163-168 respectively) in chain 
A are not formed. The latter secondary structure elements are altered to a coiled loop, buried 
into the active site of the A’ (described above) and thereby stabilising the formation of the 
crystal. 
 
 
3.2.e Ordered Hexahistidine Tag 
The complete hexahistidine tag on the C-terminus (amino acids 178-183) can be traced in 
electron density for chain C and it binds between chain B and A’ (Figure 3.20). The His6-tag 
is bound in a groove on the surface of molecule A and B and enters hydrophilic and 
hydrophobic contacts. Indeed, the histidine tag is binding in the active site of molecule A’. It 
is in close proximity to the secondary structure elements α4, β3, β1, β4 from A’ and β7, β8 
belonging to chain B (to distinguish between the chains the subscript letters A, A’, B, C, D are 
used). The catalytic residues Gln57A’ and Asn106A’ (Castro et al., 2005) are in vicinity to the 
histidine-tag, but neither of them make contacts to the hexahistidines. The residue Glu59A’ 
from loop β2-β3 hydrogen bond with His181C. The main-chain carbonyl oxygen of His179C 
and the nitrogen of the main-chain amide of Glu59A’ do also hydrogen bond. Arg119A’ from 
α4 forms a hydrogen bond to the main chain carbonyl oxygen of His178C. Between His183C 
and the main-chain carbonyl oxygen of Lys144B from loop α5-β7 a hydrogen bond is 
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established. Hydrophobic interactions are identified between the carbon-β of His183C and the 
carbon-γ of Lys144B. The carbon-β of Ala108A’ from loop β4-α4 and the carbon-δ1 of Ile112A’ 
from α4 form a hydrophobic interaction with the carbon of the terminal His183C and the 
carbon-β of His182C respectively. In the centre of the histidine-tag aromatic-ring stacking 
between Trp146B-His179C is observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20: Ordered hexa-histidine tag. The complete histidine tag from chain C situated between chain B and 
A’ in the electron density 2Fo – Fc at the 1 δ level. His6-tag and residues interacting with the hexa histidines are 
visible in sticks, with nitrogen, blue; oxygen, red. Hydrogen bonds are showed as dashed lines in grey. Chain B, 
A‘ and the histidine tag are rendered in wheat, cyan and dark green respectively.    
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3.2.f Inhibited Dimer  
The homodimer of the catalytic domain of Rv0386 buries 1497 Å2 of solvent-accessible 
surface area per monomer (Brunger et al., 1998). The homodimer forms a head-to head 
contact, where the catalytic residues do not form active sites. The catalytic residues in Rv0386 
are not in the interface of the dimer, but 50 Å apart (Figure 3.17 C). The monomers are 
arranged to each other in a non-crystallographic two-fold axis. The interface between the 
homodimers AB and CD are identical. The secondary structure elements forming the interface 
are α5AB, β4AB and α3AB, with hydrophobic and hydrophilic interactions. In the centre of the 
interface the hydrophobic region is formed between Leu136B and Val132A, Leu136A and 
Val132B. In the periphery, two hydrogen bonds are formed between Ser71A and Glu98B, 
Ser71B and Glu98A. All interacting residues are facing each other across the two-fold axis 
(Figure 3.21). The extensive interactions in the interface of the two monomers, suggest that 
our structure exists in solution. Several attempts were made of co-crystallising the catalytic 
domain of Rv0386 with ATP non-hydrolysable analogues to force the active form. We 
observe this construct of the AC only in this inhibited dimeric state.  
 
 
 
Figure 3.21: Interface of the catalytic domain of Rv0386. The monomers A and B in a head-to-head 
conformation are in cartoon and rendered in grey and wheat respectively. Polar and hydrophobic interactions 
are identified in the interface and shown in dark green-light green and red-pink respectively. Hydrogen bonds 
are formed between Glu98A and Ser71B, Glu98B and Ser71A. Hydrophobic interactions are found between 
Val132A and Leu136B, Val132B and Leu136A. 
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3.3 Analysis of the Shape of CHD Rv0386 in Solution 
 
 
3.3.a Small Angle X-ray Scattering   
In contrast to other crystal structures from homologous proteins, our crystal structure shows 
an elongated shape with a new dimeric form of the protein, which we postulate to be a novel 
regulatory state of adenylyl cyclases. Small angle x-ray scattering (SAXS) is a sensitive 
technique to detect macromolecular shape in solution and was therefore applied to the 
catalytic domain of Rv0386. SAXS data were collected in the protein concentration range of 
1-20 mg/ml. For the evaluation of the SAXS data a number of models were designed, and 
these were tested for a good fit to the experimental data. The models included the X-ray 
structure, symmetry related molecules and the modeled active state of the catalytic core of 
Rv0386 in a number of conformations and oligomeric states. The modeled active state of 
CHD Rv0386 was generated by superimposing the X-ray structure of CHD Rv0386 on CHD 
Rv1900c open and closed state (Sinha et al., 2005). The oligomeric contact of the models was 
based on the interface from head-to-tail, head-to-head CHD dimers and the binding region of 
CHDs to Gsα. The dimeric model based on the head-to-head contact and the tetrameric model 
on head-to-head and head-to-tail contacts fit very well to the experimental data (Figure 3.24). 
Examples of models which did not give a good fit to the small angle X-ray scattering data are 
presented in Figure 3.22 and 3.23 and based on head-to-tail dimers, symmetry related 
molecules in oligomeric states. Table 3.5 summarizes the overall parameters calculated from 
the scattering data: molecular mass Mr, radius of gyration Rg, maximum particle size Dmax and 
the volume. At 1 mg/ml aggregation is observed, but at higher concentrations the solutions 
were monodisperse, which is an essential requirement for the analysis.  
 
The protein is in a concentration-dependent equilibrium oligomeric mixture. At protein 
concentration 1mg/ml the protein shows the elongated shape of an inhibited head-to-head 
dimer (Figure 3.24). The model yields a good fit with the discrepancy of χ = 1.79 (Table 3.5). 
The systematic deviations may be explained by the presence of higher oligomers, i.e. 
tetramers. Models of open and closed head-to-tail dimers of CHD Rv1900c did not give a 
good fit (χ = 2.26 and χ =2.42 respectively) to the experimental data. At concentration 4.4 
mg/ml a tetramer is observed (Figure 3.24). The tetrameric model was created by 
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superimposing the elongated catalytic domain of Rv0386 on the open form of Rv1900c CHD 
(PDB entry code: 1YBT) (r.m.s.d of 1.60 Å for 144 Cα-atoms). 
 
 
 
 
 
 
 
 
 
Figure 3.22: Small angle X-ray scattering models of CHD Rv0386. Dimers are depicted in the upper panel and 
tetramers in the lower panel. The models are designed from inhibited-and modelled active states and symmetry 
related molecules in the crystal. None of the models above gave a good fit to the experimental data.  
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Figure 3.23: Small angle X-ray scattering models of higher oligomers. Inhibited, symmetry related 
molecules and modelled active state of CHD Rv0386 in various oligomeric conformations. None of the 
models presented above did give a good fit to the small angle X-ray scattering data. The best model of a 
hexamer at protein concentration 8 mg/ml gave a χ of 13.9, depicted in the most upper right panel.  
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Two head-to-head dimers forming two catalytic sites in the centre of the open tetramer fit best 
the experimental SAXS data (discrepancies provided by high resolution models, χ = 1.03) see 
Table 3.5. At this concentration protein is nearly tetrameric, possibly with 5% of dimers 
(suggested by OLIGOMER). Head-to-tail models forming tetramers gave an impaired fit. At 
protein concentrations of 8 mg/ml the suggested species is that of a hexamer, octamer or a 
mixture of the two (data not shown). The best model of the octamer was constructed by rigid 
body modelling by GLOBSYMM (Petoukhov and Svergun, 2005) from two tetramers 
(described above), in an elongated shape (χ = 3.8) forming head-to-tail contacts however, the 
model shows steric clashes. The best model of a hexamer (Figure 3.23) gives a bad fit to the 
experimental data (χ = 13.9). The model was created from three head-to-head dimers forming 
head-to-tail contacts and four catalytic centres.  
 
Manganese treated CHD Rv0386 was observed as monomer by SAXS (Table 3.5). The fit of 
one catalytic monomer of the X.-ray structure CHD Rv0386 to the experimental SAXS data 
                                                                SAXS Data 
________________________________________________________________________ 
Sample Mrseqa 
(kD) 
Mrexpa 
(kD) 
Dmaxb 
(nm) 
Volumec 
(nm3) 
Rgd  
(nm) 
χe Model 
Rv0386CHD  
c= 1mg/ml 
 
18.5 
 
18 + 2 
 
6 + 0.5 
 
45 + 5 
 
18.9 + 0.5 
 
0.83 
 
Monomer 
Rv0386CHD  
c= 1mg/ml 
 
37 
 
45 + 4.5 
 
10 +1.0 
 
88 + 8.8 
 
29.66 + 1.5 
 
1.79 
 
Dimer 
Rv0386CHD  
c= 4.4 mg/ml 
 
74 
 
70 + 7.0 
 
11 + 1.1 
 
120 +12 
 
32.1 + 1.6 
 
1.03 
 
Tetramer 
Table 3.5: Small angle X-ray scattering data of the catalytic domain of Rv0386. 
a Mr seq and Mr exp are molecular masses predicted from the primary sequence and calculated from SAXS 
scattering data, respectively. 
b Dmax are experimental maximum diameters computed with the program GNOM (Svergun, 1992). 
c Volume  is the Porod volume of hydrated particle. 
d Rg experimental radius of gyration calculated with GNOM (Svergun, 1992). 
eχ Chi-square between experimental and theoretical curve. 
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gave a very good fit of χ = 0.83. This result is in agreement with observed size exclusion 
chromatography and analytical ultracentrifugation experiments. 
    
The SAXS data verifies the elongated shape observed for CHD Rv0386 dimer in the crystal 
structure. At protein concentrations of 1 mg/ml Rv0386 catalytic domain is observed as a 
head-to-head dimer possibly within a mixture of tetramers. At 4 mg/ml a tetrameric species is 
observed, composing two active sites from two head-to-head dimers. The tetramer is most 
likely only formed in vitro, in contrast to the head-to-head dimer which might also be a state 
of the protein in vivo. The oligomerisation in SAXS correlates the results described earlier on 
size exclusion chromatography and activity assays in vitro. 
  
 
 
 
 
 
Figure 3.24: X-ray scattering patterns and models. A) Experimental scattering patterns from mycobacterial 
adenylyl cyclase Rv0386 solutions at concentrations 1, 4.4 and 8.0 mg/ml (blue, magenta and black lines) along 
with the fits computed by a mixture of dimers and tetramers (red), from open tetramers (green) and from tentative 
octamers (dark blue). The plot displays the logarithm of the scattering intensity as a function of momentum transfer 
s = 4π sin(θ)/λ where 2θ is the scattering angle and λ = 1.5 Å is the X-ray wavelength. The curves are displaced 
along the abscissa axis for better visualization. The figure has been prepared with Sigmaplot B) Upper panel: The 
model of the dimer in solution, corresponding to the inhibited dimer as observed in the crystal structure. The dimer 
is in cartoon and cyan. Lower panel: A model of a tetramer is formed upon interaction of two head-to-head dimers. 
The interaction between the two elongated dimers is such that active sites are formed by the two central monomers
(greencyan-dark cyan).  
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3.3.b Mutagenesis of the Interface of the Head-to-head Rv0386 
The crystal structure of the catalytic core of Rv0386 was determined in a unique inhibited 
dimeric conformation. In order to analyse the interface of the catalytic core of Rv0386 
mutation analysis was carried out. The mutant Val132Ala behaves as the wild type 
concerning adenylyl cyclase/guanylyl cyclase activity. In contrast, the activity of the 
Glu98Ala mutant is only 15% of the wild type. The former mutation did not have any effect. 
The bad protein expression of the latter mutation points to a folding problem. The mutation 
E98A most likely disrupts the interface of the head-to-head dimer and consequently is in a 
monomeric conformation. Monomers easily aggregate and precipitate without stabilising 
agents such as glycerol and high salt. Subsequently, the unspecific aggregation might have 
been the cause of the decreased activity.   
 
In conclusion, interpretation of Glu98 as an interface residue of the catalytic domain of 
Rv0386 in the inhibited state is correlated with the mutagenesis data presented. The interface 
is important for stability of the protein. In the modeled active state Glu98 is not located in the 
interface and would not bind the substrate. Therefore, it is unlikely that E98A mutant would 
have a direct effect on the activity, if the CHD of Rv0386 would have formed a head-to-tail 
dimer, i.e the active state.   
 
 
3.3.c Analytical Ultracentrifugation  
Sedimentation velocity experiments were applied to analyse the elongated shape and to 
characterise the oligomeric state of the catalytic domain of Rv0386 in solution. The velocity 
data were analysed by the Lamm equation for a dimer and monomer model and the 
continuous size distribution function C(M). C(M) supplies a distribution of weight averaged 
molecular weights or sedimentation coefficients that fit best to the data. For the protein 
dialysed in 20 mM Tris-HCl pH 8.5, 10 mM NaCl, 5 % glycerol and 0.5 mM DTT a dimer 
was expected. The buffer density and viscosity were calculated with the program Sednterp to 
1.01433 kg/m3 and 1.179x10-2 Ns/m2 respectively. Additionally, the program Sedfit 
calculated the sedimentation coefficient, S to 2.5, corresponding to the molecular weight of 
42900 Da, compatible to the theoretical Mw of 40 400 Da, i.e a dimer (Figure 3.25). 
RESULTS 
___________________________________________________________________________ 
100
 
 
 
For the Mn2+ treated protein dialysed in 50 mM Tris-HCl pH 8.5, 500 mM NaCl, 5 % 
glycerol, 0.5 mM DTT a monomer was expected. The buffer density and viscosity were 
calculated with the program Sednterp to 1.03429 kg/m3 and 1.2262x10-2 Ns/m2 respectively. 
The program Sedfit determined the sedimentation coefficient, S to 1.68, corresponding to a 
molecular weight of 23 kD, consistent with the theoretical Mw of 20.2 kD, corresponding to a 
monomer (Figure 3.26).  
 
      
Figure 3.25: Sedimentation velocity of the catalytic domain of Rv0386. A) Data generated from a 
sedimentation velocity experiment at 200 000g and absorbance at 280 nm. The lines are the best fit to the 
data. B) Residuals from the fit in A. C) C(M) function corresponding to the best fit to the data in A. The 
actual S value calculated from Sedfit is 2.5, corresponding to the molecular weight of 42900 Da, similar to 
the theoretical Mw of 40 400 Da, i.e a dimer.  
RESULTS 
___________________________________________________________________________ 
101
 
 
 
The inhibited head-to-head crystal structure, the modeled active catalytic core of Rv0386 and 
the monomer were employed to calculate the theoretical S values with the program Hydropro. 
A monomer with and without the histidine tag contribute to the theoretical sedimentation 
coefficient, S of 1.50 and 1.56, consistent with the experimental S value of 1.68. The inhibited 
CHD dimer of the X-ray structure of Rv0386 result in the theoretical S value of 2.23 and the 
theoretical S value 2.47 for the modeled active state was compared to the experimental S of 
2.5. Since the differences in S values for the inhibited X-ray structure and the modeled active 
  
Figure 3.26: Sedimentation velocity of the CHD of Rv0386. A) Data produced from a sedimentation velocity 
experiment, run at 200 000g and absorbance at 280 nm. The lines are the best fit to the data. B) Residuals from the 
fit above. C) C(M) function corresponding to the best fit to the data in A. The actual S value calculated from Sedfit 
is 1.68, matching the molecular weight of 23 kDa, consistent to the theoretical Mw of 20.2 kDa, i.e monomer.       
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structure of CHD Rv0386 were small, the inhibited conformation could not be verified in 
solution by analytical ultracentrifugation. However, the dimeric and monomeric state of the 
catalytic core of Rv0386 analysed by size exclusion chromatography was confirmed by 
sedimentation velocity experiments. 
 
 
3.4 Crystallisation of the Monomer or Active Dimer 
of the Catalytic Core of Rv0386 
 
 
The catalytic domain of Rv0386 purified as a monomer and incubated with the non- 
hydrolysable ATP analogue α1βCH2ATP, gave rise to crystals in new conditions. The crystals 
had different morphologies as seen in (Figure 3.27). Small crystals were grown and further 
optimisation would have been required to improve the quality and size for higher resolution 
data. Due to time restrictions, the crystals were not improved.  
 
 
 
 
 
 
 
 
Figure 3.27: Crystals of the monomer or active state of the catalytic core of Rv0386. A) Crystals grown in 15 % 
PEG4000, 0.1 M BTP pH 8.0, 0.2 M NaCl and in 16.5 % PEG4000, 0.1 M CHES pH 9.8, 0.2 M NaCl at 12°C. B) 
Crystals were grown in 5 % PEG3350, 0.1 M Hepes pH 7.5, 0.2 M KAc at 12°C. C) Crystals grown in 28% PEG400, 
0.1M Hepes· Na pH 7.5, 0.2M CaCl2 at 12°C. 
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Chapter 4 
 
 
DISCUSSION 
 
 
_________________________________________________________________________ 
 
 
 
Each year 3000 000 people are killed by the pathogen Mycobacterium tuberculosis. One third 
of the world’s population is infected, but only 10% develop the disease tuberculosis. 
Signalling pathways used by M. tuberculosis are investigated in order to develop new 
methods for elimination of the disease. In this thesis, the catalytic domain of the adenylyl 
cyclase Rv0386 has been studied, which is one of in total 15 class III ACs from M. 
tuberculosis. The AC Rv0386 is unusual in the sense that it uses both ATP and GTP as 
substrate, converting it into cAMP and cGMP respectively. We have determined the X-ray 
structure of the catalytic core of AC Rv0386 from Mycobacterium tuberculosis in a new 
elongated dimeric state. Small angle X-ray scattering confirmed the shape of the protein in 
solution and the oligomerisation effect by the cofactor Mn2+ gives an explanation of the low 
activity of the CHD Rv0386. The low activity AC Rv0386 could possibly be stimulated by 
regulatory domains or by an unknown effector. The suggested model of the active dimer is 
likely to reflect the native state of the activated catalytic core of AC Rv0386. An activation 
mechanism of the cyclase homology domain of Rv0386 is proposed. 
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4.1 Inhibited CHD of Rv0386 from M. tuberculosis 
 
 
4.1.a X-ray Structure of the Inhibited Catalytic Core of Rv0386  
Non diffracting crystals grown in several conditions were successfully improved and the X-
ray structure of the inhibited CHD Rv0386 was determined with SAD, to a resolution of 2.95 
Å. The CHD is in a new elongated dimeric fashion, forming a head-to-head dimer. The active 
CHDs from M. tuberculosis have the catalytic residues in the interface of the homodimer, 
contributing to the formation of two active sites. In contrast, the CHD of Rv0386 comprises 
catalytic residues that are not in the interface of the dimer, but 50 Å away (Figure 3.17C). 
With disrupted catalytic sites, the substrate cannot bind and catalysis cannot take place. 
Therefore, the crystal structure of the catalytic domain of Rv0386 is in an inhibited state.  
 
The homodimer of the catalytic domain of Rv0386 buries 1497 Å2 of solvent-accessible 
surface area per monomer (Brunger et al., 1998) and contains hydrophobic and hydrophilic 
interactions (3.17B,C). This extensive interface makes it reasonable to believe that the 
structure is existing in solution. To confirm this, small angle X-ray scattering was applied. 
High resolution models of the head-to-head and head-to-tail open and closed catalytic 
domains of Rv0386 were used for SAXS. The crystal structure of the CHD Rv0386 gave the 
best fit to the experimental data (Figure 3.24, Table 3.5), which confirms that the head-to-
head CHD Rv0386 is present in solution and in an inhibited state. 
  
Co-crystallisation of the CHD Rv0386 with ATP non-hydrolysable analogues to force the 
active form was conducted. We observe this construct of the AC only in this inhibited dimeric 
state. High affinity inhibitors are not available for the mycobacterial class III soluble adenylyl 
cyclases: P-site inhibitors that bind to the mammalian G-protein dependent adenylyl cyclases 
with nanomolar affinity have only low affinity. This can possibly be explained by differences 
in the ability to bind substrate. The catalytic residues in class III ACs are indicated in the 
sequence alignment in Figure 4.1.  
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Figure 4.1: Sequence alignment of homologous CHDs. The sequence of M. tuberculosis Rv0386 
(homodimer) on top, followed by Trypanosoma brucei Gresag 4.1(monomer), M. tuberculosis Rv1900c 
(homodimer), M. tuberculosis Rv1264, canine VC1 and rat IIC2 (heterodimer). Amino acid numbering 
(below of each block) is according to the AC Rv0386 sequence. Eight residues involved in catalysis are in 
coloured boxes. Pink: metal-binding (Me) (Rv0386: D16 and D61), cyan: purine-binding (Pu) (Rv0386: 
Q57 and N106), violet: γ-phosphate binding (Pγ) (Rv0386: R91), yellow: β-phosphate binding (Pβ) 
(Rv0386: R156), green: transition state stabilising (Ts)  (Rv0386: N113 and R117).   
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4.1.b Low Activity and the Effect of Mn2+ in Oligomerisation        
The catalytic domain of Rv0386 is a low activity protein, displaying a Vmax of 5.6 nmol 
cAMP·mg-1·min-1 at 850 µM ATP, which is 180 fold lower compared to high activity CHDs 
Rv1900c and Rv1264 from Mycobacterium tuberculosis (Castro, 2004; Castro et al., 2005). 
The cofactor Mn2+ gives rise to higher activity in vitro compared to the divalent cofactor Mg2+ 
(Castro, 2004). In this work, it was observed by size exclusion chromatography that addition 
of Mn2+ changes the state of CHD Rv0386, from dimeric to monomeric. This is in agreement 
with analytical ultracentrifugation and small angle X-ray scattering data. The monomeric 
species precipitates easily in 5% glycerol and low salt (10 mM NaCl). In contrast, the Rv0386 
CHD head-to-head dimers stay in solution in 10 mM NaCl and 5% glycerol over three days.  
 
From the SAXS experiment and the crystal structure head-to-head dimers can be observed 
(Figure 3.17C, Figure 3.24). Binding of Mn2+ to the catalytic residues in the active centre 
might induce a conformational change in the CHD of Rv0386 destabilising the head-to-head 
homodimer interface and generating the monomers. This is observed as aggregation and 
precipitation in size exclusion chromatography, activity studies, analytical ultracentrifugation 
and small angle X-ray scattering. The monomers are unstable in solution, due to the exposure 
of hydrophobic surfaces and absence of interaction partners. For stabilisation, a part of the 
monomers form inhibited head-to-head dimers, higher head-to-head oligomers and active 
head-to-tail dimers.  The Kd is determined to 140 nM (Castro, 2004), indicative of a high 
affinity of the catalytic domains for each other. Since the head-to-tail dimers are in minority, 
the catalysis takes place in less extent. This is in agreement with the low activity of CHD 
Rv0386 (Castro, 2004; Castro et al., 2005). In contrast to Mn2+, cofactor Mg2+ does not 
contribute to any change in oligomeric state in AC Rv0386, observed by size exclusion 
chromatography. Indicating that Mn2+ is essential for inducing the inhibited to active state of 
CHD of Rv0386. An external activator and addition of regulatory domains would be a 
prerequisite for confirmation of the suggested regulation of AC Rv0386. 
 
The low activity could possibly be stimulated by the other regulatory domains and by an 
unknown activator (Castro, 2004; Castro et al., 2005). An example of this is the CHD of 
Rv3645 which can be stimulated 21-fold by the HAMP domain (Linder et al., 2004). To test 
this for Rv0386 the CHD has been cloned with its neighbouring AAA-ATPase domain 
(Castro, 2004) but the protein was observed in inclusion bodies in recombinant expression. 
The individual domains of Rv0386, i.e AAA-ATPase, tetratricopeptide repeat (TPR) domain, 
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luxR helix-turn-helix DNA binding domain as well as the full length protein were also 
observed in inclusion bodies (Castro, 2004). Further cloning and expression is required. 
Expression with more constructs including fusion proteins, chaperons, weaker promoters, 
stepwise increase/decrease of 1-3 residues, lower expression temperatures, low IPTG 
concentrations, glucose-lactose expression, media with more or less nutrients, are a 
commonly used strategy to increase solubility of the single domains as well as for the full 
length Rv0386. Furthermore, identification and co-expression of the activator with the 
additional CHD would be of advantage. Another possibility is to design a linker between the 
CHDs, thus creating a head-to-tail CHD of Rv0386.  
 
 
4.1.c Putative Activator 
The activator and its binding region of Rv0386 is not known. A putative modulator could bind 
to α2, α3 of one catalytic monomer including the N-terminal region of the other catalytic 
monomer, in the active state of Rv0386. This is in agreement with the mammalian AC in 
complex with Gsα (Tesmer et al., 1997).  
 
It is suggested that prokaryotic class III ACs comprising the purine binding residues Thr and 
Lys are activated by bicarbonate in vitro (Cann et al., 2003; Chen et al., 2000). These ACs 
include conserved substrate binding residues, except for the purine binding Thr (Table 1.3). 
Other ACs with non conserved substrate binding residues might also be regulated by an 
external activator. This could also be true for non conserved Asn106 and Gln57 in AC 
Rv0386. It is possible that the activator stabilises the residues responsible for substrate 
selectivity, thereby allowing efficient nucleotide binding and increasing the activity. The 
bicarbonate might mimic an in vivo external regulator or regulatory domains. Another 
example is forskolin involved in gluing the mammalian cyclic homology domains together in 
vitro, most likely mimicking an unknown activator in vivo. Most of the mycobacterial CHDs 
have low intrinsic activity (Castro et al., 2005) and might need an activator for enhanced 
activity.  
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4.1.d Crystals of Rv0386 CHD in the Active State?  
The catalytic domain of Rv0386 was also produced in a monomeric state, observed by size 
exclusion chromatography, analytical ultracentrifugation, activity studies and small angle X-
ray scattering. The monomer is unstable and precipitates easily, unless high amount of salt 
and glycerol is added. Prior to crystallisation non hydrolysable substrate analogues were 
added to the protein, to induce the active state of the catalytic domains as homodimer (head-
to-tail).  This could happen, since the substrate analogue stabilises the interface of the head-
to-tail dimer. The analogue would stabilise the active dimer conformation. Crystals were 
grown in new conditions and crystal forms, possibly related to a conformation of the enzyme 
as monomer or a dimer with bound substrate analogue. The head-to-tail Rv1900c (Sinha et al., 
2005) and Rv1264 (Tews et al., 2005) have been structurally determined with bound substrate 
analogue and apoform respectively. The latter comprises a SO42- in the interface from the 
crystallisation buffer, stabilising the interface of the active dimer. Due to time restrictions, the 
crystals of Rv0386 were not improved.   
 
 
4.2 Comparison with Homologous Structures  
 
 
4.2.a Similarity of the Catalytic Domain of Rv0386 with Related Proteins  
The catalytic domain of Rv0386 is structurally highly related to all class III CHDs of ACs. 
The sequence identities of the catalytic domain of Rv0386 compared to the mammalian 
domains is only 14 % with canine type VC1 and 14 % with rat type IIC2. Superimposing the 
CHD of Rv0386 on the type IIC2 domain from rat gives a r.m.s.d of 1.85 Å for 115 Cα-atoms 
and on type VC1 domain from canine gives a r.m.s.d of 1.57 Å for 133 Cα-positions (PDB 
entry code: 1CJK). The superimposition of CHD of Rv0386 on Rv1900c in the open 
conformation (r.m.s.d of 1.60 Å for 144 Cα-atoms) (PDB entry code: 1YBT) and on Rv1264 
active and inhibited conformation give a r.m.s.d of 1.66 Å for 124 Cα-atoms and 1.60 Å for 
120 Cα- atoms respectively. 
 
The topology of the catalytic domain of Rv0386 shows a divergence compared to the 
topology of mammalian, trypanosomal and mycobacterial catalytic domains (Table 4.1). The 
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catalytic domain of Rv0386 is similar to other mycobacterial catalytic domains,  lacking the 
∆-subdomain of the GRESAG proteins from Trypanosoma brucei (Bieger and Essen, 2001). 
The dimerisation arm, (Linder et al., 2002; Linder and Schultz, 2003; Tesmer et al., 1997) 
situated between β4-β5 in all CHDs, contains a 6-residues gap in Rv0386 compared to the 
mammalian, trypanosomal and Rv1900c ACs. The dimerisation arm of Rv0386 has the 
similar length as the CHD of Rv1264. Unusually, the β5 is only missing in Rv0386 (Figure 
4.2) consistent with DSSP assignment, but present in all other catalytic domains. The shorter 
β4 and longer α4 contributes to that the highly conserved β-hairpin motif (β4-β5) is missing in 
Rv0386 catalytic domain.  
 
The 6-amino acids gap and the missing ß5 make the dimer interface more unstable and could 
drive the protein into a head-to-head  conformation. In the X-ray structure of Rv0386 the 
dimerisation arm is in the vicinity of the dimer interface, but it is not part of the dimer 
interface. 
 
Interestingly, residues in vicinity to the missing dimerisation arm and the regions involved in 
catalysis have high B-factors, indicative of disorder or high flexibility in Rv0386. The His6-
tag and the elongated region from the A chain do not have high B-factors, since they are 
stabilised by the surrounding B chain and A’ and molecule A’ respectively.  
 
 
 
M. tuberculosis Rv0386 β1α1α2β2β3α3β4    α4β6α5β7β8
Rat type II C2 (homodimer) β1α1α2β2β3α3β4β5α4β6α5β7β8
Canine type VC1 β1α1α2β2β3α3β4β5 6α7α4β6α5β7α β8
M. tuberculosis Rv1900 β1α1α2β2β3α3β4β5α4β6α5β7β8
M. tuberculosis Rv1264 (active)          β1α1α2β2β3α3β4β5α4β6α5β7β8
M. tuberculosis Rv1264 (inhibited) β1     α2β2β3α3β4β5α4β6α5β7β8
T. Brucei GRESAG β1α1α2β2β3α3α3aα3bβ4β5β6 6α4β7α5α β8β9
Table 4.1: Topology of the catalytic domain of class III adenylyl cyclases, according to DSSP.                    
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Figure 4.2: Missing dimerisation arm of Rv0386 compared to Rv1264. The CHD of Rv0386 and Rv1264 
are in cartoon and rendered in wheat and olive respectively. 
 
4.3 Expected Active Conformation 
 
 
4.3.a Model of the Active State of Rv0386 in Comparison with the 
Mammalian Heterodimer 
When the CHD of Rv0386 was superimposed on the AMPCPP-bound CHD dimer of 
Rv1900c (PDB entry code1YBU) (rmsd of 1.75 Å for 142 Cα-atoms) clashes were observed 
between Asn113A and Thr21B, Thr21A and Asn113B, Gly58B and Gly58A. No clashes were 
observed when superimposing the catalytic domain of Rv0386 on the mammalian AC type 
IIC2 domain from rat and on type VC1 domain from canine (r.m.s.d of 1.85 Å for 115 Cα-
atoms and  r.m.s.d of 1.57 Å for 133 Cα-positions respectively, PDB: 1CJK) and therefore, 
the overlay was done with the mammalian AC. From this superposition a model of the active 
site of Rv0386 in complex with P-site inhibitor ATPαS-Rp (Figure 4.3B) and GTP (Figure 
4.3C) was created. Nucleotides ATP and GTP are accepted as substrate of the enzyme (Castro 
DISCUSSION 
___________________________________________________________________________ 
111
et al., 2005), and the model shows how the two residues Gln57B (loop β2-β3) and Asn106B 
(loop β4- α4) take up their function in substrate recognition, by an amide switch. Nitrogen and 
oxygen of the Gln57B amide hydrogen bond to adenine N1 and N6 respectively. 
 
Amide nitrogen of Asn106B hydrogen bonds to the amide oxygen of Gln57B. Asn106B and 
Gln57B correspond respectively to Lys938 and Asp1018 from mammalian IIC2 (Figure 4.3). 
Single or double mutation of either Gln57B or Asn106B to the usual substrate-specifying 
lysine-aspartate pair; Q57K/N106D abolished AC and GC activity. Mutation Gln57Glu 
neither showed any detectable activity. Interestingly, Asn106Ser had 36% of wild type AC 
activity and no GC activity. This confirms that the AC and GC activity are dependent on the 
Gln57 and Asn106 pair. Asn106 can act as a hydrogen-bond acceptor via its carbonyl oxygen 
from the amide and as a hydrogen-bond donor via the nitrogen in the amide. Aspartate and 
glutamate can only act as hydrogen-bond acceptors in contrast to serine that can serve as a 
hydrogen-bond donor. Therefore, this supports that Rv0386 uses a novel mode for substrate 
selection (Castro et al., 2005). In Rv1900c CHD the non conserved substrate-specifying 
residues Asn342-Asp395 (Sinha et al., 2005) differ to the usual lysine-aspartate couple. The 
Asn342-Asp395 pair does not hydrogen bond to the AMPCPP adenine moiety and is 
therefore nonessential for catalysis.  
 
Asp61A (loop β2-β3) and Asp16A (β1) could coordinate the Mn2+ as shown for Asp440 and 
Asp396 respectively of VC1 (Tesmer and Sprang, 1998; Tesmer et al., 1999). Manganese is 
an essential co-factor required for the activity of the catalytic domain of Rv0386 and other 
ACs from Mycobacterium tuberculosis (Castro, 2004; Guo et al., 2001; Linder et al., 2004; 
Linder and Schultz, 2003; Shenoy et al., 2004). Manganese may very well be physiologically 
relevant, since a putative Mn2+ transporter is found in the genome of M. tuberculosis, possibly 
sustaining high concentrations of intracellular Mn2+ (Cole et al., 1998; Linder et al., 2004; 
Reddy et al., 2001). Many ACs from bacteria prefer the cofactor Mn2+ over Mg2+. A few 
bacterial CHDs and the mammalian ACs use Mg2+ instead (Dessauer and Gilman, 1997). 
Asn113B (α4) is equivalent to Asn1025B of type IIC2, and likely binds to the ATP ribose 
oxygen orienting the substrate during catalysis (Tesmer et al., 1997; Yan et al., 1997). 
Arg117B (α4) potentially binds to the α-phosphate of ATPαS-Rp, as the corresponding 
Arg1029 of IIC2. Arg91A (β4) is equivalent to Arg484 of VC1, binding to the γ-phosphate of 
the ATPαS-Rp. Arg156B (loop β7- β8) corresponds to Lys1065 of IIC2 and Rv0386 would in 
the active state potentially move towards the γ-phosphate of ATPαS-Rp and bind there. With 
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the exception of the purine binding residues Asn106 and Gln57, the conserved substrate 
binding residues in Rv0386 depicted in the sequence alignment (Figure 4.1) and the modeled 
active Rv0386 (Figure 4.3)  suggest the catalytic mechanism of Rv0386 may be similar to that 
in most of the other ACs.  
 
 
 
Figure 4.3: Model of the catalytic site of Rv0386 in comparison with the active site of the mammalian AC
(PDB code: 1CJK). The catalytic domains of the AC Rv0386 were superimposed onto the active state of the 
mammalian heterodimeric AC with ATPαS-Rp. Rv0386 forms a regular dimer without clashes with two 
active sites. Residues playing a role in substrate binding and catalysis, ATPαS-Rp and GTP are shown in 
sticks with nitrogen, blue; oxygen, red; sulphur, orange; α-phosphate, cyan; β-phosphate, black; γ-phosphate, 
grey. Mg2+ and Mn2+ are highlighted in pink and violet respectively. Substrate specifying residues Gln57 and 
Asn106 binding ATP analogue (B left panel) and GTP (C right panel) by a possible amide switch are 
encircled in ruby. A) A view of the structure of the G-protein activated hetero-dimeric canine AC type V C1 
and rat AC type II C2 active site in complex with P-site inhibitor ATPαS-Rp. VC1 (chain A) and IIC2 (chain 
B) is coloured in brown and  beige respectively. ATPαS-Rp is depicted in wheat. B) Model of Rv0386 CHD 
 
 
in the active site modeled after the mammalian AC. View of the catalytic site of Rv0386 in complex with 
ATPαS-Rp. The rendered monomers chain B and chain A are coloured in cyangreen and darkcyan 
respectively. C) Active site of Rv0386 in complex with GTP as a model. GTP is rendered in dark green and 
the monomers are described in B. 
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The modelled active state of CHD Rv0386 buries 1361 Å2 of solvent-accessible surface area 
per monomer. In comparison, the mammalian AC type VC1 domain from canine and type 
IIC2 domain from rat is contributing to the interface of 3800 Å2. The dimerisation arm 
(Linder et al., 2002; Linder and Schultz, 2003; Tesmer et al., 1997) of the modeled active 
state of Rv0386 excludes 6 amino acids (Figure 4.4B) relative to the mammalian heterodimer 
(Figure 4.4A). The missing dimerisation arm and shorter loops are important reasons of the 
difference in buried interface.  
 
Modelled active Rv0386 comprises diminished interactions in the interface compared to 
homologous ACs. The missing β5, 6-residues gap in the dimerisation arm, shorter loops and 
declined interactions in interface of the active dimer could make it more demanding forming 
the head-to-tail dimer, driving the formation to the head-to-head dimer. Upon, stimulation by 
the other regulatory domains and by an unknown activator in vivo, Rv0386 could arrange in 
the active state (Castro et al., 2005). A potent non-hydrolysable analogue is important as well, 
hence stabilising the interaction between the monomers in the active conformation. This has 
been shown in vitro by, class III AC crystal structures containing a non-hydrolysable ATP 
analogue (Sinha et al., 2005; Tesmer et al., 1997) or a sulphate (Tews et al., 2005), which has 
contributed to the stability and formation of the active state.  
 
 
 
Figure 4.4: Modelled active CHD of Rv0386 compared to the rat AC type II C2 AC and canine AC type V 
C1 (PDB code: 1CJK). The ATPαS-Rp as described in Figure 4.3. A) Mammalian heterodimer C2 in beige, 
C1 in brown rendered in cartoon. Dimerisation arm high lighted in magenta and violet. B) Rv0386 
homodimer in cartoon rendered in greencyan and darkcyan.  
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4.4 Modelled Active Interface  
 
 
4.4.a CHD Interface of Modelled Active State of Rv0386 Compared to 
Active Rv1264  
The catalytic domain of Rv0386 was superimposed on the active apo-form CHD of Rv1264 
(PDB entry code1Y11) (rmsd of 1.66 Å for 124 Cα-atoms). Molecule D and B of Rv0386 
were overlaid on active Rv1264 B and A respectively. Rv1264 was chosen for comparison, 
since the dimerisation arm as well is missing and it is crystallised in the active and inhibited 
state. The modeled active state of the catalytic domain of Rv0386 embodies an interface of 
1361 Å2 compared to the catalytic domain of Rv1264 that forms an interface of 1900 Å2. The 
interface of the modelled active state of Rv0386 CHD contains hydrophobic and polar 
interactions. The interactions in the interface are described as follows. Nitrogen of the main-
chain amide Leu158D (loop β7- β8) hydrogen bonds to the side-chain of Glu25B (α1). Polar 
contacts are also established between the side-chains of Thr21B (α1), and Arg117D (α4) and 
the nitrogen side-chain of Asn113D (α4). Side-chains of Asp120D (α4), Arg119D (α4) and 
Glu59B (loop β2-β3) form polar contacts. Main-chain carbonyl oxygen of Glu56B (loop β2-β3) 
hydrogen bond to nitrogen of the main-chain amide of Glu59D (loop β2-β3). The side–chain of 
Glu104B (β4- α4) is as well hydrogen bonding to the nitrogen of the amide Gly32D (α2). A 
hydrophobic interaction is established between Trp24B (α1) and Ala108D (β4- α4). 
 
The model of the catalytic domain of Rv0386 demonstrates that Rv0386 can arrange in the 
active state. Minor clashes are observed in the model between Gly58B and Gly58D (loop β2-
β3), and between side-chains of Asn113B (α4) and Thr21D (α1). In the genuine active state, 
loop β2-β3 could be flexible and possible interactions can be established between Asn/Thr.  
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4.5 Transition of the Inhibited to the Expected Active 
State 
 
 
 
4.5.a Regulation of CHD of Rv0386 
In this study the X-ray structure of the catalytic domain of the adenylyl cyclase Rv0386 has 
been determined. For the first time an AC is established in an inhibited head-to-head fashion. 
The exact alignment of CHDs in the active state is important for the regulation of adenylyl 
cyclases, as the catalytic dimer recognises residues from both chains to form proper catalytic 
centres. The movement required to convert the inhibited to the modelled active conformation 
of CHD Rv0386 was investigated using the program DynDom {Hayward, 1998 #93; 
http://www.sys.uea.ac.uk/dyndom}. The inhibited and the active states were superimposed, 
generating one fixed molecule for the two states. DynDom calculated the domain motion i.e 
the rotation/translation vector to convert one conformation into the other.  
 
The catalytic residues in the inhibited state of CHD Rv0386 are 50 Å apart. For the active 
state to be formed, the catalytic monomers are rotated with 48.2° and translated with 16.8 Å 
along the rotation axis, (Figure 4.5) creating two catalytic sites in the interface between the 
monomers with catalytic residues 25 Å apart. A schematic drawing visualises this effect 
(Figure 4.6).  
  
Other crystal structures of adenylyl cyclases also show domain movements. The active 
mammalian heterodimer of the C1, C2 catalytic domain bound to an activating Gsα protein 
and ATP analogue (Tesmer et al., 1997) has been compared to the C2 homodimer (Zhang et 
al., 1997) resulting in a rotation of 7°, which has been suggested to be the activation 
mechanism. The significance of this comparison is unclear, due to two different constructs 
employed. One is an inactive homodimer with no catalytic centres and the other an active 
heterodimer with two catalytic centres. Still, the crystal structure of the mammalian CHD 
including the transmembrane helices is missing and the complete AC enzyme could possibly 
generate a larger movement with additional membrane spanning segments and Giα protein. 
The open to closed conformation of CHD Rv1900c binding AMPCPP, results in a rotation of 
16.6° and translation of 11.4 Å along the rotation axis (Sinha et al., 2005). The additional N 
terminal α/β-hydrolase domain of Rv1900c has not been crystallised together with the 
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catalytic domain and therefore one cannot derive its regulatory foundation. It is not clear if 
Rv1900c also might form an inhibited state just as Rv0386 and Rv1264. The only known 
inhibited structure so far, has been from holoenzyme Rv1264 (Tews et al., 2005). For the 
active state of Rv1264 to be formed from the inhibited state, the αN10-switch helix unforms, 
α1-switch forms and the catalytic monomers are rotated 55° with a translation of 6 Å along 
the rotation axis. These sterical changes causes 40 fold activation. The regulatory domain is 
barely changed and interacts mainly with the catalytic domain. Rv0386 in the active state is 
likewise expected to be stabilised by interaction of the catalytic domain with other regulatory 
domains.  
 
 
 
Figure 4.5: Movement of the inhibited to the modelled active conformation of CHD Rv0386. The two protein 
states in ribbon, and superimposed where the fixed chain and the screw axis is coloured in blue. Inhibited 
catalytic domain of Rv0386 rotates 48.2 ° and 16.8 Å translation along rotation axis creating the active state. 
The inhibited head-to-head dimer in red, blue and the modelled active head-to-tail dimer in blue, white. Picture 
was generated by DynDom (Hayward and Berendsen, 1998)and Rasmol (Sayle and Milner-White, 1995). 
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Figure 4.6: Schematic drawing of the model of Rv0386 CHD activation. Left panel: inhibited state with 
disassembled active sites in grey and beige. Middle panel: movement of the monomers with rotation of 48.2° and 
translation of 16.8 Å along the rotation axis. Monomers coloured in light green. Right panel: active state in dark blue 
and aqua marine with two ATPs bound in the active sites.  
 
4.5.b Putative β5-switch  
Comparison of the catalytic domain of Rv0386 with homologous CHDs revealed a difference 
in the secondary structure elements (Table 4.1). In other class III CHD structures from M. 
tuberculosis, T. Brucei and mammals, β5 is present. So far, the Rv0386 CHD structure is the 
only one with absent β5. Instead, a random coiled loop is observed. This region comprises the 
non conserved catalytic residue Asn106, which binds to the purine of the substrate in the 
modeled active state. This is in agreement with the purine binding residues D1018 and I1019 
from mammalian AC as well located at β5 (Figure 1.8). In the inhibited crystal structure of 
CHD Rv0386 this catalytic residue is not oriented in the same direction as corresponding 
residue in other CHD crystal structures. In the electron density Asn106 has two 
conformations, which shows its flexibility. The active conformation of the protein would 
contain Asn106 in a different orientation and binding the substrate.  
 
The structures of the holoenzyme Rv1264 show the relationship between the catalytic and 
regulatory domains in the inhibited and active state (Tews et al., 2005). The α1-switch binds 
to the β/γ-phosphates in the mammalian ACs and it is expected to do that as well for Rv1264. 
The inhibited state of Rv1264 contains an unformed α1-switch and in the active state it is 
forming an α-helix. As a comparison, the inhibited head-to-head CHD Rv0386 has an 
unformed β5. For the active state of Rv0386 to be created it is possible that β5 is formed. This 
region could also improve the stability of the active dimer, increasing the affinity of the 
substrate and the buried surface. It is possible that unformed β5 in homologous structures 
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could result in an inhibited head-to-head conformation. Other AC structures need to be 
determined, to confirm this hypothesis.  
 
 
4.6 Conclusions 
 
 
This work presents the crystal and solution structure of the catalytic core of AC Rv0386. The 
enzyme was determined by X-ray in an inhibited state forming the unique head-to-head 
homodimer. The extensive interface buries 1497 Å2 of solvent-accessible surface area per 
monomer and is in agreement with the solution structure determined by SAXS where this 
confirmation could be confirmed. The two active sites are 50 Å apart and cannot bind and 
convert ATP and GTP to cAMP and cGMP respectively. This study suggests that Mn2+ or a 
putative external activator make the transition of the inhibited to form the proper active state 
of the catalytic core of Rv0386. This rearrangement requires the monomers to rotate by 48.2° 
and translate by 16.8 Å along the rotation axis, creating two catalytic sites in the interface 
between the monomers with catalytic residues 25 Å apart.  
 
A difference in secondary structure elements of our head-to-head dimer compared to general 
head-to-tail ACs, reveals a shorter β-sheet i.e absence of β5 in CHD Rv0386, highly 
conserved in all class III ACs. This β5 is a part of the modeled active interface responsible for 
the purine binding residue Asn106. This study suggests that β5 is formed in the active state of 
Rv0386. The region might improve the stability of the active dimer, increasing the affinity of 
the substrate. It would also increase the buried surface of 1361 Å. It is possible that not 
formed β5 in homologous structures could result in an inhibited head-to-head conformation. 
 
The binding mode of ATP and GTP has been proposed from the modeled active state of 
Rv0386. The non conserved purine binding residues Asn106 and Gln57 are able to bind both 
substrates, possibly by 180° rotation of both amide side chains. 
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